

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number
WO 02/081668 A2(51) International Patent Classification⁷: C12N 9/00

(21) International Application Number: PCT/US02/01924

(22) International Filing Date: 24 January 2002 (24.01.2002)


(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/769,863 25 January 2001 (25.01.2001) US
Not furnished 22 January 2002 (22.01.2002) US(71) Applicant: ABBOTT LABORATORIES [US/US];
Dept. 377/AP6D-2, 100 Abbott Park Road, Abbott Park,
IL 60064-6050 (US).(72) Inventors: MUKERJI, Pradip; 1069 Arcaro Drive,
Gahanna, OH 43230 (US). HUANG, Yung-Sheng; 2462
Danvers Court, Columbus, OH 43220 (US). DAS, Tapas;
936 Linkfield Drive, Worthington, OH 43085 (US).THURMOND, Jennifer; 3702 Adirondack, Columbus,
OH 43231 (US). PEREIRA, Suzette, L.; 719 Westray
Drive, Westerville, OH 43081 (US).(74) Agents: BECKER, Cheryl, L. et al.; Dept 377/AP6D-2,
100 Abbott Park Road, Abbott Park, IL 60064-6050 (US).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZM, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

[Continued on next page]

(54) Title: DESATURASE GENES AND USES THEREOF



(57) Abstract: The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 5 (i.e., "Δ5-desaturase") and at carbon 6 (i.e., "Δ6-desaturase") and to uses thereof. In particular, Δ5-desaturase may be utilized, for example, in the conversion of dihomog-linolenic acid (DGLA) to arachidonic acid (AA) and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA). Delta-6 desaturase may be used, for example, in the conversion of linoleic acid (LA) to g-linolenic acid (GLA). AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.



Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

DESATURASE GENES AND USES THEREOF

BACKGROUND OF THE INVENTIONTechnical Field

The subject invention relates to the identification and isolation of genes that encodes enzymes (i.e., Thraustochytrium aureum $\Delta 5$ -desaturase, Saprolegnia diclina $\Delta 5$ -desaturase, Saprolegnia diclina $\Delta 6$ -desaturase and Isochrysis galbana $\Delta 5$ -desaturase) involved in the synthesis of polyunsaturated fatty acids and to uses thereof. In particular, $\Delta 5$ -desaturase catalyzes the conversion of, for example, dihomo- γ -linolenic acid (DGLA) to arachidonic acid (AA) and (n-3)-eicosatetraenoic acid (20:4n-3) to eicosapentaenoic acid (20:5n-3). Delta-6 desaturase catalyzes the conversion of, for example, α -linolenic acid (ALA) to stearidonic acid (STA). The converted products may then be utilized as substrates in the production of other polyunsaturated fatty acids (PUFAs). The product or other polyunsaturated fatty acids may be added to pharmaceutical compositions, nutritional composition, animal feeds as well as other products such as cosmetics.

Background Information

Desaturases are critical in the production of long-chain polyunsaturated fatty acids that have many important functions. For example, polyunsaturated fatty acids (PUFAs) are important components of the plasma membrane of a cell, where they are found in the form of phospholipids. They also serve as precursors to mammalian prostacyclins, eicosanoids, leukotrienes and prostaglandins. Additionally, PUFAs are necessary for the proper development of the developing infant brain as well as for tissue formation and repair. In view of the biological significance of PUFAs, attempts are being made

to produce them, as well as intermediates leading to their production, in an efficient manner.

A number of enzymes are involved in PUFA biosynthesis in addition to $\Delta 5$ -desaturase and $\Delta 6$ -desaturase. For example,
5 elongase (elo) catalyzes the conversion of γ -linolenic acid (GLA) to dihomogamma-linolenic acid (DGLA) and of stearidonic acid (18:4n-3) to (n-3)-eicosatetraenoic acid (20:4n-3). Linoleic acid (LA, 18:2- $\Delta 9,12$ or 18:2n-6) is produced from oleic acid (18:1- $\Delta 9$) by a $\Delta 12$ -desaturase. GLA (18:3- $\Delta 6,9,12$) is produced
10 from linoleic acid by a $\Delta 6$ -desaturase.

It must be noted that animals cannot desaturate beyond the $\Delta 9$ position and therefore cannot convert oleic acid into linoleic acid. Likewise, α -linolenic acid (ALA, 18:3- $\Delta 9,12,15$) cannot be synthesized by mammals. However, α -linolenic acid
15 can be converted to stearidonic acid (STA, 18:4- $\Delta 6,9,12,15$) by a $\Delta 6$ -desaturase (see PCT publication WO 96/13591 and The FASEB Journal, Abstracts, Part I, Abstract 3093, page A532 (Experimental Biology 98, San Francisco, CA, April 18-22, 1998); see also U.S. Patent No. 5,552,306), followed by
20 elongation to (n-3)-eicosatetraenoic acid (20:4- $\Delta 8,11,14,17$) in mammals and algae. This polyunsaturated fatty acid (i.e., 20:4- $\Delta 8,11,14,17$) can then be converted to eicosapentaenoic acid (EPA, 20:5- $\Delta 5,8,11,14,17$) by a $\Delta 5$ -desaturase, such as that of the present invention. Other eukaryotes, including fungi
25 and plants, have enzymes which desaturate at carbon 12 (see PCT publication WO 94/11516 and U.S. Patent No. 5,443,974) and carbon 15 (see PCT publication WO 93/11245). The major polyunsaturated fatty acids of animals therefore are either derived from diet and/or from desaturation and elongation of
30 linoleic acid or α -linolenic acid. In view of these difficulties, it is of significant interest to isolate genes involved in PUFA synthesis from species that naturally produce

these fatty acids and to express these genes in a microbial, plant, or animal system which can be altered to provide production of commercial quantities of one or more PUFAs.

One of the most important long chain PUFAs, noted above, is arachidonic acid (AA). AA is found in filamentous fungi and can also be purified from mammalian tissues including the liver and adrenal glands. As noted above, AA production from dihomog-
5 γ -linolenic acid is catalyzed by a $\Delta 5$ -desaturase. EPA is another important long-chain PUFA. EPA is found in fungi and also in marine oils. As noted above, EPA is produced from (n-
10 3)-eicosatetraenoic acid and is catalyzed by a $\Delta 5$ -desaturase. In view of the above discussion, there is a definite need for the $\Delta 5$ -desaturase and $\Delta 6$ -desaturase enzymes, the respective genes encoding these enzymes, as well as recombinant methods of
15 producing these enzymes. Additionally, a need exists for oils containing levels of PUFAs beyond those naturally present as well as those enriched in novel PUFAs. Such oils can only be made by isolation and expression of the $\Delta 5$ -desaturase and $\Delta 6$ -
desaturase genes.

20 All U.S. patents, priority documents and publications referred to herein are hereby incorporated in their entirety by reference.

SUMMARY OF THE INVENTION

25 The present invention includes an isolated nucleotide sequence or fragment comprising or complementary to at least about 50% of a nucleotide sequence comprising SEQ ID NO:13 (Figure 2), SEQ ID NO:19 (Figure 4), SEQ ID NO:28 (Figure 6),
SEQ ID NO:30 (Figure 8), SEQ ID NO:32 (Figure 10) or SEQ ID
30 NO:34 (Figure 14). In particular, the isolated nucleotide sequence may be represented by SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32 or SEQ ID NO:34. These

sequences may encode a functionally active desaturase which utilizes a polyunsaturated fatty acid as a substrate.

Furthermore, the present invention encompasses an isolated nucleotide sequence or fragment comprising or complementary to
5 a nucleotide sequence encoding a polypeptide having desaturase activity and having at least 50% identity or similarity to an amino acid sequence selected from the group consisting of SEQ ID NO:20, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33 and SEQ ID NO:35.

10 The nucleotide sequences may be derived from, for example, a fungus such as Saprolegnia diclina (SEQ ID NO:13 and SEQ ID NO:19) or Thraustochytrium aureum (SEQ ID NO:28, SEQ ID NO:30 and SEQ ID NO:32), or an algae such as, for example, Isochrysis galbana (SEQ ID NO:34).

15 The present invention also includes purified proteins or polypeptides (SEQ ID NO:14 (Figure 3), SEQ ID NO:20 (Figure 5), SEQ ID NO:29 (Figure 7), SEQ ID NO: 31 (Figure 31), SEQ ID NO:33 (Figure 11) and SEQ ID NO:35 (Figure 15)) encoded by the nucleotide sequences referred to above.

20 Additionally, the present invention includes a purified polypeptide which desaturates polyunsaturated fatty acids at carbon 5 or carbon 6 and has at least about 50% amino acid identity or similarity to the amino acid sequence of the purified proteins referred to directly above (i.e., SEQ ID
25 NO:14, SEQ ID NO:20, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33 and SEQ ID NO:35).

Furthermore, the present invention also encompasses a method of producing a desaturase (i.e., $\Delta 5$ or $\Delta 6$). This method comprises the steps of: a) isolating the nucleotide sequence
30 comprising SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:13, SEQ ID NO:30, SEQ ID NO:32, or SEQ ID NO:34 as appropriate; b) constructing a vector comprising: i) the isolated nucleotide sequence operably linked to ii) a promoter or some type of

regulatory sequence; and c) introducing the vector into a host cell for a time and under conditions sufficient for expression of the $\Delta 5$ -desaturase or $\Delta 6$ -desaturase, as appropriate. The host cell may be, for example, a eukaryotic cell or a
5 prokaryotic cell. In particular, the prokaryotic cell may be, for example, E. coli, Cyanobacteria or B. subtilis. The eukaryotic cell may be, for example, a mammalian cell, an insect cell, a plant cell or a fungal cell (e.g., a yeast cell such as Saccharomyces cerevisiae, Saccharomyces carlsbergensis,
10 Candida spp., Lipomyces starkey, Yarrowia lipolytica, Kluyveromyces spp., Hansenula spp., Trichoderma spp. or Pichia spp.).

Additionally, the present invention also encompasses a vector comprising: a) a nucleotide sequence as represented by
15 SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32 or SEQ ID NO:34 operably linked to b) a promoter or regulatory sequence. The invention also includes a host cell comprising this vector. The host cell may be, for example, a eukaryotic cell or a prokaryotic cell. Suitable eukaryotic
20 cells and prokaryotic cells are as defined above.

Moreover, the present invention also includes a plant cell, plant or plant tissue comprising the above vector, wherein expression of the nucleotide sequence of the vector results in production of at least one polyunsaturated fatty
25 acids by the plant cell, plant or plant tissue. The polyunsaturated fatty acid may be, for example, selected from the group consisting of AA, EPA, GLA or STA, depending upon whether the nucleotide sequence encodes a $\Delta 5$ - or $\Delta 6$ -desaturase. The invention also includes one or more plant oils or acids
30 expressed by the above plant cell, plant or plant tissue.

Additionally, the present invention also encompasses a transgenic plant comprising the above vector, wherein expression of the nucleotide sequence of the vector results in

production of a polyunsaturated fatty acid in seeds of the transgenic plant.

Also, the invention includes a mammalian cell comprising the above vector wherein expression of the nucleotide sequence of the vector results in production of altered levels of AA, EPA, GLA and/or STA when the cell is grown in a culture media comprising a fatty acid selected from the group consisting of, for example, LA, ALA, DGLA and ETA.

It should also be noted that the present invention encompasses a transgenic, non-human mammal whose genome comprises a DNA sequence encoding a $\Delta 5$ -desaturase or a $\Delta 6$ -desaturase, operably linked to a promoter or regulatory sequence. The DNA sequence may be represented by SEQ ID NO:13 ($\Delta 6$), SEQ ID NO:19 ($\Delta 5$), SEQ ID NO:28 ($\Delta 5$), SEQ ID NO:30 ($\Delta 5$), SEQ ID NO:32 ($\Delta 6$) and SEQ ID NO:34 ($\Delta 5$). Additionally, the present invention includes a fluid (e.g., milk) produced by the transgenic, non-human mammal wherein the fluid comprises a detectable level of at least $\Delta 5$ -desaturase or at least $\Delta 6$ -desaturase, as appropriate.

Additionally, the present invention includes a method (i.e., "first" method) for producing a polyunsaturated fatty acid comprising the steps of: a) isolating the nucleotide sequence represented by, for example, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30 or SEQ ID NO:34; b) constructing a vector comprising the isolated nucleotide sequence; c) introducing the vector into a host cell under time and conditions sufficient for expression of $\Delta 5$ -desaturase enzyme; and d) exposing the expressed human $\Delta 5$ -desaturase enzyme to a substrate polyunsaturated fatty acid in order to convert the substrate to a product polyunsaturated fatty acid. The substrate polyunsaturated fatty acid may be, for example, DGLA or $20:4n-3$ and the product polyunsaturated fatty acid may be, for example, AA or EPA, respectively. This method may further comprise the step of exposing the product polyunsaturated fatty acid to an

elongase or desaturase in order to convert the product polyunsaturated fatty acid to another polyunsaturated fatty acid (i.e., "second" method). In this method containing the additional step (i.e., "second" method), the product

5 polyunsaturated fatty acid may be, for example, AA or EPA, and the "another" polyunsaturated fatty acid may be adrenic acid or (n-3)-docosapentaenoic acid, respectively. The method containing the additional step may further comprise a step of exposing the another polyunsaturated fatty acid to an
10 additional desaturase or elongase in order to convert the another polyunsaturated fatty acid to a final polyunsaturated fatty acid (i.e., "third" method). The final polyunsaturated fatty acid may be, for example, (n-6)-docosapentaenoic acid or docosahexaenoic (DHA) acid.

15 Additionally, the present invention includes a method for producing a polyunsaturated fatty acid comprising the steps of:

a) isolating the nucleotide sequence represented by SEQ ID NO:13 or SEQ ID NO:33; b) constructing a vector comprising the isolated nucleotide sequence; c) introducing the vector into a

20 host cell for a time and under conditions sufficient for expression of $\Delta 6$ -desaturase enzyme; and d) exposing the expressed $\Delta 6$ -desaturase enzyme to a substrate polyunsaturated fatty acid in order to convert the substrate to a product polyunsaturated fatty acid. The substrate polyunsaturated

25 fatty acid may be, for example, LA or ALA, and the product polyunsaturated fatty acid may be, for example, GLA or STA, respectively. This method may further comprise the step of exposing the product polyunsaturated fatty acid to an elongase (or desaturase) in order to convert the product polyunsaturated
30 fatty acid to another polyunsaturated fatty acid. In this method containing the additional step, the product polyunsaturated fatty acid may be, for example, GLA or STA, and the "another" polyunsaturated fatty acid may be DGLA or eicosatetraenoic acid (ETA), respectively. The method

containing the additional step may further comprise a step of exposing the another polyunsaturated fatty acid to an additional desaturase (or elongase) in order to convert the another polyunsaturated fatty acid to a final polyunsaturated fatty acid. The final polyunsaturated fatty acid may be, for example, AA or EPA.

The present invention also encompasses a nutritional composition comprising at least one polyunsaturated fatty acid selected from the group consisting of the product polyunsaturated fatty acid produced according to the methods described above, the another polyunsaturated fatty acid produced according to the methods described above, and the final polyunsaturated fatty acid produced according to the methods described above. The product polyunsaturated fatty acid may be, for example, AA, EPA, GLA or STA, depending upon whether one is using a $\Delta 5$ - or $\Delta 6$ -desaturase nucleotide sequence. The another polyunsaturated fatty acid may be, for example, adrenic acid, (n-3)-docosapentaenoic acid, DGLA and EPA, again depending upon whether one is using a $\Delta 5$ - or $\Delta 6$ -desaturase nucleotide sequence. The final polyunsaturated fatty acid may be, for example, (n-6)-docosapentaenoic acid, DHA, AA or EPA, again, depending upon whether one is using a $\Delta 5$ - or $\Delta 6$ -desaturase nucleotide sequence.

The present invention also includes a pharmaceutical composition comprising 1) at least one polyunsaturated fatty acid (PUFA) selected from the group consisting of the "product" PUFA produced according to the methods described above, the "another" PUFA produced according to the methods described above, or the "final" PUFA produced according to the methods described above and 2) a pharmaceutically acceptable carrier.

Additionally, the present invention encompasses an animal feed or cosmetic comprising at least one PUFA selected from the group consisting of the product PUFA produced according to the methods described above, the another PUFA produced according to

the methods described above and the final PUFA produced according to the methods described above. These PUFAs have been listed above and are exemplified in Figure 1.

Additionally, the present invention encompasses a method
5 of preventing or treating a condition caused by insufficient intake of polyunsaturated fatty acids comprising administering to the patient the nutritional composition above in an amount sufficient to effect prevention or treatment.

It should also be noted that each nucleotide and amino
10 acid sequence referred to herein has been assigned a particular sequence identification number. The Sequence Listing (which is found herein) lists each such sequence and its corresponding number.

15 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates the fatty acid biosynthetic pathway and the roles of $\Delta 5$ -desaturase and $\Delta 6$ -desaturase in this pathway.

Figure 2 illustrates the nucleotide sequence encoding $\Delta 6$ -
20 desaturase of Saprolegnia diclina (ATCC 56851) (SEQ ID NO:13).

Figure 3 illustrates the amino acid sequence of $\Delta 6$ -desaturase of Saprolegnia diclina (ATCC 56851) (SEQ ID NO:14).

Figure 4 illustrates the nucleotide sequence encoding $\Delta 5$ -desaturase of Saprolegnia diclina (ATCC 56851) (SEQ ID NO:19).

25 Figure 5 illustrates the amino acid sequence of $\Delta 5$ -desaturase of Saprolegnia diclina (ATCC 56851) (SEQ ID NO:20).

Figure 6 illustrates the nucleotide sequence encoding $\Delta 5$ -desaturase of Thraustochytrium aureum (ATCC 34304) (SEQ ID NO:28).

30 Figure 7 illustrates the amino acid sequence of $\Delta 5$ -desaturase of Thraustochytrium aureum (ATCC 34304) (SEQ ID NO:29).

Figure 8 illustrates the nucleotide sequence encoding $\Delta 5$ -desaturase from Thraustochytrium aureum (BICC7091) (SEQ ID NO:30).

Figure 9 illustrates the translated amino acid sequence of $\Delta 5$ -desaturase from Thraustochytrium aureum (BICC7091) (SEQ ID NO:31).

Figure 10 illustrates the nucleotide sequence encoding $\Delta 6$ -desaturase from Thraustochytrium aureum (BICC7091) (SEQ ID NO:32).

Figure 11 illustrates the translated amino acid sequence of $\Delta 6$ -desaturase from Thraustochytrium aureum (BICC7091) (SEQ ID NO:33).

Figure 12 illustrates the $\Delta 5$ -desaturase amino acid sequence identity between pRAT-2a and pRAT-2c clones.

Figure 13 illustrates the $\Delta 6$ -desaturase amino acid sequence identity between pRAT-1a and pRAT-1b clones.

Figure 14 illustrates the nucleotide sequence encoding $\Delta 5$ -desaturase gene from Isochrysis galbana CCMP1323 (SEQ ID NO:34).

Figure 15 illustrates the translated amino acid sequence from $\Delta 5$ -desaturase from Isochrysis galbana CCMP1323 (SEQ ID NO:35).

DETAILED DESCRIPTION OF THE INVENTION

The subject invention relates to the nucleotide and translated amino acid sequences of a $\Delta 5$ -desaturase gene derived from Saprolegnia diclina, a $\Delta 6$ -desaturase gene derived from Saprolegnia diclina, two $\Delta 5$ -desaturase genes derived from Thraustochytrium aureum and a $\Delta 6$ -desaturase gene derived from Isochrysis galbana. Furthermore, the subject invention also includes uses of these genes and of the enzymes encoded by these genes. For example, the genes and corresponding enzymes

may be used in the production of polyunsaturated fatty acids such as, for instance, arachidonic acid, eicosapentaenoic acid, and/or adrenic acid which may be added to pharmaceutical compositions, nutritional compositions and to other valuable products.

The $\Delta 5$ -Desaturase Genes, The $\Delta 6$ -Desaturase Genes, and Enzymes Encoded Thereby

As noted above, the enzymes encoded by the $\Delta 5$ -desaturase genes and the $\Delta 6$ -desaturase genes of the present invention are essential in the production of highly unsaturated polyunsaturated fatty acids having a length greater than 20 and 18 carbons, respectively. The nucleotide sequence of the isolated Thraustochytrium aureum $\Delta 5$ -desaturase gene (ATCC 34304) is shown in Figure 6, and the amino acid sequence of the corresponding purified protein is shown in Figure 7. The nucleotide sequence of the isolated Saprolegnia diclina $\Delta 5$ -desaturase gene is shown in Figure 4, and the amino acid sequence of the corresponding purified protein is shown in Figure 5. The nucleotide sequence of the isolated Saprolegnia diclina $\Delta 6$ -desaturase gene is shown in Figure 2, and the amino acid sequence of the corresponding purified protein is shown in Figure 3. The nucleotide sequence of the isolated Thraustochytrium aureum (BICC7091) $\Delta 5$ -desaturase gene is shown in Figure 8, and the amino acid sequence of the corresponding purified protein is shown in Figure 9. The nucleotide sequence of the isolated Thraustochytrium aureum $\Delta 6$ -desaturase gene is shown in Figure 10, and the amino acid sequence of the corresponding purified protein is shown in Figure 11. Finally, the nucleotide sequence of the isolated Isochrysis galbana $\Delta 5$ -desaturase gene is shown in Figure 14, and the amino acid

sequence of the corresponding purified protein is shown in Figure 15.

As an example of the importance of the genes of the present invention, the isolated $\Delta 5$ -desaturase genes convert
5 DGLA to AA or convert eicosatetraenoic acid to EPA. AA, for example, cannot be synthesized without the $\Delta 5$ -desaturase genes and enzymes encoded thereby. The isolated $\Delta 6$ -desaturase gene of the present invention converts, for example, linoleic acid (18:2n-6) to γ -linoleic acid (GLA) and γ -linolenic acid (GLA) to
10 stearidonic acid (STA).

It should be noted that the present invention also encompasses nucleotide sequences (and the corresponding encoded proteins) having sequences comprising or complementary to at least about 50%, preferably at least about 60%, more preferably
15 at least about 70%, even more preferably at least about 80%, and most preferably at least about 90% of the nucleotides in sequence (i.e., having sequence identity) to SEQ ID NO:19 (i.e., the nucleotide sequence of the $\Delta 5$ -desaturase gene of Saprolegnia diclina), SEQ ID NO:13 (i.e., the nucleotide
20 sequence of the $\Delta 6$ -desaturase gene of Thraustochytrium aureum), SEQ ID NO:28 (i.e., the nucleotide sequence of the $\Delta 5$ -desaturase gene of Thraustochytrium aureum (ATCC 34304), SEQ ID NO:30 (i.e., the nucleotide sequence of the $\Delta 5$ -desaturase gene of Thraustochytrium aureum (BICC7091), SEQ ID NO:32 (i.e., $\Delta 6$ -
25 desaturase gene of Thraustochytrium aureum) and SEQ ID NO:34 (i.e., $\Delta 5$ -desaturase gene of Isochrysis galbana), described herein. (All integers between 50% and 100% are also considered to be within the scope of the present invention with respect to percent identity.) Such sequences may be derived from human
30 sources as well as other non-human sources (e.g., C. elegans or mouse).

Furthermore, the present invention also encompasses fragments and derivatives of the nucleotide sequences of the

present invention (i.e., SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32 and SEQ ID NO:34), as well as of the sequences derived from other sources, and having the above-described complementarity or correspondence. Functional equivalents of the above-sequences (i.e., sequences having $\Delta 5$ -desaturase activity or $\Delta 6$ -desaturase activity, as appropriate) are also encompassed by the present invention.

The invention also includes a purified polypeptide which desaturates polyunsaturated fatty acids at the carbon 5 position or carbon 6 position and has at least about 50% amino acid similarity or identity, preferably at least about 60% similarity or identity, more preferably at least about 70% similarity or identity, even more preferably at least about 80% similarity or identity, and most preferably at least about 90% similarity or identity to the amino acid sequences (i.e., SEQ ID NO:14 (shown in Figure 3), SEQ ID NO:20 (shown in Figure 5), SEQ ID NO:29 (shown in Figure 7), SEQ ID NO:31 (shown in Figure 9), SEQ ID NO:33 (shown in Figure 11) and SEQ ID NO:35 (shown in Figure 15)) of the above-noted proteins which are, in turn, encoded by the above-described nucleotide sequences. All integers between 50-100% similarity or identity are also included within the scope of the invention.

The term "identity" refers to the relatedness of two sequences on a nucleotide-by-nucleotide basis over a particular comparison window or segment. Thus, identity is defined as the degree of sameness, correspondence or equivalence between the same strands (either sense or antisense) of two DNA segments. "Percentage of sequence identity" is calculated by comparing two optimally aligned sequences over a particular region, determining the number of positions at which the identical base occurs in both sequence in order to yield the number of matched positions, dividing the number of such positions by the total number of positions in the segment being compared and multiplying the result by 100. Optimal alignment of sequences

may be conducted by the algorithm of Smith & Waterman, Appl. Math. 2:482 (1981), by the algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the method of Pearson & Lipman, Proc. Natl. Acad. Sci. (USA) 85:2444 (1988) and by computer
5 programs which implement the relevant algorithms (e.g., Clustal Macaw Pileup (<http://cmgm.stanford.edu/biochem218/11Multiple.pdf>; Higgins et al., CABIOS. 5L151-153 (1989)), FASTDB (Intelligenetics), BLAST (National Center for Biomedical Information; Altschul et al., Nucleic Acids Research
10 25:3389-3402 (1997)), PILEUP (Genetics Computer Group, Madison, WI) or GAP, BESTFIT, FASTA and TFASTA (Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, Madison, WI). (See U.S. Patent No. 5,912,120.)

For purposes of the present invention, "complementarity is
15 defined as the degree of relatedness between two DNA segments. It is determined by measuring the ability of the sense strand of one DNA segment to hybridize with the antisense strand of the other DNA segment, under appropriate conditions, to form a double helix. In the double helix, adenine appears in one
20 strand, thymine appears in the other strand. Similarly, wherever guanine is found in one strand, cytosine is found in the other. The greater the relatedness between the nucleotide sequences of two DNA segments, the greater the ability to form hybrid duplexes between the strands of the two DNA segments.

25 "Similarity" between two amino acid sequences is defined as the presence of a series of identical as well as conserved amino acid residues in both sequences. The higher the degree of similarity between two amino acid sequences, the higher the correspondence, sameness or equivalence of the two sequences.
30 ("Identity between two amino acid sequences is defined as the presence of a series of exactly alike or invariant amino acid residues in both sequences.) The definitions of "complementarity", "identity" and "similarity" are well known to those of ordinary skill in the art.

"Encoded by" refers to a nucleic acid sequence which codes for a polypeptide sequence, wherein the polypeptide sequence or a portion thereof contains an amino acid sequence of at least 3 amino acids, more preferably at least 8 amino acids, and even
5 more preferably at least 15 amino acids from a polypeptide encoded by the nucleic acid sequence.

The present invention also encompasses an isolated nucleotide sequence which encodes PUFA desaturase activity and that is hybridizable, under moderately stringent conditions, to
10 a nucleic acid having a nucleotide sequence comprising or complementary to the nucleotide sequence comprising SEQ ID NO:13 (shown in Figure 2), SEQ ID NO:19 (shown in Figure 4), SEQ ID NO:28 (shown in Figure 6), SEQ ID NO:30 (shown in Figure 8), SEQ ID NO:32 (shown in Figure 10) or SEQ ID NO:34 (shown in
15 Figure 14) . A nucleic acid molecule is "hybridizable" to another nucleic acid molecule when a single-stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and ionic strength (see Sambrook et al., "Molecular Cloning: A
20 Laboratory Manual, Second Edition (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York)). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. "Hybridization" requires that two nucleic acids contain complementary sequences.
25 However, depending on the stringency of the hybridization, mismatches between bases may occur. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation. Such variables are well known in the art. More specifically, the
30 greater the degree of similarity or homology between two nucleotide sequences, the greater the value of T_m for hybrids of nucleic acids having those sequences. For hybrids of

greater than 100 nucleotides in length, equations for calculating T_m have been derived (see Sambrook et al., *supra*). For hybridization with shorter nucleic acids, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (see Sambrook et al., *supra*).

As used herein, an "isolated nucleic acid fragment or sequence" is a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. An isolated nucleic acid fragment in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA. (A "fragment" of a specified polynucleotide refers to a polynucleotide sequence which comprises a contiguous sequence of approximately at least about 6 nucleotides, preferably at least about 8 nucleotides, more preferably at least about 10 nucleotides, and even more preferably at least about 15 nucleotides, and most preferable at least about 25 nucleotides identical or complementary to a region of the specified nucleotide sequence.) Nucleotides (usually found in their 5'-monophosphate form) are referred to by their single letter designation as follows: "A" for adenylate or deoxyadenylate (for RNA or DNA, respectively), "C" for cytidylate or deoxycytidylate, "G" for guanylate or deoxyguanylate, "U" for uridylate, "T" for deoxythymidylate, "R" for purines (A or G), "Y" for pyrimidines (C or T), "K" for G or T, "H" for A or C or T, "I" for inosine, and "N" for any nucleotide.

The terms "fragment or subfragment that is functionally equivalent" and "functionally equivalent fragment or subfragment" are used interchangeably herein. These terms refer to a portion or subsequence of an isolated nucleic acid

fragment in which the ability to alter gene expression or produce a certain phenotype is retained whether or not the fragment or subfragment encodes an active enzyme. For example, the fragment or subfragment can be used in the design of
5 chimeric constructs to produce the desired phenotype in a transformed plant. Chimeric constructs can be designed for use in co-suppression or antisense by linking a nucleic acid fragment or subfragment thereof, whether or not it encodes an active enzyme, in the appropriate orientation relative to a
10 plant promoter sequence.

The terms ``homology'', ``homologous'', ``substantially similar'' and ``corresponding substantially'' are used interchangeably herein. They refer to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect
15 the ability of the nucleic acid fragment to mediate gene expression or produce a certain phenotype. These terms also refer to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially alter the functional
20 properties of the resulting nucleic acid fragment relative to the initial, unmodified fragment. It is therefore understood, as those skilled in the art will appreciate, that the invention encompasses more than the specific exemplary sequences.

``Gene'' refers to a nucleic acid fragment that expresses
25 a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence.

``Native gene'' refers to a gene as found in nature with its own regulatory sequences. In contrast, ``chimeric
30 construct'' refers to a combination of nucleic acid fragments that are not normally found together in nature. Accordingly, a chimeric construct may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same
35 source, but arranged in a manner different than that normally

found in nature. (The term ``isolated'' means that the sequence is removed from its natural environment.)

A ``foreign'' gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric constructs. A ``transgene'' is a gene that has been introduced into the genome by a transformation procedure.

``Coding sequence'' refers to a DNA sequence that codes for a specific amino acid sequence. ``Regulatory sequences'' refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include, but are not limited to, promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

``Promoter'' refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an ``enhancer'' is a DNA sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoter sequences can also be located within the transcribed portions of genes, and/or downstream of the transcribed sequences. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a gene to be expressed in most cell types at most times are commonly referred to as ``constitutive promoters''. New promoters of various types useful in plant cells are constantly being discovered; numerous

examples may be found in the compilation by Okamuro and Goldberg, (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of some variation may have identical promoter activity.

An ``intron'' is an intervening sequence in a gene that does not encode a portion of the protein sequence. Thus, such sequences are transcribed into RNA but are then excised and are not translated. The term is also used for the excised RNA sequences. An ``exon'' is a portion of the sequence of a gene that is transcribed and is found in the mature messenger RNA derived from the gene, but is not necessarily a part of the sequence that encodes the final gene product.

The ``translation leader sequence'' refers to a DNA sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner, R. and Foster, G. D. (1995) *Molecular Biotechnology* 3:225).

The ``3' non-coding sequences'' refer to DNA sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al., (1989) *Plant Cell* 1:671-680.

``RNA transcript'' refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from post-transcriptional processing of the primary transcript and is referred to as the mature RNA.

``Messenger RNA (mRNA)'' refers to the RNA that is without introns and that can be translated into protein by the cell.

``cDNA'' refers to a DNA that is complementary to and synthesized from a mRNA template using the enzyme reverse transcriptase. The cDNA can be single-stranded or converted into the double-stranded form using the Klenow fragment of DNA polymerase I. ``Sense'' RNA refers to RNA transcript that includes the mRNA and can be translated into protein within a cell or *in vitro*. ``Antisense RNA'' refers to an RNA

transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (U.S. Patent No. 5,107,065). The complementarity of an antisense RNA may be with any part of the specific gene transcript, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. ``Functional RNA'' refers to antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes. The terms ``complement'' and ``reverse complement'' are used interchangeably herein with respect to mRNA transcripts, and are meant to define the antisense RNA of the message.

The term ``endogenous RNA'' refers to any RNA which is encoded by any nucleic acid sequence present in the genome of the host prior to transformation with the recombinant construct of the present invention, whether naturally-occurring or non-naturally occurring, i.e., introduced by recombinant means, mutagenesis, etc.

The term ``non-naturally occurring'' means artificial, not consistent with what is normally found in nature.

The term ``operably linked'' refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is regulated by the other. For example, a promoter is operably linked with a coding sequence when it is capable of regulating the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in a sense or antisense orientation. In another example, the complementary RNA regions of the invention can be operably linked, either

directly or indirectly, 5' to the target mRNA, or 3' to the target mRNA, or within the target mRNA, or a first complementary region is 5' and its complement is 3' to the target mRNA.

5 The term "expression", as used herein, refers to the production of a functional end-product. Expression of a gene involves transcription of the gene and translation of the mRNA into a precursor or mature protein. "Antisense inhibition" refers to the production of antisense RNA transcripts capable
10 of suppressing the expression of the target protein. "Co-suppression" refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Patent No. 5,231,020).

15 "Mature" protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. "Precursor" protein refers to the primary product of translation of mRNA; i.e., with pre- and propeptides
20 still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

 "Stable transformation" refers to the transfer of a nucleic acid fragment into a genome of a host organism, including both nuclear and organellar genomes, resulting in
25 genetically stable inheritance. In contrast, "transient transformation" refers to the transfer of a nucleic acid fragment into the nucleus, or DNA-containing organelle, of a host organism resulting in gene expression without integration or stable inheritance. Host organisms containing the
30 transformed nucleic acid fragments are referred to as "transgenic" organisms. The preferred method of cell transformation of rice, corn and other monocots is the use of particle-accelerated or "gene gun" transformation technology (Klein et al., (1987) *Nature (London)* 327:70-73; U.S. Patent
35 No. 4,945,050), or an *Agrobacterium*-mediated method using an appropriate Ti plasmid containing the transgene (Ishida Y. et al., 1996, *Nature Biotech.* 14:745-750). The term

``transformation'' as used herein refers to both stable transformation and transient transformation.

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook, J., Fritsch, E.F. and Maniatis, T. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter ``Sambrook``).

The term ``recombinant'' refers to an artificial combination of two otherwise separated segments of sequence, e.g., by chemical synthesis or by the manipulation of isolated segments of nucleic acids by genetic engineering techniques.

``PCR'' or ``Polymerase Chain Reaction'' is a technique for the synthesis of large quantities of specific DNA segments, consists of a series of repetitive cycles (Perkin Elmer Cetus Instruments, Norwalk, CT). Typically, the double stranded DNA is heat denatured, the two primers complementary to the 3' boundaries of the target segment are annealed at low temperature and then extended at an intermediate temperature. One set of these three consecutive steps is referred to as a cycle.

Polymerase chain reaction (``PCR'') is a powerful technique used to amplify DNA millions of fold, by repeated replication of a template, in a short period of time. (Mullis et al, *Cold Spring Harbor Symp. Quant. Biol.* 51:263-273 (1986); Erlich et al, European Patent Application 50,424; European Patent Application 84,796; European Patent Application 258,017, European Patent Application 237,362; Mullis, European Patent Application 201,184, Mullis et al U.S. Patent No. 4,683,202; Erlich, U.S. Patent No. 4,582,788; and Saiki et al, U.S. Patent No. 4,683,194). The process utilizes sets of specific in vitro synthesized oligonucleotides to prime DNA synthesis. The design of the primers is dependent upon the sequences of DNA that are desired to be analyzed. The technique is carried out through many cycles (usually 20-50) of melting the template at high temperature, allowing the primers to anneal to complementary sequences within the template and then replicating the template with DNA polymerase.

The products of PCR reactions are analyzed by separation in agarose gels followed by ethidium bromide staining and visualization with UV transillumination. Alternatively, radioactive dNTPs can be added to the PCR in order to incorporate label into the products. In this case the products of PCR are visualized by exposure of the gel to x-ray film. The added advantage of radiolabeling PCR products is that the levels of individual amplification products can be quantitated.

The terms "recombinant construct", "expression construct" and "recombinant expression construct" are used interchangeably herein. These terms refer to a functional unit of genetic material that can be inserted into the genome of a cell using standard methodology well known to one skilled in the art. Such construct may be itself or may be used in conjunction with a vector. If a vector is used then the choice of vector is dependent upon the method that will be used to transform host plants as is well known to those skilled in the art. For example, a plasmid vector can be used. The skilled artisan is well aware of the genetic elements that must be present on the vector in order to successfully transform, select and propagate host cells comprising any of the isolated nucleic acid fragments of the invention. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al., (1985) *EMBO J.* 4:2411-2418; De Almeida et al., (1989) *Mol. Gen. Genetics* 218:78-86), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

Production of the $\Delta 5$ -Desaturase Enzymes and the $\Delta 6$ -Desaturase Enzymes

Once the gene encoding any one of the desaturase enzymes has been isolated, it may then be introduced into either a prokaryotic or eukaryotic host cell through the use of a vector

or construct. The vector, for example, a bacteriophage, cosmid or plasmid, may comprise the nucleotide sequence encoding either of the $\Delta 5$ -desaturase enzymes, or the $\Delta 6$ -desaturase enzyme, as well as any regulatory sequence (e.g., promoter) which is functional in the host cell and is able to elicit expression of the desaturase encoded by the nucleotide sequence. The regulatory sequence is in operable association with or operably linked to the nucleotide sequence. (As noted above, regulatory is said to be "operably linked" with a coding sequence if the regulatory sequence affects transcription or expression of the coding sequence.) Suitable promoters include, for example, those from genes encoding alcohol dehydrogenase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglucosomerase, phosphoglycerate kinase, acid phosphatase, T7, TPI, lactase, metallothionein, cytomegalovirus immediate early, whey acidic protein, glucoamylase, and promoters activated in the presence of galactose, for example, GAL1 and GAL10. Additionally, nucleotide sequences which encode other proteins, oligosaccharides, lipids, etc. may also be included within the vector as well as other regulatory sequences such as a polyadenylation signal (e.g., the poly-A signal of SV-40T-antigen, ovalalbumin or bovine growth hormone). The choice of sequences present in the construct is dependent upon the desired expression products as well as the nature of the host cell.

As noted above, once the vector has been constructed, it may then be introduced into the host cell of choice by methods known to those of ordinary skill in the art including, for example, transfection, transformation and electroporation (see Molecular Cloning: A Laboratory Manual, 2nd ed., Vol. 1-3, ed. Sambrook et al., Cold Spring Harbor Laboratory Press (1989)).

The host cell is then cultured under suitable conditions permitting expression of the genes leading to the production of the desired PUFA, which is then recovered and purified.

Examples of suitable prokaryotic host cells include, for example, bacteria such as Escherichia coli, Bacillus subtilis as well as cyanobacteria such as Spirulina spp. (i.e., blue-green algae). Examples of suitable eukaryotic host cells include, for example, mammalian cells, plant cells, yeast cells such as Saccharomyces cerevisiae, Saccharomyces carlsbergensis,
10 Lipomyces starkey, Candida spp. such as Yarrowia (Candida) lipolytica, Kluyveromyces spp., Pichia spp., Trichoderma spp. or Hansenula spp., or fungal cells such as filamentous fungal cells, for example, Aspergillus, Neurospora and Penicillium. Preferably, Saccharomyces cerevisiae (baker's yeast) cells are
15 utilized.

Expression in a host cell can be accomplished in a transient or stable fashion. Transient expression can occur from introduced constructs which contain expression signals functional in the host cell, but which constructs do not
20 replicate and rarely integrate in the host cell, or where the host cell is not proliferating. Transient expression also can be accomplished by inducing the activity of a regulatable promoter operably linked to the gene of interest, although such inducible systems frequently exhibit a low basal level of
25 expression. Stable expression can be achieved by introduction of a construct that can integrate into the host genome or that autonomously replicates in the host cell. Stable expression of the gene of interest can be selected for through the use of a selectable marker located on or transfected with the expression
30 construct, followed by selection for cells expressing the marker. When stable expression results from integration, the site of the construct's integration can occur randomly within

the host genome or can be targeted through the use of constructs containing regions of homology with the host genome sufficient to target recombination with the host locus. Where constructs are targeted to an endogenous locus, all or some of the transcriptional and translational regulatory regions can be provided by the endogenous locus.

A transgenic mammal may also be used in order to express the enzyme(s) of interest (i.e., one or more of the $\Delta 5$ -desaturases, one or more of the $\Delta 6$ -desaturases, or a combination thereof), and ultimately the PUFA(s) of interest. More specifically, once the above-described construct is created, it may be inserted into the pronucleus of an embryo. The embryo may then be implanted into a recipient female. Alternatively, a nuclear transfer method could also be utilized (Schnieke et al., Science 278:2130-2133 (1997)). Gestation and birth are then permitted (see, e.g., U.S. Patent No. 5,750,176 and U.S. Patent No. 5,700,671). Milk, tissue or other fluid samples from the offspring should then contain altered levels of PUFAs, as compared to the levels normally found in the non-transgenic animal. Subsequent generations may be monitored for production of the altered or enhanced levels of PUFAs and thus incorporation of the gene encoding the desired desaturase enzyme into their genomes. The mammal utilized as the host may be selected from the group consisting of, for example, a mouse, a rat, a rabbit, a pig, a goat, a sheep, a horse and a cow. However, any mammal may be used provided it has the ability to incorporate DNA encoding the enzyme of interest into its genome.

For expression of a desaturase polypeptide, functional transcriptional and translational initiation and termination regions are operably linked to the DNA encoding the desaturase

polypeptide. Transcriptional and translational initiation and termination regions are derived from a variety of nonexclusive sources, including the DNA to be expressed, genes known or suspected to be capable of expression in the desired system, 5 expression vectors, chemical synthesis, or from an endogenous locus in a host cell. Expression in a plant tissue and/or plant part presents certain efficiencies, particularly where the tissue or part is one which is harvested early, such as seed, leaves, fruits, flowers, roots, etc. Expression can be 10 targeted to that location with the plant by utilizing specific regulatory sequence such as those of U.S. Patent Nos. 5,463,174, 4,943,674, 5,106,739, 5,175,095, 5,420,034, 5,188,958, and 5,589,379. Alternatively, the expressed protein can be an enzyme which produces a product which may be 15 incorporated, either directly or upon further modifications, into a fluid fraction from the host plant. Expression of a desaturase gene, or antisense desaturase transcripts, can alter the levels of specific PUFAs, or derivatives thereof, found in plant parts and/or plant tissues. The desaturase polypeptide 20 coding region may be expressed either by itself or with other genes, in order to produce tissues and/or plant parts containing higher proportions of desired PUFAs or in which the PUFA composition more closely resembles that of human breast milk (Prieto et al., PCT publication WO 95/24494). The 25 termination region may be derived from the 3' region of the gene from which the initiation region was obtained or from a different gene. A large number of termination regions are known to and have been found to be satisfactory in a variety of hosts from the same and different genera and species. The 30 termination region usually is selected as a matter of convenience rather than because of any particular property.

As noted above, a plant (e.g., Glycine max (soybean) or Brassica napus (canola)) or plant tissue may also be utilized as a host or host cell, respectively, for expression of the desaturase enzyme which may, in turn, be utilized in the production of polyunsaturated fatty acids. More specifically, desired PUFAS can be expressed in seed. Methods of isolating seed oils are known in the art. Thus, in addition to providing a source for PUFAs, seed oil components may be manipulated through the expression of the desaturase gene, as well as perhaps other desaturase genes and elongase genes, in order to provide seed oils that can be added to nutritional compositions, pharmaceutical compositions, animal feeds and cosmetics. Once again, a vector which comprises a DNA sequence encoding the desaturase operably linked to a promoter, will be introduced into the plant tissue or plant for a time and under conditions sufficient for expression of the desaturase gene. The vector may also comprise one or more genes that encode other enzymes, for example, $\Delta 4$ -desaturase, elongase, $\Delta 12$ -desaturase, $\Delta 15$ -desaturase, $\Delta 17$ -desaturase, and/or $\Delta 19$ -desaturase. The plant tissue or plant may produce the relevant substrate (e.g., DGLA (in the case of $\Delta 5$ -desaturase), ALA (in the case of $\Delta 6$ -desaturase), etc.) upon which the enzymes act or a vector encoding enzymes which produce such substrates may be introduced into the plant tissue, plant cell or plant. In addition, substrate may be sprayed on plant tissues expressing the appropriate enzymes. Using these various techniques, one may produce PUFAs (e.g., n-6 unsaturated fatty acids such as AA, or n-3 fatty acids such as EPA or STA) by use of a plant cell, plant tissue or plant. It should also be noted that the invention also encompasses a transgenic plant comprising the above-described vector, wherein expression of the nucleotide

sequence of the vector results in production of a polyunsaturated fatty acid in, for example, the seeds of the transgenic plant.

The regeneration, development, and cultivation of plants from single plant protoplast transformants or from various transformed explants is well known in the art (Weissbach and Weissbach, In: Methods for Plant Molecular Biology, (Eds.), Academic Press, Inc. San Diego, CA, (1988)). This regeneration and growth process typically includes the steps of selection of transformed cells, culturing those individualized cells through the usual stages of embryonic development through the rooted plantlet stage. Transgenic embryos and seeds are similarly regenerated. The resulting transgenic rooted shoots are thereafter planted in an appropriate plant growth medium such as soil.

The development or regeneration of plants containing the foreign, exogenous gene that encodes a protein of interest is well known in the art. Preferably, the regenerated plants are self-pollinated to provide homozygous transgenic plants. Otherwise, pollen obtained from the regenerated plants is crossed to seed-grown plants of agronomically important lines. Conversely, pollen from plants of these important lines is used to pollinate regenerated plants. A transgenic plant of the present invention containing a desired polypeptide is cultivated using methods well known to one skilled in the art.

There are a variety of methods for the regeneration of plants from plant tissue. The particular method of regeneration will depend on the starting plant tissue and the particular plant species to be regenerated.

Methods for transforming dicots, primarily by use of *Agrobacterium tumefaciens*, and obtaining transgenic plants have been published for cotton (U.S. Patent No. 5,004,863, U.S. Patent No. 5,159,135, U.S. Patent No. 5,518, 908); soybean (U.S. Patent No. 5,569,834, U.S. Patent No. 5,416,011, McCabe et. al., *BiolTechnology* 6:923 (1988), Christou et al., *Plant Physiol.* 87:671-674 (1988)); *Brassica* (U.S. Patent No. 5,463,174); peanut (Cheng et al., *Plant Cell Rep.*

15:653-657 (1996), McKently et al., *Plant Cell Rep.* 14:699-703 (1995)); papaya; and pea (Grant et al., *Plant Cell Rep.* 15:254-258, (1995)).

Transformation of monocotyledons using electroporation, particle bombardment, and *Agrobacterium* have also been reported. Transformation and plant regeneration have been achieved in asparagus (Bytebier et al., *Proc. Natl. Acad. Sci. (USA)* 84:5354, (1987)); barley (Wan and Lemaux, *Plant Physiol* 104:37 (1994)); *Zea mays* (Rhodes et al., *Science* 240:204 (1988), Gordon-Kamm et al., *Plant Cell* 2:603-618 (1990), Fromm et al., *BiolTechnology* 8:833 (1990), Koziel et al., *BiolTechnology* 11: 194, (1993), Armstrong et al., *Crop Science* 35:550-557 (1995)); oat (Somers et al., *BiolTechnology* 10: 15 89 (1992)); orchard grass (Horn et al., *Plant Cell Rep.* 7:469 (1988)); rice (Toriyama et al., *TheorAppl. Genet.* 205:34, (1986); Part et al., *Plant Mol. Biol.* 32:1135-1148, (1996); Abedinia et al., *Aust. J. Plant Physiol.* 24:133-141 (1997); Zhang and Wu, *Theor. Appl. Genet.* 76:835 (1988); Zhang et al. *Plant Cell Rep.* 7:379, (1988); Battraw and Hall, *Plant Sci.* 20 86:191-202 (1992); Christou et al., *Bio/Technology* 9:957 (1991)); rye (De la Pena et al., *Nature* 325:274 (1987)); sugarcane (Bower and Birch, *Plant J.* 2:409 (1992)); tall fescue (Wang et al., *BiolTechnology* 10:691 (1992)), and wheat (Vasil et al., *Bio/Technology* 10:667 (1992); U.S. Patent 25 No. 5,631,152).

Assays for gene expression based on the transient expression of cloned nucleic acid constructs have been developed by introducing the nucleic acid molecules into plant cells by polyethylene glycol treatment, electroporation, or particle bombardment (Marcotte et al., *Nature* 335:454-457 (1988); Marcotte et al., *Plant Cell* 1:523-532 (1989); McCarty et al., *Cell* 66:895-905 (1991); Hattori et al., *Genes Dev.* 6:609-618 (1992); Goff et al., *EMBO J.* 9:2517-2522 (1990)).

Transient expression systems may be used to functionally dissect gene constructs (see generally, Maliga et al., *Methods in Plant Molecular Biology*, Cold Spring Harbor Press (1995)).

It is understood that any of the nucleic acid molecules of the present invention can be introduced into a plant cell in a permanent or transient manner in combination with other genetic elements such as vectors, promoters, enhancers etc.

5 In addition to the above discussed procedures, practitioners are familiar with the standard resource materials which describe specific conditions and procedures for the construction, manipulation and isolation of macromolecules (e.g., DNA molecules, plasmids, etc.), generation of
10 recombinant organisms and the screening and isolating of clones, (see for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989); Maliga et al., Methods in Plant Molecular Biology, Cold Spring Harbor Press (1995); Birren et al., Genome Analysis: Detecting Genes,
15 1, Cold Spring Harbor, New York (1998); Birren et al., Genome Analysis: Analyzing DNA, 2, Cold Spring Harbor, New York (1998); Plant Molecular Biology: A Laboratory Manual, eds. Clark, Springer, New York (1997)).

20 The substrates which may be produced by the host cell either naturally or transgenically, as well as the enzymes which may be encoded by DNA sequences present in the vector which is subsequently introduced into the host cell, are shown in Figure 1.

25 In view of the above, the present invention encompasses a method of producing the desaturase enzymes (i.e., $\Delta 5$ or $\Delta 6$) comprising the steps of: 1) isolating the nucleotide sequence of the gene encoding the desaturase enzyme; 2) constructing a vector comprising said nucleotide sequence; and 3) introducing said vector into a host cell under time and conditions
30 sufficient for the production of the desaturase enzyme.

 The present invention also encompasses a method of producing polyunsaturated fatty acids comprising exposing an

acid to the enzyme such that the desaturase converts the acid to a polyunsaturated fatty acid. For example, when 20:3n-6 is exposed to a $\Delta 5$ -desaturase enzyme, it is converted to AA. AA may then be exposed to elongase which elongates the AA to
5 adrenic acid (i.e., 22:4n-6). Alternatively, $\Delta 5$ -desaturase may be utilized to convert 20:4n-3 to 20:5n-3 which may be exposed to elongase and converted to (n-3)-docosapentaenoic acid. The (n-3)-docosapentaenoic acid may then be converted to DHA by use of $\Delta 4$ -desaturase. Thus, $\Delta 5$ -desaturase may be used in the
10 production of polyunsaturated fatty acids which may be used, in turn, for particular beneficial purposes.

With respect to the role of $\Delta 6$ -desaturase, linoleic acid may be exposed to the enzyme such that the enzyme converts the acid to GLA. An elongase may then be used to convert the GLA
15 to DGLA. The DGLA then may be converted to AA by exposing the DGLA to a $\Delta 5$ -desaturase. As another example, ALA may be exposed to a $\Delta 6$ -desaturase in order to convert the ALA to STA. The STA may then be converted to 20:4n-3 by using an elongase. Subsequently, the 20:4n-3 may be converted to EPA by exposing
20 the 20:4n-3 to a $\Delta 5$ -desaturase. Thus, the $\Delta 6$ -desaturase may be used in the production of PUFAs which have many advantageous properties or may be used in the production of other PUFAs.

25 Uses of the $\Delta 5$ -Desaturases Genes, the $\Delta 6$ -Desaturase Genes, and Enzymes Encoded Thereby

As noted above, the isolated desaturase genes and the desaturase enzymes encoded thereby have many uses. For example, the gene and corresponding enzyme may be used
30 indirectly or directly in the production of polyunsaturated fatty acids, for example, $\Delta 5$ -desaturase may be used in the

production of AA, adrenic acid or EPA. Delta-6 desaturase may be used either indirectly or directly in the production of GLA, DGLA, STA or 20:4n-3. ("Directly" is meant to encompass the situation where the enzyme directly converts the acid to
5 another acid, the latter of which is utilized in a composition (e.g., the conversion of DGLA to AA). "Indirectly" is meant to encompass the situation where an acid is converted to another acid (i.e., a pathway intermediate) by the desaturase (e.g., DGLA to AA) and then the latter acid is converted to
10 another acid by use of a non-desaturase enzyme (e.g., AA to adrenic acid by elongase or by use of another desaturase enzyme (e.g., AA to EPA by $\Delta 17$ -desaturase.)). These polyunsaturated fatty acids (i.e., those produced either directly or indirectly by activity of the desaturase enzyme) may be added to, for
15 example, nutritional compositions, pharmaceutical compositions, cosmetics, and animal feeds, all of which are encompassed by the present invention. These uses are described, in detail, below.

20 Nutritional Compositions

The present invention includes nutritional compositions. Such compositions, for purposes of the present invention, include any food or preparation for human consumption including for enteral or parenteral consumption, which when taken into
25 the body (a) serve to nourish or build up tissues or supply energy and/or (b) maintain, restore or support adequate nutritional status or metabolic function.

The nutritional composition of the present invention comprises at least one oil or acid produced directly or
30 indirectly by use of the desaturase gene, in accordance with the present invention, and may either be in a solid or liquid form. Additionally, the composition may include edible

macronutrients, vitamins and minerals in amounts desired for a particular use. The amount of such ingredients will vary depending on whether the composition is intended for use with normal, healthy infants, children or adults having specialized
5 needs such as those which accompany certain metabolic conditions (e.g., metabolic disorders).

Examples of macronutrients which may be added to the composition include but are not limited to edible fats, carbohydrates and proteins. Examples of such edible fats
10 include but are not limited to coconut oil, soy oil, and mono- and diglycerides. Examples of such carbohydrates include but are not limited to glucose, edible lactose and hydrolyzed starch. Additionally, examples of proteins which may be utilized in the nutritional composition of the invention
15 include but are not limited to soy proteins, electrodialysed whey, electrodialysed skim milk, milk whey, or the hydrolysates of these proteins.

With respect to vitamins and minerals, the following may be added to the nutritional compositions of the present
20 invention: calcium, phosphorus, potassium, sodium, chloride, magnesium, manganese, iron, copper, zinc, selenium, iodine, and Vitamins A, E, D, C, and the B complex. Other such vitamins and minerals may also be added.

The components utilized in the nutritional compositions of
25 the present invention will be of semi-purified or purified origin. By semi-purified or purified is meant a material which has been prepared by purification of a natural material or by synthesis.

Examples of nutritional compositions of the present
30 invention include but are not limited to infant formulas, dietary supplements, dietary substitutes, and rehydration compositions. Nutritional compositions of particular interest

include but are not limited to those utilized for enteral and parenteral supplementation for infants, specialist infant formulas, supplements for the elderly, and supplements for those with gastrointestinal difficulties and/or malabsorption.

5 The nutritional composition of the present invention may also be added to food even when supplementation of the diet is not required. For example, the composition may be added to food of any type including but not limited to margarines, modified butters, cheeses, milk, yogurt, chocolate, candy,
10 snacks, salad oils, cooking oils, cooking fats, meats, fish and beverages.

 In a preferred embodiment of the present invention, the nutritional composition is an enteral nutritional product, more preferably, an adult or pediatric enteral nutritional product.
15 This composition may be administered to adults or children experiencing stress or having specialized needs due to chronic or acute disease states. The composition may comprise, in addition to polyunsaturated fatty acids produced in accordance with the present invention, macronutrients, vitamins and
20 minerals as described above. The macronutrients may be present in amounts equivalent to those present in human milk or on an energy basis, i.e., on a per calorie basis.

 Methods for formulating liquid or solid enteral and parenteral nutritional formulas are well known in the art.
25 (See also the Examples below.)

 The enteral formula, for example, may be sterilized and subsequently utilized on a ready-to-feed (RTF) basis or stored in a concentrated liquid or powder. The powder can be prepared by spray drying the formula prepared as indicated above, and
30 reconstituting it by rehydrating the concentrate. Adult and pediatric nutritional formulas are well known in the art and are commercially available (e.g., Similac®, Ensure®, Jevity®

and Alimentum® from Ross Products Division, Abbott Laboratories, Columbus, Ohio). An oil or acid produced in accordance with the present invention may be added to any of these formulas.

5 The energy density of the nutritional compositions of the present invention, when in liquid form, may range from about 0.6 Kcal to about 3 Kcal per ml. When in solid or powdered form, the nutritional supplements may contain from about 1.2 to more than 9 Kcals per gram, preferably about 3 to 7 Kcals per
10 gm. In general, the osmolality of a liquid product should be less than 700 mOsm and, more preferably, less than 660 mOsm.

 The nutritional formula may include macronutrients, vitamins, and minerals, as noted above, in addition to the PUFAs produced in accordance with the present invention. The
15 presence of these additional components helps the individual ingest the minimum daily requirements of these elements. In addition to the provision of PUFAs, it may also be desirable to add zinc, copper, folic acid and antioxidants to the composition. It is believed that these substance boost a
20 stressed immune system and will therefore provide further benefits to the individual receiving the composition. A pharmaceutical composition may also be supplemented with these elements.

 In a more preferred embodiment, the nutritional
25 composition comprises, in addition to antioxidants and at least one PUFA, a source of carbohydrate wherein at least 5 weight percent of the carbohydrate is indigestible oligosaccharide. In a more preferred embodiment, the nutritional composition additionally comprises protein, taurine, and carnitine.

30 As noted above, the PUFAs produced in accordance with the present invention, or derivatives thereof, may be added to a dietary substitute or supplement, particularly an infant

formula, for patients undergoing intravenous feeding or for preventing or treating malnutrition or other conditions or disease states. As background, it should be noted that human breast milk has a fatty acid profile comprising from about
5 0.15% to about 0.36% as DHA, from about 0.03% to about 0.13% as EPA, from about 0.30% to about 0.88% as AA, from about 0.22% to about 0.67% as DGLA, and from about 0.27% to about 1.04% as GLA. Thus, fatty acids such as AA, EPA and/or docosahexaenoic acid (DHA), produced in accordance with the present invention,
10 can be used to alter, for example, the composition of infant formulas in order to better replicate the PUFA content of human breast milk or to alter the presence of PUFAs normally found in a non-human mammal's milk. In particular, a composition for use in a pharmacologic or food supplement, particularly a
15 breast milk substitute or supplement, will preferably comprise one or more of AA, DGLA and GLA. More preferably, the oil will comprise from about 0.3 to 30% AA, from about 0.2 to 30% DGLA, and/or from about 0.2 to about 30% GLA.

Parenteral nutritional compositions comprising from about
20 2 to about 30 weight percent fatty acids calculated as triglycerides are encompassed by the present invention. The preferred composition has about 1 to about 25 weight percent of the total PUFA composition as GLA (U.S. Patent No. 5,196,198). Other vitamins, particularly fat-soluble vitamins such as
25 vitamin A, D, E and L-carnitine can optionally be included. When desired, a preservative such as alpha-tocopherol may be added in an amount of about 0.1% by weight.

In addition, the ratios of AA, DGLA and GLA can be adapted for a particular given end use. When formulated as a breast
30 milk supplement or substitute, a composition which comprises one or more of AA, DGLA and GLA will be provided in a ratio of about 1:19:30 to about 6:1:0.2, respectively. For example, the

breast milk of animals can vary in ratios of AA:DGLA:GLA ranging from 1:19:30 to 6:1:0.2, which includes intermediate ratios which are preferably about 1:1:1, 1:2:1, 1:1:4. When produced together in a host cell, adjusting the rate and percent of conversion of a precursor substrate such as GLA and DGLA to AA can be used to precisely control the PUFA ratios. For example, a 5% to 10% conversion rate of DGLA to AA can be used to produce an AA to DGLA ratio of about 1:19, whereas a conversion rate of about 75% TO 80% can be used to produce an AA to DGLA ratio of about 6:1. Therefore, whether in a cell culture system or in a host animal, regulating the timing, extent and specificity of desaturase expression, as well as the expression of other desaturases and elongases, can be used to modulate PUFA levels and ratios. The PUFAs/acids produced in accordance with the present invention (e.g., AA and EPA) may then be combined with other PUFAs/acids (e.g., GLA) in the desired concentrations and ratios.

Additionally, PUFA produced in accordance with the present invention or host cells containing them may also be used as animal food supplements to alter an animal's tissue or milk fatty acid composition to one more desirable for human or animal consumption.

Pharmaceutical Compositions

The present invention also encompasses a pharmaceutical composition comprising one or more of the acids and/or resulting oils produced using the desaturase genes described herein, in accordance with the methods described herein. More specifically, such a pharmaceutical composition may comprise one or more of the acids and/or oils as well as a standard, well-known, non-toxic pharmaceutically acceptable carrier, adjuvant or vehicle such as, for example, phosphate buffered saline, water, ethanol, polyols, vegetable oils, a wetting

agent or an emulsion such as a water/oil emulsion. The composition may be in either a liquid or solid form. For example, the composition may be in the form of a tablet, capsule, ingestible liquid or powder, injectible, or topical
5 ointment or cream. Proper fluidity can be maintained, for example, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride and the like. Besides such inert
10 diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents and perfuming agents.

Suspensions, in addition to the active compounds, may comprise suspending agents such as, for example, ethoxylated
15 isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth or mixtures of these substances.

Solid dosage forms such as tablets and capsules can be
20 prepared using techniques well known in the art. For example, PUFAs produced in accordance with the present invention can be tableted with conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders such as acacia, cornstarch or gelatin, disintegrating agents such as
25 potato starch or alginic acid, and a lubricant such as stearic acid or magnesium stearate. Capsules can be prepared by incorporating these excipients into a gelatin capsule along with antioxidants and the relevant PUFA(s). The antioxidant and PUFA components should fit within the guidelines presented
30 above.

For intravenous administration, the PUFAs produced in accordance with the present invention or derivatives thereof may be incorporated into commercial formulations such as Intralipids™. The typical normal adult plasma fatty acid

profile comprises 6.64 to 9.46% of AA, 1.45 to 3.11% of DGLA, and 0.02 to 0.08% of GLA. These PUFAs or their metabolic precursors can be administered alone or in combination with other PUFAs in order to achieve a normal fatty acid profile in a patient. Where desired, the individual components of the formulations may be provided individually, in kit form, for single or multiple use. A typical dosage of a particular fatty acid is from 0.1 mg to 20 g (up to 100 g) daily and is preferably from 10 mg to 1, 2, 5 or 10 g daily.

Possible routes of administration of the pharmaceutical compositions of the present invention include, for example, enteral (e.g., oral and rectal) and parenteral. For example, a liquid preparation may be administered, for example, orally or rectally. Additionally, a homogenous mixture can be completely dispersed in water, admixed under sterile conditions with physiologically acceptable diluents, preservatives, buffers or propellants in order to form a spray or inhalant. The route of administration will, of course, depend upon the desired effect. For example, if the composition is being utilized to treat rough, dry, or aging skin, to treat injured or burned skin, or to treat skin or hair affected by a disease or condition, it may perhaps be applied topically.

The dosage of the composition to be administered to the patient may be determined by one of ordinary skill in the art and depends upon various factors such as weight of the patient, age of the patient, immune status of the patient, etc.

With respect to form, the composition may be, for example, a solution, a dispersion, a suspension, an emulsion or a sterile powder which is then reconstituted.

The present invention also includes the treatment of various disorders by use of the pharmaceutical and/or nutritional compositions described herein. In particular, the compositions of the present invention may be used to treat restenosis after angioplasty. Furthermore, symptoms of

inflammation, rheumatoid arthritis, asthma and psoriasis may also be treated with the compositions of the invention. Evidence also indicates that PUFAs may be involved in calcium metabolism; thus, the compositions of the present invention
5 may, perhaps, be utilized in the treatment or prevention of osteoporosis and of kidney or urinary tract stones.

Additionally, the compositions of the present invention may also be used in the treatment of cancer. Malignant cells have been shown to have altered fatty acid compositions.

10 Addition of fatty acids has been shown to slow their growth, cause cell death and increase their susceptibility to chemotherapeutic agents. Moreover, the compositions of the present invention may also be useful for treating cachexia associated with cancer.

15 The compositions of the present invention may also be used to treat diabetes (see U.S. Patent No. 4,826,877 and Horrobin et al., Am. J. Clin. Nutr. Vol. 57 (Suppl.) 732S-737S). Altered fatty acid metabolism and composition have been demonstrated in diabetic animals.

20 Furthermore, the compositions of the present invention, comprising PUFAs produced either directly or indirectly through the use of the desaturase enzymes, may also be used in the treatment of eczema, in the reduction of blood pressure, and in the improvement of mathematics examination scores.

25 Additionally, the compositions of the present invention may be used in inhibition of platelet aggregation, induction of vasodilation, reduction in cholesterol levels, inhibition of proliferation of vessel wall smooth muscle and fibrous tissue (Brenner et al., Adv. Exp. Med. Biol. Vol. 83, p.85-101, 1976),
30 reduction or prevention of gastrointestinal bleeding and other side effects of non-steroidal anti-inflammatory drugs (see U.S. Patent No. 4,666,701), prevention or treatment of endometriosis and premenstrual syndrome (see U.S. Patent No. 4,758,592), and

treatment of myalgic encephalomyelitis and chronic fatigue after viral infections (see U.S. Patent No. 5,116,871).

Further uses of the compositions of the present invention include use in the treatment of AIDS, multiple sclerosis, and
5 inflammatory skin disorders, as well as for maintenance of general health.

Additionally, the composition of the present invention may be utilized for cosmetic purposes. It may be added to pre-existing cosmetic compositions such that a mixture is formed or
10 may be used as a sole composition.

Veterinary Applications

It should be noted that the above-described pharmaceutical and nutritional compositions may be utilized in connection with
15 animals (i.e., domestic or non-domestic), as well as humans, as animals experience many of the same needs and conditions as humans. For example, the oil or acids of the present invention may be utilized in animal or aquaculture feed supplements, animal feed substitutes, animal vitamins or in animal topical
20 ointments.

The present invention may be illustrated by the use of the following non-limiting examples:

Example 1

25 Design of Degenerate Oligonucleotides for the Isolation of Desaturases from Fungi and cDNA Library Construction

Analysis of the fatty acid composition of *Saprolegnia diclina* (*S.diclina*) (ATCC 56851) revealed the presence of a
30 considerable amount of arachidonic acid (ARA, 20:4 n-6) and eicosapentanoic acid (EPA, 20:5 n-3). Thus, it was thought that this organism contained an active Δ 6-desaturase capable of converting linoleic acid (LA, 18:2 n-6) to gamma-linolenic acid (GLA, 18:3 n-6), and an active Δ 5-desaturase that would convert

dihomo-gamma-linolenic acid (DGLA, 20:3 n-6) to arachidonic acid (ARA, 20:4 n-6) (Figure 1). In addition, it was thought that *S. diclina* also contained a $\Delta 17$ -desaturase capable of desaturating ARA to EPA.

5 The fatty acid composition analysis of *Thraustochytrium aureum* (*T. aureum*) (ATCC 34304) revealed not only ARA and EPA but also longer chain PUFAs such as adrenic acid (ADA, 22:4n-6), $\omega 6$ -docosapentaenoic acid ($\omega 6$ -DPA, 22:5n-6), $\omega 3$ -docosapentaenoic acid ($\omega 3$ -DPA, 22:5n-3), and docosahexaenoic
10 acid (DHA, 22:6n-3). Thus, in addition to $\Delta 6$ -, $\Delta 5$ - and $\Delta 17$ -desaturases, it was thought that *T. aureum* perhaps contained a $\Delta 19$ -desaturase which converts ADA to $\omega 3$ -DPA or $\omega 6$ -DPA to DHA and/or a $\Delta 4$ -desaturase which desaturates ADA to $\omega 6$ -DPA or $\omega 3$ -DPA to DHA. The goal thus was to attempt to isolate these
15 predicted desaturase genes from *S. diclina* and *T. aureum*, and eventually to verify the functionality by expression in an alternate host.

To isolate genes encoding functional desaturase enzymes, a cDNA library was constructed for each organism. *Saprolegnia*
20 *diclina* (ATCC 56851) cultures were grown in potato dextrose media Difco # 336 (Difco Laboratories, Detroit, Michigan) at room temperature for 4 days with constant agitation. The mycelia were harvested by filtration through several layers of cheese cloth, and the cultures crushed in liquid nitrogen using
25 a mortar and pestle. Total RNA was purified from it using the Qiagen RNeasy Maxi kit (Qiagen, Valencia, CA) as per manufacturer's protocol.

T. aureum (ATCC 34304) cells were grown in BY+ Media (Difco #790) at room temperature for 4 days, in the presence of
30 light, and with constant agitation (250 rpm) to obtain the maximum biomass. These cells were harvested by centrifugation

at 5000 rpm for 10 minutes and rinsed in ice-cold RNase-free water. These cells were then lysed in a French press at 10,000 psi, and the lysed cells directly collected into TE buffered phenol. Proteins from the cell lysate were removed by repeated
5 phenol:chloroform (1:1 v/v) extraction, followed by a chloroform extraction. The nucleic acids from the aqueous phase were precipitated out at -70°C for 30 minutes using 0.3M (final concentration) sodium acetate (pH 5.6) and one volume of isopropanol. The precipitated nucleic acids were collected by
10 centrifugation at 15,000rpm for 30 minutes at 4°C, vacuum-dried for 5 minutes and then treated with DNaseI (RNase-free) in 1X DNase buffer (20 mM Tris-Cl, pH 8.0; 5mM MgCl₂) for 15 minutes at room temperature. The reaction was quenched with 5 mM EDTA (pH 8.0) and the RNA further purified using the Qiagen RNeasy
15 Maxi kit (Qiagen, Valencia, CA) as per the manufacturer's protocol.

mRNA was isolated from total RNA from each organism using oligo dT cellulose resin. The pBluescript II XR library construction kit (Stratagene, La Jolla, CA) was then used to
20 synthesize double stranded cDNA which was then directionally cloned (5' *EcoRI*/3' *XhoI*) into pBluescript II SK(+) vector. The *S.diclina* and *T. aureum* libraries contained approximately 2.5 x 10⁶ clones each with an average insert size of approximately 700 bp. Genomic DNA from PUFA producing cultures
25 of *S.diclina* and *T. aureum* was isolated by crushing the culture in liquid nitrogen and purified using Qiagen Genomic DNA Extraction Kit (Qiagen, Valencia, CA).

The approach taken was to design degenerate
oligonucleotides (i.e., primers) that represent amino acid
30 motifs that are conserved in known desaturases. These primers could be used in a PCR reaction to identify a fragment containing the conserved regions in the predicted desaturase

genes from fungi. Since the only fungal desaturases identified are $\Delta 5$ - and $\Delta 6$ -desaturase genes from *Mortierella alpina* (Genbank accession numbers AF067650, AB020032, respectively), desaturase sequences from plants as well as animals were taken
5 into consideration during the design of these degenerate primers. Known $\Delta 5$ - and $\Delta 6$ -desaturase sequences from the following organisms were used for the design of these degenerate primers: *Mortierella alpina*, *Borago officinalis*, *Helianthus annuus*, *Brassica napus*, *Dictyostelium discoideum*,
10 *Rattus norvegicus*, *Mus musculus*, *Homo sapien*, *Caenorhabditis elegans*, *Arabidopsis thaliana*, and *Ricinus communis*. The degenerate primers used were as follows using the CODEHOP Blockmaker program (<http://blocks.fhcrc.org/codehop.html>):

- 15 A. Protein motif 1 (SEQ ID NO:53):
 NH₃- VYDVTEWVKRHPGG -COOH
 Primer RO 834 (SEQ ID NO:1):
 5'-GTBTAYGAYGTBACCGARTGGGTBAAGCGYCA YCCBGGHGGH-3'
- 20 B. Protein Motif 2 (SEQ ID NO:54):
 NH₃- GASANWWKHQHNVHH -COOH
 Primer RO835 (Forward) (SEQ ID NO:2):
 5'-GGHGCYTCCGCYAACTGGTGAAGCAYCAGCAYAACGTBCAYCAY-3'
 Primer RO836 (Reverse) (SEQ ID NO:3)
25 5'-RTGRTGVACGTTRTGCTGRTGCTTCCACCAGTTRGCGGARGCDCC-3'
- C. Protein Motif 3 (SEQ ID NO:55):
 NH₃- NYQIEHHLFPTM -COOH
 Primer RO838 (Reverse) (SEQ ID NO:4)
30 5'-TTGATRGTCTARCTYGTGTRGASAARGGVTGGTAC-3'

In addition, two more primers were designed based on the 2nd and 3rd conserved 'Histidine-box' found in known $\Delta 6$ -desaturases. These were:

5 Primer RO753 (SEQ ID NO:5)
5'-CATCATCATNGGRAANARRTGRTG-3'
Primer RO754 (SEQ ID NO:6)
5'-CTACTACTACTACAYCAYACNTAYACNAAY-3'

10 The degeneracy code for the oligonucleotide sequences was:
B=C,G,T; H=A,C,T; S=C,G; R=A,G; V=A,C,G; Y=C,T; D= A+T+C;
N= A,C,G,or T/U, unknown or other

Example 2

15 Isolation of $\Delta 6$ -Desaturase Nucleotide Sequences from
Saprolegnia diclina (ATCC 56851)

Total RNA from *Saprolegnia diclina* (ATCC 56851) was isolated using the lithium chloride method (Hoge, et al., Exp. Mycology (1982) 6:225-232). Five μ g of the total RNA was reverse transcribed, using the SuperScript Preamplification system (LifeTechnologies, Rockville, MD) and the oligo(dT)₁₂₋₁₈ primer supplied with the kit, to generate the first strand cDNA.

25 To isolate the $\Delta 6$ -desaturase gene, various permutations and combinations of the above mentioned degenerate oligonucleotides were used in PCR reactions. Of the various primer sets tried, the only primers to give distinct bands were RO834 /RO838. PCR amplification was carried out in a 100 μ l volume containing: 2 μ l of the first strand cDNA template, 20mM Tris-HCl, pH 8.4, 50mM KCl, 1.5mM MgCl₂, 200 μ M each deoxyribonucleotide triphosphate and 2 pmole of each primer.

Thermocycling was carried out at two different annealing temperatures, 42°C and 45°C, and these two PCR reactions were combined, resolved on a 1.0% agarose gel, and the band of ~1000bp was gel purified using the QiaQuick Gel Extraction Kit (Qiagen, Valencia, CA). The staggered ends on these fragments were 'filled-in' using T4 DNA polymerase (LifeTechnologies, Rockville, MD) as per manufacturer's specifications, and these DNA fragments were cloned into the PCR-Blunt vector (Invitrogen, Carlsbad, CA). The recombinant plasmids were transformed into TOP10 supercompetent cells (Invitrogen, Carlsbad, CA), and clones were sequenced.

Two clones were thus isolated that showed sequence homology to previously identified $\Delta 6$ -desaturases. These clones are described as follows:

a. Clone#20-2 was partially sequenced and the deduced amino acid sequence from 702 bp showed 30.2% identity with $\Delta 6$ -desaturase from *Mortierella alpina* as the highest scoring match in a TfastA search.

b. Clone #30-1 was partially sequenced, and the deduced amino acid sequence of 687 bp showed 48.5% amino acid identity with *Mortierella alpina*'s $\Delta 6$ -desaturase as the highest scoring match in a TfastA search. These two sequences also overlapped each other indicating they belonged to a single putative $\Delta 6$ -desaturase from *S. diclina*. This novel $\Delta 6$ -desaturase sequence was then used to design primers to retrieve the 3'- and the 5'-end of the full-length $\Delta 6$ -desaturase gene from the cDNA library generated from the mRNA of *S. diclina*.

To isolate the 3'-end, PCR amplification was carried out using plasmid DNA purified from the cDNA library as the template and oligonucleotides RO923 (SEQ ID NO:7) (5'-CGGTGCAGTGGTGGGAACAAGCACAAC-3') and RO899 (SEQ ID NO:8) (5'-AGCGGATAACAATTTTCACACAGGAAACAGC-3'). Oligonucleotide RO923 was designed based on the #20-2 fragment of this putative $\Delta 6$ -desaturase, and oligonucleotide RO899 corresponded to sequence from the pBluescript II SK(+) vector used for preparation of the cDNA library. Amplification was carried out using 10 pmols of each primer and the Taq PCR Master Mix (Qiagen, Valencia, CA). Samples were denatured initially at 94°C for 3 minutes, followed by 30 cycles of the following: 94°C for 1 minute, 60°C for 1 minute, 72°C for 2 minutes. A final extension cycle at 72°C for 10 minutes was carried out before the reaction was terminated. The PCR fragments were resolved on a 0.8% agarose gel and gel purified using the Qiagen Gel Extraction Kit. The staggered end on these fragments were 'filled-in' using T4 DNA polymerase (LifeTechnologies, Rockville, MD) as per manufacturer's specifications, and these DNA fragments were cloned into the PCR-Blunt vector (Invitrogen, Carlsbad, CA). The recombinant plasmids were transformed into TOP10 supercompetent cells (Invitrogen, Carlsbad, CA), and clones were sequenced. Clone sd2-2 contained a 958 bp insert which was identified to contain the 3'-end of the putative $\Delta 6$ -gene based on sequence homology with known $\Delta 6$ -desaturases and the presence of the 'TAA' stop codon and Poly A tail.

To isolate the 5'-end of this $\Delta 6$ -desaturase from *Saprolegnia diclina*, the oligonucleotide RO939 (SEQ ID NO:9) (5'-CGTAGTACTGCTCGAGGAGCTTGAGCGCCG-3') was designed based on the sequence of the #30-1 fragment identified earlier. This oligonucleotide was used in combination with RO898 (SEQ ID NO:10) (5'-CCCAGTCACGACGTTGTAAACGACGGCCAG-3') (designed based

on the sequence of from the pBluescript SK(+) vector) to PCR amplify the 5'-end of the $\Delta 6$ -desaturase from the cDNA library. In this case, the Advantage-GC cDNA PCR kit (Clonetech, Palo Alto, CA) was used to overcome PCR amplification problems that occur with GC rich regions, predicted to be present at the 5'-end of this $\Delta 6$ -desaturase. PCR thermocycling conditions were as follows: The template was initially denatured at 94°C for 1 minute, followed by 30 cycles of [94°C for 30 seconds, 68°C for 3 minutes], and finally an extension cycle at 68°C for 5 minutes. The PCR products thus obtained were cloned into the PCR-Blunt vector (Invitrogen, Carlsbad, CA) following the same protocol as described above. Clone sd21-2 was thus obtained that contained a 360 bp insert that contained the putative 'ATG' start site of the novel $\Delta 6$ -desaturase. The deduced amino acid sequence of this fragment, when aligned with known $\Delta 6$ -desaturases showed 37-45% identity.

This novel $\Delta 6$ -desaturase gene was isolated in its entirety by PCR amplification using, the *S. diclina* cDNA library, or *S. diclina* genomic DNA as a template, and the following oligonucleotides:

a. RO 951 (SEQ ID NO:11)

(5'- TCAACAGAAATTCATGGTCCAGGGGCAAAGGCCGAGAAGATCTCG-3')

that contained sequence from the 5' end of clone sd21-2 as well as an *EcoRI* site (underlined) to facilitate cloning into a yeast expression vector

b. RO960 (SEQ ID NO:12)

(5'- ATACGTAAGCTTTTACATGGCGGGAAACTCCTTGAAGAACTCGATCG-3')

that contained sequence from the 3' end of clone sd2-2

including the stop codon as well as a *HindIII* site
(underlined) for cloning in an expression vector.

PCR amplification was carried out using 200 ng of the cDNA
5 library plasmid template, 10 pmoles of each primer and the Taq
PCR Master Mix (Qiagen, Valencia, CA), or 200 ng of genomic
DNA, 10 pmoles of each primer, and the Advantage-GC cDNA PCR
kit (Clontech, Palo Alto, CA). Thermocycling conditions were
as follows: the template was initially denatured at 94°C for 1
10 minute, followed by 30 cycles of [94°C for 30 seconds, 68°C for
3 minutes], and finally an extension cycle at 68°C for 5
minutes. The PCR product thus obtained was digested with
EcoRI/HindIII and cloned into the yeast expression vector
pYX242 (Invitrogen, Carlsbad, CA) to generate clones pRSP1
15 (genomic DNA-derived) and pRSP2 (library-derived) which were
then sequenced and used for expression studies.

The $\Delta 6$ -desaturase full-length gene insert was 1362 bp (SEQ
ID NO:13, Figure 2) in length and, beginning with the first
ATG, contained an open reading frame encoding 453 amino acids.
20 (The nucleotide sequence encoding the $\Delta 6$ -desaturase was
deposited as plasmid pRSP1 with the American Type Culture
Collection (ATCC), 10801 University Boulevard, Manassas, VA
20110 under the terms of the Budapest Treaty on January 23,
2001 and was accorded accession number PTA-2829.) The amino
25 acid sequence of the full-length gene (SEQ ID NO:14, Figure 3)
contained regions of homology to $\Delta 6$ -desaturases from
Mortierella alpina, *Caenorhabditis elegans* and *Borago*
officinalis. It also contained the three conserved 'histidine
boxes' found in all known membrane-bound desaturases (Okuley,
30 et al. (1994) *The Plant Cell* 6: 147-158). These were present
at amino acid positions 171-176, 208-212, and 391-395. As with

other membrane-bound $\Delta 6$ -desaturases, the third Histidine-box motif (HXXHH) in the *S.diclina* $\Delta 6$ -desaturase was found to be QXXHH. This sequence also contained a cytochrome b5 domain at the 5'-end. This cytochrome b5 domain is found in a number of
5 membrane-bound desaturase enzymes, and cytochrome b5 is thought to function as an electron donor in these enzymes. The presence of this domain may be advantageous when expressing the desaturase in heterologous systems for PUFA production. Since the proposed use of this gene is for the reconstruction of the
10 PUFA biosynthetic pathway in plants, the base composition of this gene may be important. (It is known that some recombinant genes show poor expression because of variations in their base composition as compared to that of the host. The overall G+C content of this gene was 59%, which is close to that of the *M.*
15 *alpina* desaturases that have been successfully expressed in plants.)

Example 3

Isolation of $\Delta 5$ -Desaturase Nucleotide Sequences from 20 *Saprolegnia diclina* (ATCC 56851)

Saprolegnia diclina (ATCC 56851) produces both arachidonic acid (ARA, 20:4 n-6) and eicosapentanoic acid (EPA, 20:5 n-3); thus, it was thought to have, perhaps, a $\Delta 5$ -desaturase which
25 can convert dihomo-gamma-linolenic acid (DGLA, 20:3n-6) to arachidonic acid (ARA, 20:4 n-6).

As with the $\Delta 6$ -desaturase isolation, for the $\Delta 5$ -desaturase isolation from *S. diclina*, various combinations of the degenerate primers were used in PCR reactions, using first
30 strand cDNA as the template. The primer combination, R0753 and R0754, generated a distinct band of 588 bp using the following PCR conditions: 2 μ l of the first strand cDNA template, 20mM

Tris-HCl, pH 8.4, 50mM KCl, 1.5mM MgCl₂, 200 μM each deoxyribonucleotide triphosphate, 2 pmole of each primer and 1U cDNA polymerase (Clonetech, Palo Alto, CA), in a final reaction volume of 50 μl. Thermocycling was carried out as follows: an
5 initial denaturation at 94°C for 3 minutes, followed by 35 cycles of: denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds and extension at 72°C for 1 minute. This was followed by a final extension at 72°C for 7 minutes, and the reaction was terminated at 4°C. This fragment thus
10 generated was cloned (clone # 18-1), sequenced and, when translated, showed 43% amino acid identity with *Mortierella alpina* Δ5-desaturase (Genbank accession # AF067654) and 38.7% identity with *Dictyostelium discoideum* Δ5-desaturase (Genbank accession # AB029311). The second PCR fragment was identified
15 using Primers R0834 and R0838 in the reaction described in Example 2. This fragment, of approximately 1000 bp in length, was cloned (Clone # 20-8) and the deduced amino acid sequence derived from 775 bp showed 42% identity with Δ5-desaturase from *Dictyostelium discoideum* Δ5-desaturase (Genbank accession #
20 AB029311). These two sequences, #18-1 and #20-8, overlapped each other indicating they belonged to a single putative Δ5-desaturase from *S. diclina*. These sequences were then used to design primers to retrieve the 3'- and the 5'-end of the novel Δ5-desaturase gene from the cDNA library generated from the
25 mRNA of *S. diclina*.

To isolate the 3'-end of this putative Δ5-desaturase, PCR amplification was carried out using plasmid DNA purified from the cDNA library, as the template and oligonucleotides R0851 (SEQ ID NO:15) (5'-CCATCAAGACGTACCTTGCGATC-3') and R0899 (SEQ
30 ID NO:8) (5'- AGCGGATAACAATTTACACAGGAAACAGC-3').

Oligonucleotide R0851 was designed based on the #18-1 fragment

of this putative $\Delta 5$ -desaturase, and oligonucleotide R0899 corresponded to sequence from the pBluescript II SK(+) vector. Amplification was carried out using 200 ng of template plasmid DNA, 10 pmoles of each primer and the Taq PCR Master Mix (Qiagen, Valencia, CA). Samples were denatured initially at 94°C for 3 minutes, followed by 35 cycles of the following: 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 1 minutes. A final extension cycle at 72°C for 7 minutes was carried out before the reaction was terminated. The PCR fragments were cloned into the PCR-Blunt vector (Invitrogen, Carlsbad, CA) as per the protocol described in Example 2. The recombinant plasmids were transformed into TOP10 supercompetent cells (Invitrogen, Carlsbad, CA), and clones were sequenced. Clone sd12-11 contained a 648 bp insert which contained the 3'-end of the putative $\Delta 5$ -gene based on sequence homology with known $\Delta 5$ -desaturases and the presence of the 'TAA' stop codon and polyA tail.

The 5'-end of this $\Delta 5$ -desaturase from *Saprolegnia diclina* was isolated using primers R0941 and R0898. The oligonucleotide R0941 (SEQ ID NO:16) (5'-GCTGAACGGGTGGTACGAGTCGAACGTG-3') was designed based on the sequence of the #20-8 fragment identified earlier. This oligonucleotide was used in combination with R0898 (SEQ ID NO:10) (5'-CCCAGTCACGACGTTGTAAACGACGGCCAG-3') (designed based on the sequence of from the pBluescript II SK(+) vector) in a PCR amplification reaction using the cDNA library plasmid DNA as the template. Here the Advantage-GC cDNA PCR kit (Clontech, Palo Alto, CA) was used as per the manufacturer's protocol, and the thermocycling conditions were as follows: an initial denaturation was carried out at 94°C for 1 minute, followed by 30 cycles of [denaturation at 94°C for 30 seconds, annealing and extension 68°C for 3 minutes], and a final

extension cycle at 68°C for 5 minutes. These PCR products were purified, cloned into the PCR-Blunt vector (Invitrogen, Carlsbad, CA), and sequenced as described above. Clone sd24-1 was identified to contain a 295 bp insert that contained the putative 'ATG' start site of the novel $\Delta 5$ -desaturase. Analysis of the deduced amino acid sequence of this fragment showed regions of high homology with known $\Delta 5$ -desaturases and also the presence of a cytochrome b5 domain.

The full-length $\Delta 5$ -desaturase gene was isolated by PCR amplification using *S. diclina* genomic DNA as a template and the following oligonucleotides:

a. RO 953 (SEQ ID NO:17)

(5'-ACGAGAGAAATTCATGGCCCCGCAGACGGAGCTCCGCCAG

CGC-3') that contained sequence from the 5' end of clone sd24-1 as well as an *EcoRI* site (underlined) to facilitate cloning into a yeast expression vector; and

b. RO956 (SEQ ID NO:18)

(5'-AAAAGACTCGAGTTAGCCCATGTGGATCGTGGCGGCGATGCCC

TGC-3') that contained sequence from the 3' end of clone sd12-11 including the stop codon as well as a *XhoI* site (underlined) for cloning in an expression vector.

Conditions for the PCR amplification of the 'full length' gene were similar to those described for the amplification of the $\Delta 6$ -desaturase from genomic DNA (Example 2). The PCR product thus obtained was digested with *EcoRI/XhoI* and cloned into the yeast expression vector pYX242 (Invitrogen, Carlsbad, CA). Clone pRSP3 (genomic DNA-derived) was shown to contain a 1413 bp insert and was used for expression studies.

The 1413 bp full-length gene (SEQ ID NO:19, Figure 4) of the putative $\Delta 5$ -desaturase from *S. diclina* contained an open reading frame encoding 471 amino acids (SEQ ID NO:20, Figure 5). (The nucleotide sequence encoding the $\Delta 5$ -desaturase was deposited (as plasmid pRSP3) with the American Type Culture Collection, 10810 University Boulevard, Manassas, VA 20110 under the terms of the Budapest Treaty on January 23, 2001 and was accorded accession number PTA-2928.) This translated protein showed 40.5% overall identity with the *Mortierella*
10 *alpina* $\Delta 5$ -desaturase (Genbank accession # AF067654) and 39.5% identity with the *Dictyostelium discoideum* $\Delta 5$ -desaturase (Genbank accession # AB022097). It also contained the three conserved 'histidine boxes' at amino acid positions 186-190, 223-228, 406-410. Like the $\Delta 6$ -desaturase, this sequence also
15 contained a cytochrome b5 domain at the 5'-end. The overall G+C content of this gene was 61.5%.

Example 4

Expression of *S. diclina* Desaturase Genes in Baker's Yeast

20

Clone pRSP2, which consisted of the full length $\Delta 6$ -desaturase cloned into PYX242 (Invitrogen, Carlsbad, CA), and clone pRSP3, which consisted of the full-length Delta 5-desaturase gene in pYX242, were transformed into competent
25 *Saccharomyces cerevisiae* strain 334. Yeast transformation was carried out using the Alkali-Cation Yeast Transformation Kit (BIO 101, Vista, CA) according to conditions specified by the manufacturer. Transformants were selected for leucine auxotrophy on media lacking leucine (DOB [-Leu]). To detect
30 the specific desaturase activity of these clones, transformants were grown in the presence of 50 μ M specific fatty acid substrates as listed below:

a. Stearic acid (18:0) (conversion to oleic acid would indicate $\Delta 9$ -desaturase activity)

b. Oleic acid (18:1) (conversion to linoleic acid would indicate $\Delta 12$ -desaturase activity)

5 c. Linoleic acid (18:2 n-6) (conversion to alpha-linolenic acid would indicate $\Delta 15$ -desaturase activity and conversion to gamma-linolenic acid would indicate $\Delta 6$ -desaturase activity)

10 d. Alpha-linolenic acid (18:3 n-3) (conversion to stearidonic acid would indicate $\Delta 6$ -desaturase activity)

e. Dihomo-gamma-linolenic acid (20:3 n-6) (conversion to arachidonic acid would indicate $\Delta 5$ -desaturase activity).

The negative control strain was *S. cerevisiae* 334 containing the unaltered pYX242 vector, and these were grown

15 simultaneously. The cultures were vigorously agitated (250 rpm) and grown for 48 hours at 24°C in the presence of 50 μ M (final concentration) of the various substrates. The cells were pelleted and vortexed in methanol; chloroform was added along with tritridecanoin (as an internal standard). These

20 mixtures were incubated for at least an hour at room temperature or at 4°C overnight. The chloroform layer was extracted and filtered through a Whatman filter with 1 gm anhydrous sodium sulfate to remove particulates and residual water. The organic solvents were evaporated at 40°C under a
25 stream of nitrogen. The extracted lipids were then derivitized to fatty acid methyl esters (FAME) for gas chromatography analysis (GC) by adding 2 ml of 0.5 N potassium hydroxide in methanol to a closed tube. The samples were heated to 95°C-100°C for 30 minutes and cooled to room temperature.

30 Approximately 2 ml of 14% borontrifluoride in methanol were added and the heating repeated. After the extracted lipid

mixture cooled, 2 ml of water and 1 ml of hexane were added to extract the FAME for analysis by GC. The percent conversion was calculated by dividing the product produced by the sum of (the product produced + the substrate added) and then
5 multiplying by 100.

Table 1 represents the enzyme activity of the genes isolated based on the percent conversion of substrate added. The pRSP1 clone that contained the $\Delta 6$ -desaturase gene from *S. diclina* converted 28% of the 18:2n-6 substrate to 18:3n-3, as
10 well as 37% of the 18:3n-3 substrate to 18:4n-3. This confirms that the gene encodes a $\Delta 6$ -desaturase. There was no background (non-specific conversion of substrate) in this case. (All tables referred to herein are presented after the Abstract of the Disclosure.)

15 The pRSP3 clone that contained the $\Delta 5$ -desaturase gene from *S. diclina* was capable of converting 27% of the added 20:3n-6 substrate to 20:4n-6, indicating that the enzyme it encodes is a $\Delta 5$ -desaturase. In this case too, there was no background substrate conversion detected. This data indicates that
20 desaturases with different substrate specificity can be expressed in a heterologous system and can also be used to produce polyunsaturated fatty acids.

Table 2 represents fatty acids of interest as a percentage of the total lipid extracted from *S. cerevisiae* 334 with the
25 indicated plasmid. No glucose was present in the growth media. Affinity gas chromatography was used to separate the respective lipids. GC/MS was employed to identify the products. From this table, it is apparent that exogenously added substrates, when added in the free form was taken up by the recombinant
30 yeast and the incorporated into their membranes. In the yeast clone containing the $\Delta 6$ -desaturase gene (pRSP1), GLA (γ -18:3)

was identified as a novel PUFA when LA (18:2) was added as the substrate, and arachidonic acid was detected in yeast containing the $\Delta 5$ -desaturase gene (pRSP3) when DGLA (20:3) was added as a substrate.

5

Example 5

Co-Expression of *S. diclina* Desaturases with Elongases

The plasmid pRSP1 ($\Delta 6$) and pRSP3 ($\Delta 5$) were individually co-transformed with pRAE73-A3, a clone that contains the Human Elongase gene (SEQ ID NO:21) in the yeast expression vector pYES2, into yeast as described in Example 4. This elongase gene catalyzes some of the elongation steps in the PUFA pathway. Co-transformants were selected on minimal media lacking leucine and uracil (DOB[-Leu-Ura]).

15

Table 3 shows that when 50 μ M of the substrate LA (18:2 n-6) was added, that the $\Delta 6$ -desaturase converted this substrate to GLA (18:3 n-6) and the elongase was able to add two carbons to GLA to produce DGLA (20:3 n-6). The percent conversion of the substrate to the final product by these co-transformed enzymes is 26.4%, with no background observed from the negative control. Similarly, the co-transformed enzymes can act on ALA (18:3n-3) to finally form (20:4n-3) with a percentage conversion of 34.39%. Thus, *S. diclina* $\Delta 6$ -desaturase was able to produce a product in a heterologous expression system that could be further utilized by another heterologous enzyme from the PUFA biosynthetic pathway to produce the expected PUFA.

25

Table 4 shows results of the pRSP3($\Delta 5$)/Human Elongase co-transformation experiment. In this case, substrate GLA (18:3n-6) was converted to DGLA (20:3n-6) by human elongase and this was further converted to ARA (20:4n-6) by the action of *S.*

30

diclina $\Delta 5$ -desaturase. The percent conversion of the substrate to the final product by these co-transformed enzymes is 38.6%, with no background observed from the negative control.

The other substrate tested in this case was STA (18:4
5 n-3) which was eventually converted to EPA (20:5n-3) by the concerted action of the two enzymes. Similar results were observed when the pRSP1 and pRSP3 were cotransformed with an elongase gene derived from *M. alpina* (pRPB2) (SEQ ID NO:22), and both genes were shown to be functional in the presence of
10 each other (see Table 3 and Table 4).

Example 6

Isolation of $\Delta 5$ -Desaturase Nucleotide Sequences from *Thraustochytrium aureum* (ATCC 34303)

15 To isolate putative desaturase genes, total RNA was isolated as described in Example 2. Approximately 5 μ g was reverse transcribed using the SuperScript Preamplification system (LifeTechnologies, Rockville, MD) as shown in Example 2
20 to produce first strand cDNA. Using the degenerate primers RO834 (SEQ ID NO:1) and 838 (SEQ ID NO:4) designed with the block maker program in a 50 μ l reaction, the following components were combined: 2 μ l of the first strand cDNA
template, 20mM Tris-HCl, pH 8.4, 50mM KCl, 1.5mM MgCl₂, 200 μ M
25 each deoxyribonucleotide triphosphate, 2 pmole final concentration of each primer and cDNA polymerase (Clonetech, Palo Alto, CA). Thermocycling was carried out as follows: an initial denaturation at 94°C for 3 minutes, followed by 35
cycles of denaturation at 94°C for 30 seconds, annealing at 60°C
30 for 30 seconds and extension at 72°C for 1 minute. This was followed by a final extension at 72°C for 7 minutes. Two faint bands of approximately 1000 bp were separated on a 1% agarose

gel, excised, and purified with the QiaQuick Gel Extraction Kit (Qiagen, Valencia, CA). The ends were filled in with T4 DNA polymerase and the blunt-end fragments cloned into PCR Blunt as described in Example 2. Sequencing of the obtained clones
5 identified the partial sequence of 680 bp from clone 30-9 whose translation of 226 amino acids had 31.5% identity with $\Delta 6$ -desaturase from adult zebrafish (Genbank accession number AW281238). A similar degree of amino acid (29.6%- 28.7%) homology was found with human $\Delta 6$ -desaturase (Genbank accession
10 number AF126799), *Physcomitrella patens* (moss) $\Delta 6$ -desaturase (Genbank accession number AJ222980), *Brassica napus* (canola) $\Delta 8$ -sphingolipid desaturase (Genbank accession number AJ224160), and human $\Delta 5$ -desaturase (ATCC accession number 203557, Genbank accession number AF199596). Since there was a reasonable
15 degree of amino acid homology to known desaturases, a full-length gene encoding a potential desaturase was sought to determine its activity when expressed in yeast.

To isolate the 3' end of the gene, 10 pmol of primer R0936 (SEQ ID NO:23) (5'-GTCGGGCAAGGCGGAAAAGTACCTCAAGAG-3')
20 and vector primer R0899 (SEQ ID NO:8) were combined in a reaction with 100 ng of purified plasmid from the *T. aureum* cDNA library in reaction volume of 100 μ l in Taq PCR Master Mix (Qiagen, Valencia, CA). Thermocycling conditions were as follows: an initial melt at 94°C for 3 minutes followed by 30
25 cycles of 94°C for 1 minute, 60°C for 1 minute, and 72°C for 2 minutes. This was followed by an extension step of 10 minutes at 72°C. Several bands, including the predicted size of 1.2 kb, were separated on a 1 % agarose gel and purified as stated earlier. Also as described earlier, the ends of the fragments
30 were blunt ended,
cloned into PCR Blunt and sequenced. Fragment #70-2 of

approximately 1.2 kb was sequenced and contained an open reading frame and a stop codon, which overlapped fragment 30-9.

To isolate the 5' end of the gene, RO937 (SEQ ID NO:24) (5'-AAACCTGTAGACAATGTGGAGGGGCGTGGG-3') and RO 899 (SEQ ID NO:8) were used in a 50 µl PCR reaction with Advantage-GC cDNA PCR kit (Clonetech, Palo Alto, CA), as per the manufacturer's protocol, with 100 ng of purified plasmid DNA from the library and 10 pmol of each primer. The thermocycling conditions were as follows: An

initial denaturation was carried out at 94°C for 1 minute, followed by 30 cycles of [denaturation at 94°C for 30 seconds, annealing and extension 68°C for 3 minutes], and a final extension cycle at 68°C for 5 minutes. A band of approximately 500bp, in the range of the expected size, was gel purified, blunt ended and cloned into PCR Blunt as previously described. Clone 95-2 contained an open reading frame with a start codon. This fragment also overlapped with clone 30-9, indicating that they were indeed pieces of the same gene.

To isolate the full-length gene, primers were designed with restriction sites 5' and 3' (underlined) with *EcoRI* and *XhoI*, respectively, as follows: 5' primer RO972 (SEQ ID NO:25) (5'-ATACTTGAATTCATGGGACGCGGCGGCGAAGGTCAGGTGAAC-3'), 3' primer RO949 (SEQ ID NO: 26) (5'-CTTATACTCGAGCTAAGCGG CCTTGGCCGCCGCTGGCC-3') and 3' primer RO950 (SEQ ID NO:27) (5'-CTTATACTCGAGTAAATGGCTCGCGAGGCGAAGCGAGTGGC-3'). Two primers were used for the 3' end of the gene in the initial isolation attempt since the primer RO949, containing the stop codon had 66% GC content, while the alternate primer RO950, which was outside the stop codon, had only a 56% GC content. A 50 µl PCR reaction with RO972/RO949 and RO972/950 was performed with Advantage-GC cDNA PCR kit (Clonetech, Palo Alto, CA) under

identical conditions noted in the preceding paragraph. Only the primer set R0972/950 produced a band of approximately 1.6 kb. Use of genomic DNA as a template (under identical conditions with 100 ng of target) also produced a similar-sized band. Fragments were separated on an agarose gel, gel purified, blunt-ended and cloned into PCR Blunt as previously described. Fragments were evaluated by sequencing, and a number of clones were cut with *EcoRI/XhoI* to excise the full length gene, ligated to pYX242 *EcoRI/XhoI* which had been treated with shrimp alkaline phosphatase (Roche, Indianapolis, IN) with the Rapid ligation kit (Roche, Indianapolis, IN). Clone 99-3, designated pRTA4, contained the full length gene of 1317 bp (SEQ ID NO:28, Figure 6) and an open reading frame of 439 aa (SEQ IN NO: 29, Figure 7). (The nucleotide sequence encoding the $\Delta 5$ -desaturase was deposited with the ATCC, 10801 University Boulevard, Manassas, VA 20110 under the terms of the Budapest Treaty on January 23, 2001 and was accorded accession number PTA-2927.) This gene contained three histidine boxes at amino acid numbers 171-175, 208-212, and 376-380. The 5'-end of the gene, when translated, also shows homology to cytochrome b5.

Example 7

Expression of *T. aureum* Desaturase Gene in Baker's Yeast

The clone pRTA4 containing the full-length gene was transformed into the yeast host *S. cerevisiae* 334 and plated on selective media as described in Example 4. The cultures were grown at 24°C for 48 hours in minimal media lacking leucine with 50 μ M of exogenous free fatty acid added as a substrate as shown in Table 5. The only conversion of a substrate was DGLA (20:3n-6) to ARA (20:4n-6). The conversion of 23.7% of the

added DGLA indicates that this gene encodes for a $\Delta 5$ -desaturase.

Table 6 shows some of the fatty acids as a percentage of the lipid extracted from the yeast host. For $\Delta 5$ -desaturase activity, there was no background (detection of ARA observed in the negative control containing the yeast expression plasmid, PYX242.)

Example 8

Co-Expression of *T. aureum* Desaturase Gene with Elongases

The plasmid pRTA4 was co-transformed with an additional enzyme in the PUFA pathway, pRAE73-A3 which contains the human elongase gene in the yeast expression vector pYES2 as described in Example 4, and co-transformants were selected on minimal media lacking leucine and uracil.

Table 7 shows that when 100 μM of the substrate DGLA was added, that the $\Delta 5$ -desaturase actively produced ARA, to which the elongase was able to add two carbons to produce ADA. The percent conversion of *T. aureum* $\Delta 5$ -desaturase, which consists of both ARA and ADA (products), was 16.7%, with no background observed from the negative control.

In view of the above results, *T. aureum* $\Delta 5$ -desaturase is able to produce a product in a heterologous expression system that can be used by an additional heterologous enzyme in the PUFA biosynthetic pathway to produce the expected PUFA.

Example 9

Isolation of $\Delta 5$ -desaturase Nucleotide Sequences from *Thraustochytrium aureum* BICC7091 (T7091)

A partial desaturase candidate was isolated using the degenerate primer combination of RO834/RO838, listed in Example 1. The genomic DNA was prepared from Thraustochytrium aureum BICC7091 (Biocon India Ltd., Bangalore, India) using the DNeasy plant maxi kit (Qiagen, Valencia, CA). The T7091 gDNA was amplified with primers RO834 (5' -GTB TAY GAY GTB ACC GAR TGG GTB AAG CGY CAY CCB GGH GGH- 3') (SEQ ID NO:1) and RO838 (5' -CAT GGT VGG RAA SAG RTG RTG YTC RAT CTG RTA GTT- 3') (SEQ ID NO:36). PCR amplification was carried out in a 100 μ l volume containing: 5 μ l of isolated T7091 gDNA, 0.2 M dNTP mix, 50 pM each primer, 10 μ l of 10X buffer and 1.0 U of cDNA Polymerase. Thermocycler conditions in Perkin Elmer 9600 were as follows: 94°C for 3 min, then 35 cycles of 94 °C for 30 sec., 60 °C for 30 sec., and 72°C for 1 min. PCR was followed by an additional extension at 72°C for 7 minutes. The PCR amplified mixture was run on a 1.0% agarose gel, and amplified fragments of approximately 1.2 Kb and 1.4 Kb were gel purified using the Qiaquick Gel Extraction Kit (Qiagen, Valencia, CA). The staggered ends on these fragments were filled-in using T4 DNA Polymerase (LifeTechnologies, Rockville, MD), the isolated fragments were cloned into the pCR-Blunt vector (Invitrogen, Co., Carlsbad, CA), and the recombinant plasmids were transformed into TOP10 supercompetent cells (Invitrogen, Carlsbad, CA).

Twenty-four clones were prepared and sequenced using ABI 373A DNA Sequencer (Applied Biosystems, Foster City, CA). The translated sequences were used as queries to search the GenEmbl database (Genetics Computer Group (GCG) (Madison, WI)), using the tFastA algorithm (a Pearson and Lipman search for similarity between a protein query sequence and any group of nucleotide sequences). A gene fragment, T7091B2, was further pursued because it had identity with known desaturases.

T7091B2 had 26.8% identity in 362 amino acids with Human $\Delta 5$ -desaturase (GenBank accession number AF226273).

To isolate the 3' and 5'-ends, new primers were designed based on the T7091B2 internal sequence. The T7091 cDNA

5 library, which contains approximately 2×10^7 clones with an average insert size of 1 Kb, was PCR amplified using the new primers and a vector primer. The primers that produced more 5' and 3' sequences with the vector primers RO898 (5' -CCC AGT CAC GAC GTT GTA AAA CGA CGG CCA G- 3') (SEQ ID NO:10) and RO899 (5' -AGC GGA TAA CAA TTT CAC ACA GGA AAC AGC- 3') (SEQ ID NO:8)

10 were RO1065 (5' -CGA CAA GAG GAA GAG TGT CCA AAT C- 3') (SEQ ID NO:37) and RO1064 (5' -CGC CTT CAA GAG TTT TTG TAC GGA ATT GGG- 3') (SEQ ID NO:38), respectively, for clone T7091B2. Two new primers were designed based on the T7091B2 5' and 3' sequences:

- 15
- a. RO1097 (5' -CTT GTA CCA TGG GTC GCG GAG CAC AGG GAG- 3) (SEQ ID NO:39), which has an added *Nco*I restriction site (underlined)
 - b. RO1098 (5' -TGA AGC TTA CTC GCT CTT GGC AGC TTG GCC- 3') (SEQ ID NO:40), which has an added *Hind*III restriction site (underlined)
- 20

This novel $\Delta 5$ -desaturase gene was isolated in its entirety by PCR amplification, using the *T. aureum* 7091 gDNA. PCR was

25 carried out in a 50 μ l volume containing:

1 μ l of isolated T7091 gDNA, 0.2 μ M dNTP mix, 50 pM each primer, 5 μ l of 10 X buffer, 1.5 μ l of 50 mM $MgSO_4$, and 0.5 U of *Taq* DNA Polymerase. Thermocycler conditions in Perkin Elmer 9600 were as follows: 94°C for 3 min, then 30 cycles of 95 °C

30 for 45 sec., 55 °C for 30 sec., and 68°C for 2 min. The PCR amplified mixture was run on a gel, an amplified fragment of

approximately 1.3 Kb was gel purified, and the isolated fragment was cloned into the pYX242(*Nco*I/*Eco*RV) vector. Two clones, designated as pRAT-2a and 2c, were prepared and sequenced. (Plasmid pRAT-2c was deposited with the American
5 Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209 on January ____, 2002 under the terms of the Budapest Treaty and was accorded ATCC deposit number ____.) The sequences were different by four amino acids (Figure 12), and the translated sequence had 67.4% identity in 436 amino acids
10 with *T. aureum* (ATCC34303) Δ 5-desaturase (see Example 6).

Example 10

Isolation of Δ 6-desaturase Nucleotide Sequences from *Thraustochytrium aureum* BICC7091 (T7091)

15

Three hundred and seventy-three templates from the T7091 cDNA library were sequenced to determine the viability of the library. The translated sequences were used as queries to search the GenEmbl database using the tFastA algorithm. Clone
20 602187281R1 (or clone 281 for short) had identity with several known desaturases. The 5' and 3' ends of the EST clone were sequenced in order to design primers for amplification. Primers RO1107 (5' -TTT AAC CAT GGG CCG CGG CGG CGA GAA AAG-3') (SEQ ID NO:41), which has an added *Nco*I restriction site
25 (underlined), and RO1108 (5' -GGG AAG AAG CTT TCT ACT GCG CCT TGG CTT TCT TTG- 3') (SEQ ID NO:42), which has an added *Hind*III restriction site (underlined), were used to PCR amplify the T7091 gDNA.

PCR was carried out in a 50 μ l volume with *Taq* DNA
30 Polymerase as above. The PCR amplified mixture was run on a gel, an amplified fragment of approximately 1.3 Kb was gel purified, and the isolated fragment was cloned into the

pYX242 (*NcoI*/*EcoRV*) vector. Two clones, designated as pRAT-1a and 1b, were prepared and sequenced. The sequences were different by one amino acid (Figure 13), and the translated sequence had 25% identity in 430 amino acids with the Human $\Delta 5$ -
5 desaturase. (Plasmid pRAT-1a was deposited with the American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209 on January ___, 2002 under the terms of the Budapest Treaty and was accorded ATCC deposit number ____.)

Example 11

Expression of *T. aureum* 7091 Desaturase Genes in Baker's Yeast

Clones pRAT-2a and pRAT-2c, which consisted of the full-
15 length $\Delta 5$ -desaturase cloned into pYX242 (Invitrogen, Carlsbad, CA), and clones pRAT-1a and pRAT-1b, which consisted of the full-length $\Delta 6$ -desaturase gene in pYX242, were transformed into competent *Saccharomyces cerevisiae* 334. Yeast transformation was carried out using the Alkali-Cation Yeast Transformation
20 Kit (BIO 101, Vista, CA). Transformants were selected for leucine auxotrophy on media lacking leucine (DOB[-leu]). Because the translated sequence of pRAT-1 cDNA did not have a strong identity with any particular known desaturase, several fatty acid substrates were tested to determine the activity of
25 the expressed enzyme. To detect the specific desaturase activity of pRAT-1a and pRAT-1b clones, transformants were grown in the presence of 100 μ M specific fatty acid substrates as listed below:

- a. Linoleic acid (LA, 18:2n-6) (conversion to α -linolenic
30 acid would indicate $\Delta 15$ -desaturase activity and conversion to γ -linolenic acid would indicate $\Delta 6$ -desaturase activity)

- b. α -linolenic acid (ALA, 18:3n-3) (conversion to stearidonic acid would indicate $\Delta 6$ -desaturase activity)
- c. $\omega 6$ -eicosadienoic acid (EDA, 20:2n-6) (conversion to dihomogamma-linolenic acid would indicate $\Delta 8$ -desaturase activity)
- d. dihomogamma-linolenic acid (DGLA, 20:3n-6) (conversion to arachidonic acid would indicate $\Delta 5$ -desaturase activity)

The substrate for pRAT-2 clones was 100 μ M of DGLA. S. cerevisiae 334 containing the unaltered pYX242 vector was used as a negative control. Both pRAT-1a and pRAT-2c were also co-transformed into *S. cerevisiae* 334 with pRAE-73-A3 (i.e, a vector containing the human elongase enzyme which converts 18C fatty acids to 20C fatty acids, SEQ ID NO:21) (see Example 5). The substrates for pRAT-1a/pRAE-73-A3 clones were LA and ALA, and the substrates for pRAT-2c/pRAE-73-A3 clones were LA, ALA, and GLA. The cultures were grown for 48 hours at 24°C, in selective media, in the presence of a particular substrate. Fatty acid analyses were performed as outlined in Example 4.

Table 8 includes an example of the production of AA by strain 334 (pRAT-2c) vs. that by the control strain 334 (pYX242). The amount of AA produced was 22.98%, vs. no detectable amount in the control strain. Strain 334 (pRAT-2a) also had no detectable amount of AA produced (data not shown). The four amino acid difference between the two clones (Figure 12, see underlined) rendered the enzyme expressed from strain 334 (pRAT-2a) to be inactive. The $\Delta 5$ -desaturase activity from clone pRAT-2c was further detected when co-expressed with pRAE-73-A3 in the presence of GLA.

Table 9 is the fatty acid analysis results of the strains 334(pRAT-1a) and 334(pYX242) expressed in the presence of substrates LA, ALA, EDA, and DGLA. The $\Delta 6$ -desaturation of LA will produce GLA, the $\Delta 8$ -desaturation of EDA will produce DGLA, and the $\Delta 5$ -desaturation of DGLA will produce AA. All three activities were detected from both strains containing the T7091 gene vs. the control strain. Based on the conversion rates, this enzyme is an active $\Delta 6$ -desaturase, which can behave like a $\Delta 5$ - or $\Delta 8$ -desaturase, given the proper substrates. However, the conversion rates of these substrates to their respective desaturated fatty acids are low, in comparison to the substrates for a $\Delta 6$ -desaturation. The single amino acid difference between the two clones (Figure 13, see underlined) had no affect on the enzymatic activity (data not shown). The percent conversions are shown in the lower box of Table 9. The $\Delta 6$ -desaturase activity was further detected when pRAT-1a was co-expressed with pRAE-73-A3 in the presence of LA or ALA. The percent conversions were not calculated for the co-expression experiment, since it is difficult to determine whether the production of the new fatty acids is due to the activity of the desaturase, or elongase, or the combination of the two enzymes.

Two different methods of isolating a novel gene were explored in order to identify desaturase genes from T. aureum 7091. These methods led to the isolation of the T7091 $\Delta 5$ -desaturase and $\Delta 6$ -desaturase genes. In the presence of these genes and the appropriate substrates, S. cerevisiae produced desaturated fatty acids at a much higher level than the control strain. Co-transformation of the constructs containing the T7091B2 gene (pRAT-2c) and the Human elongase gene (pRAE-73-A3) in yeast resulted in the conversion of the substrate GLA to AA.

This experiment confirmed that the enzyme expressed from pRAT-2c must desaturate the DGLA (produced by the elongase) to AA. Co-transformation of the constructs containing the ``281'' gene (pRAT-1a) and the Human elongase gene (pRAE-73-A3) in yeast
 5 resulted in the conversion of the substrate LA to DGLA. This experiment confirmed that the enzyme expressed from pRAT-1a must desaturate LA to GLA.

Example 13

10 Isolation of Δ 5-desaturase Nucleotide Sequence from *Isochrysis galbana* 1323

A partial desaturase candidate was isolated using the degenerate primer combination of R0834/R0838, listed in Example
 15 1. The genomic DNA was prepared from *Isochrysis galbana* CCMP1323 (Provasoli-Guillard National Center for the Culture of Marine Phytoplankton (CCMP), West Boothbay Harbor, MA) using the DNeasy plant maxi kit (Qiagen, Valencia, CA). The *I. galbana* gDNA was amplified with primers R0834 (5' -GTB TAY GAY
 20 GTB ACC GAR TGG GTB AAG CGY CAY CCB GGH GGH- 3') (SEQ ID NO:1) and R0838 (5' -CAT GGT VGG RAA SAG RTG RTG YTC RAT CTG RTA GTT- 3') (SEQ ID NO:10). PCR was carried out in a 50 μ l volume containing: 1 μ l of isolated *I. galbana* gDNA, 0.2 μ M dNTP mix, 50 pM each primer, 5 μ l of 10 X buffer, 1.5 μ l of 50 mM MgSO₄,
 25 and 0.5 U of *Taq* DNA Polymerase. Thermocycler conditions in Perkin Elmer 9600 were as follows: 94°C for 3 min, then 30 cycles of 95 °C for 45 sec., 55 °C for 30 sec., and 68°C for 2 min. The PCR amplified mixture was run on a 1.0% agarose gel, and an amplified fragment of approximately 1.1 Kb was gel
 30 purified using the Qiaquick Gel Extraction Kit (Qiagen, Valencia, CA). The staggered ends of the fragment were filled-in using T4 DNA Polymerase (LifeTechnologies, Rockville, MD),

the isolated fragment was cloned into the pCR-Blunt vector (Invitrogen, Co., Carlsbad, CA), and the recombinant plasmids were transformed into TOP10 supercompetent cells (Invitrogen, Carlsbad, CA).

5 Six clones were prepared and sequenced using ABI 373A DNA Sequencer (Applied Biosystems, Foster City, CA). All of the sequences were the same. The translated sequence of the isolated fragment had 47.5% identity in 335 amino acids with with T. aureum (ATCC 34303) Δ 5-desaturase in clone pRTA4
10 (Example 6), and 45.3% identity in 278 amino acids with T. aureum BICC7091 Δ 5-desaturase in clone pRAT-2c (Example 9).

To isolate the 5' and 3'-ends, new primers were designed based on the internal sequence of the isolated I. galbana fragment. For the 5 prime end of the gene RO1235 (5'- CGA AGT
15 TGG TGA AGA TGT AGG TGC CG-3') (SEQ ID NO:43) was used, while RO1232 (5'-GAG CGA CGC GTA CAA CAA CTT TCA CGT-3') (SEQ ID NO:44) was used for the 3 prime end of the gene.

Approximately 1.4 μ g of total RNA was used, according to the manufacturer's direction, with the Rapid amplification of cDNA
20 ends or RACE with the GeneRacer™ kit (Invitrogen, Carlsbad, CA) and Superscript II™ enzyme (Invitrogen, Carlsbad, CA) for reverse transcription to produce cDNA target. For the initial amplification of the ends, the following thermocycling protocol was used in a Perkin Elmer 9600: initial melt at 94°C for 2
25 minutes; followed by 5 cycles of 94°C for 30 seconds and 72°C for 3 minutes; 10 cycles of 94°C 30 seconds, 70°C for 30 seconds, and 72°C for 3 minutes; and 20 cycles of 94°C for 30 seconds, 68°C for 30 seconds and 72°C for 3 minutes; followed by an extension of 72°C for 10 minutes. This first PCR
30 reaction was performed with 10 pMol of RO1235 or RO1232 and GeneRacer™ 5 prime primer (5'- CGA CTG GAG CAC GAG GAC ACT GA-

3') (SEQ ID NO:45), or GeneRacer™ 3 prime primer (5'- GCT GTC AAC GAT ACG CTA CGT AAC G-3') (SEQ ID NO:46), respectively, with 1 l of Thermozyme™ (Invitrogen, Carlsbad, CA) and 1 μ l of cDNA in a final volume of 50 μ l, according to the manufacturer's directions.

A nested reaction was performed with 2 μ l of the initial reaction, 10 pmol of nested primer RO1234 (5'-AGC TCC AGG TGA TTG TGC ACG CGC AG-3') (SEQ ID NO:47) or RO1233 (5'- GAC TTT GAG AAG CTG CGC CTC GAG CTG-3') (SEQ ID NO:48) and 30 pmol the GeneRacer™ nested 5 prime primer (5'- GGA CAC TGA CAT GGA CTG AAG GAG TA-3') (SEQ ID NO:49) and GeneRacer™ nested 3 prime primer (5'- CGC TAC GTA ACG GCA TGA CAG TG -3') (SEQ ID NO:50) respectively, and Platinum Taq™ PCRx (Clonetech, Palo Alto, CA) using MgSO₄ according to the manufacturer's protocol. The thermocycling parameter was as follows in a Perkin Elmer 9600: initial melt at 94°C for 2 minutes; followed by 5 cycles of 94°C for 30 seconds and 72°C for 2 minutes; 5 cycles of 94°C 30 seconds, 70°C for 2 minutes; 20 cycles of 94°C for 30 seconds, 65°C for 30 seconds and 68°C for 2 minutes; followed by an extension of 68°C for 10 minutes. Agarose gel analysis of the PCR products showed a band around 800 base pairs for the 5 prime reactions and approximately a 1.2 kilobase band for 3 prime reaction. Subsequent cloning into pCR Blunt (Invitrogen, Carlsbad, CA), transformation into Top10 competent cells (Invitrogen, Carlsbad, CA), and sequencing, revealed an open reading frame with both a start and stop codons.

Primers RO1309 (5'- ATG ATG GAA TTC ATG GTG GCA GGC AAA TCA GGC GC-3') (SEQ ID NO:51) and RO1310 (5'- AAT AAT GTC GAC CTA GTG CGT GTG CTC GTG GTA GG-3') (SEQ ID NO:52) with restrictions sites added for cloning (see underlined *EcoRI*, and *SalI*, respectively) were used to isolate a full length gene.

As shown above, 10 pmol of primers RO1309 and 1310 were used with Platinum Taq™ PCRx (Clontech, Palo Alto, CA) using MgSO₄ according to the manufacturer's protocol, with 2 μl of the cDNA as target. The thermocycling parameters were as follows:

5 initial melt at 94°C for 2 minutes; followed by 5 cycles of 94°C for 30 seconds and 72°C for 2 minutes; 5 cycles of 94°C 30 seconds, 70°C for 2 minutes; 20 cycles of 94°C for 30 seconds, 65°C for 30 seconds and 68°C for 2 minutes; followed by an extension of 68°C for 10 minutes. The single product of the
10 reaction was gel purified using the QiaQuick gel purification kit (Qiagen, Valencia, CA), cut with *EcoRI* and *SalI*, ligated to pYX242 *EcoRI/XhoI* linearized DNA with the Rapid ligation kit (Roche, Indianapolis, IN), and designated pRIG-1. The clone pRIG-1 contained a full length gene of 1329 bp (SEQ ID NO:34;
15 Figure 14) and an open reading frame of 442 amino acid (SEQ ID NO:35; Figure 15). (Plasmid pRIG-1 was deposited with the American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209 on January ___, 2002 under the terms of the Budapest Treaty and was accorded ATCC deposit number ____.)

20

Example 13

Expression of *I. galbana* Desaturase Gene in Baker's Yeast

25

The clone pRIG-1 containing the full-length gene was transformed into the yeast host *S. cerevisiae* 334 and plated on selective media as described in Example 4. The cultures were grown at 24°C for 48 hours in minimal media lacking leucine,
30 with 50 μM of exogenous free fatty acid added as a substrate as shown in Table 10. The conversion of substrates was ETA (20:4n-3) to EPA (20:5n-3) and DGLA (20:3n-6) to AA (20:4n-6).

The 45.4% conversion to ARA and 59.75% conversion to EPA indicate that this gene encodes for a $\Delta 5$ -desaturase. Table 10 shows some of the fatty acids as a percentage of the lipid extracted from the yeast host. For $\Delta 5$ -desaturase activity, there was little or no background (detection of ARA or EPA observed in the negative control containing the yeast expression plasmid, pYX242.)

Example 14

Co-Expression of *I. galbana* Desaturase Gene with Elongases

The plasmid pRIG-1 could be co-transformed with an additional enzyme in the PUFA pathway, such as pRAE-73-A3 which contains the human elongase gene in the yeast expression vector pYES2 as described in Example 4, and co-transformants selected on minimal media lacking leucine and uracil. Substrates such as DGLA or ETA could be added so that the $\Delta 5$ -desaturase would actively produced ARA or EPA, to which the elongase is able to add two carbons to produce ADA or $\Delta 3$ -DPA. Therefore, *I. galbana* $\Delta 5$ -desaturase could produce a product in a heterologous expression system that can be used by an additional heterologous enzyme in the PUFA biosynthetic pathway, to produce the expected PUFA.

Nutritional Compositions

The PUFAs described in the Detailed Description may be utilized in various nutritional supplements, infant formulations, nutritional substitutes and other

nutritional solutions.

I. INFANT FORMULATIONS

A. Isomil® Soy Formula with Iron:

5

Usage: As a beverage for infants, children and adults with an allergy or sensitivity to cows milk. A feeding for patients with disorders for which lactose should be avoided: lactase deficiency, lactose intolerance and galactosemia.

10

Features:

- Soy protein isolate to avoid symptoms of cow's-milk-protein allergy or sensitivity.

15

- Lactose-free formulation to avoid lactose-associated diarrhea.

- Low osmolality (240 mOs/kg water) to reduce risk of osmotic diarrhea.

20

- Dual carbohydrates (corn syrup and sucrose) designed to enhance carbohydrate absorption and reduce the risk of exceeding the absorptive capacity of the damaged gut.

- 1.8 mg of Iron (as ferrous sulfate) per 100 Calories to help prevent iron deficiency.

- Recommended levels of vitamins and minerals.

25

- Vegetable oils to provide recommended levels of essential fatty acids.

- Milk-white color, milk-like consistency and pleasant aroma.

30

Ingredients: (Pareve) 85% water, 4.9% corn syrup, 2.6% sugar (sucrose), 2.1 % soy oil, 1.9% soy protein isolate, 1.4% coconut oil, 0.15% calcium citrate, 0. 11 % calcium phosphate tribasic, potassium citrate, potassium phosphate

monobasic, potassium chloride, mono- and diglycerides, soy lecithin, carrageenan, ascorbic acid, L-methionine, magnesium chloride, potassium phosphate dibasic, sodium chloride, choline chloride, taurine, ferrous sulfate, m-
5 inositol, alpha-tocopheryl acetate, zinc sulfate, L-carnitine, niacinamide, calcium pantothenate, cupric sulfate, vitamin A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, potassium iodide, phylloquinone,
10 biotin, sodium selenite, vitamin D3 and cyanocobalamin.

B. Isomil® DF Soy Formula For Diarrhea:

15 Usage: As a short-term feeding for the dietary management of diarrhea in infants and toddlers.

Features:

-First infant formula to contain added dietary fiber from soy fiber specifically for diarrhea management.
20

-Clinically shown to reduce the duration of loose, watery stools during mild to severe diarrhea in infants.

-Nutritionally complete to meet the nutritional needs of the infant.

25 -Soy protein isolate with added L-methionine meets or exceeds an infant's requirement for all essential amino acids.

-Lactose-free formulation to avoid lactose-associated diarrhea.

30 -Low osmolality (240 mOsm/kg water) to reduce the risk of osmotic diarrhea.

-Dual carbohydrates (corn syrup and sucrose) designed to enhance carbohydrate absorption and reduce the risk of exceeding the absorptive capacity of the damaged gut.

-Meets or exceeds the vitamin and mineral levels

recommended by the Committee on Nutrition of the American Academy of Pediatrics and required by the Infant Formula Act.

-1.8 mg of iron (as ferrous sulfate) per 100 Calories to help prevent iron deficiency.

-Vegetable oils to provide recommended levels of essential fatty acids.

Ingredients: (Pareve) 86% water, 4.8% corn syrup, 2.5% sugar (sucrose), 2.1% soy oil, 2.0% soy protein isolate, 1.4% coconut oil, 0.77% soy fiber, 0.12% calcium citrate, 0.11% calcium phosphate tribasic, 0.10% potassium citrate, potassium chloride, potassium phosphate monobasic, mono and diglycerides, soy lecithin, carrageenan, magnesium chloride, ascorbic acid, L-methionine, potassium phosphate dibasic, sodium chloride, choline chloride, taurine, ferrous sulfate, m-inositol, alpha-tocopheryl acetate, zinc sulfate, L-carnitine, niacinamide, calcium pantothenate, cupric sulfate, vitamin A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, potassium iodide, phylloquinone, biotin, sodium selenite, vitamin D3 and cyanocobalamin.

C. Isomil® SF Sucrose-Free Soy Formula With Iron:

Usage: As a beverage for infants, children and adults with an allergy or sensitivity to cow's-milk protein or an

intolerance to sucrose. A feeding for patients with disorders for which lactose and sucrose should be avoided.

Features:

- 5 -Soy protein isolate to avoid symptoms of cow's-milk-protein allergy or sensitivity.
- Lactose-free formulation to avoid lactose-associated diarrhea (carbohydrate source is Polycose® Glucose Polymers).
- 10 -Sucrose free for the patient who cannot tolerate sucrose.
- Low osmolality (180 mOsm/kg water) to reduce risk of osmotic diarrhea.
- 1.8 mg of iron (as ferrous sulfate) per 100 Calories to help prevent iron deficiency.
- 15 -Recommended levels of vitamins and minerals.
- Vegetable oils to provide recommended levels of essential fatty acids.
- Milk-white color, milk-like consistency and pleasant aroma.

20

Ingredients: (Pareve) 75% water, 11.8% hydrolyzed cornstarch, 4.1% soy oil, 4.1 % soy protein isolate, 2.8% coconut oil, 1.0% modified cornstarch, 0.38% calcium phosphate tribasic, 0. 17% potassium citrate, 0.13% potassium chloride, mono- and diglycerides, soy lecithin, magnesium chloride, ascorbic acid, L-methionine, calcium carbonate, sodium chloride, choline chloride, carrageenan, taurine, ferrous sulfate, m-inositol, alpha-tocopheryl acetate, zinc sulfate, L-carnitine, niacinamide, calcium

25

30 pantothenate, cupric sulfate, vitamin A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, potassium iodide, phylloquinone, biotin, sodium selenite, vitamin D3 and cyanocobalamin.

D. Isomil® 20 Soy Formula With Iron Ready To Feed,
20 Cal/fl oz.:

Usage: When a soy feeding is desired.

5

10

15

20

Ingredients: (Pareve) 85% water, 4.9% corn syrup, 2.6%
sugar(sucrose), 2.1 % soy oil, 1.9% soy protein isolate,
1.4% coconut oil, 0.15% calcium citrate, 0. 11% calcium
phosphate tribasic, potassium citrate, potassium phosphate
monobasic, potassium chloride, mono- and diglycerides, soy
lecithin, carrageenan, ascorbic acid, L-methionine,
magnesium chloride, potassium phosphate dibasic, sodium
chloride, choline chloride, taurine, ferrous sulfate, m-
inositol, alpha-tocopheryl acetate, zinc sulfate, L-
carnitine, niacinamide, calcium pantothenate, cupric
sulfate, vitamin A palmitate, thiamine chloride
hydrochloride, riboflavin, pyridoxine hydrochloride, folic
acid, manganese sulfate, potassium iodide, phylloquinone,
biotin, sodium selenite, vitamin D3 and cyanocobalamin.

25

E. Similac® Infant Formula:

Usage: When an infant formula is needed: if the decision
is made to discontinue breastfeeding before age 1 year, if
a supplement to breastfeeding is needed or as a routine
feeding if breastfeeding is not adopted.

30

Features:

-Protein of appropriate quality and quantity for good
growth; heat-denatured, which reduces the risk of milk-
associated enteric blood loss.

-Fat from a blend of vegetable oils (doubly homogenized),
providing essential linoleic acid that is easily absorbed.

-Carbohydrate as lactose in proportion similar to that of human milk.

-Low renal solute load to minimize stress on developing organs.

5 -Powder, Concentrated Liquid and Ready To Feed forms.

Ingredients: (-D) Water, nonfat milk, lactose, soy oil, coconut oil, mono- and diglycerides, soy lecithin, ascorbic acid, carrageenan, choline chloride, taurine, m-
10 inositol, alpha-tocopheryl acetate, zinc sulfate, niacinamide, ferrous sulfate, calcium pantothenate, cupric sulfate, vitamin A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, phylloquinone, biotin, sodium
15 selenite, vitamin D3 and cyanocobalamin.

F.Similac® NeoCare Premature Infant Formula With Iron:

Usage: For premature infants' special nutritional needs
20 after hospital discharge. Similac NeoCare is a nutritionally complete formula developed to provide premature infants with extra calories, protein, vitamins and minerals needed to promote catch-up growth and support development.

25

Features:

-Reduces the need for caloric and vitamin supplementation. More calories (22 Cal/fl oz) than standard term formulas (20 Cal/fl oz).

30

-Highly absorbed fat blend, with medium-chain triglycerides (MCToil) to help meet the special digestive needs of premature infants.

-Higher levels of protein, vitamins and minerals per 100 calories to extend the nutritional support initiated in-hospital.

-More calcium and phosphorus for improved bone mineralization.

Ingredients: -D Corn syrup solids, nonfat milk, lactose, whey protein concentrate, soy oil, high-oleic safflower oil, fractionated coconut oil (medium chain triglycerides), coconut oil, potassium citrate, calcium phosphate tribasic, calcium carbonate, ascorbic acid, magnesium chloride, potassium chloride, sodium chloride, taurine, ferrous sulfate, m-inositol, choline chloride, ascorbyl palmitate, L-carnitine, alpha-tocopheryl acetate, zinc sulfate, niacinamide, mixed tocopherols, sodium citrate, calcium pantothenate, cupric sulfate, thiamine chloride hydrochloride, vitamin A palmitate, beta carotene, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, phylloquinone, biotin, sodium selenite, vitamin D3 and cyanocobalamin.

G. Similac Natural Care Low-Iron Human Milk Fortifier Ready To Use, 24 Cal/fl oz.:

Usage: Designed to be mixed with human milk or to be fed alternatively with human milk to low-birth-weight infants.

Ingredients: -D Water, nonfat milk, hydrolyzed cornstarch, lactose, fractionated coconut oil (medium-chain triglycerides), whey protein concentrate, soy oil, coconut oil, calcium phosphate tribasic, potassium citrate, magnesium chloride, sodium citrate, ascorbic acid, calcium carbonate, mono and diglycerides, soy lecithin, carrageenan, choline chloride, m-inositol, taurine,

niacinamide, L-carnitine, alpha tocopheryl acetate, zinc sulfate, potassium chloride, calcium pantothenate, ferrous sulfate, cupric sulfate, riboflavin, vitamin A palmitate, thiamine chloride hydrochloride, pyridoxine hydrochloride, biotin, folic acid, manganese sulfate, phylloquinone, vitamin D3, sodium selenite and cyanocobalamin.

Various PUFAs of this invention can be substituted and/or added to the infant formulae described above and to other infant formulae known to those in the art.

II. NUTRITIONAL FORMULATIONS

A. ENSURE®

Usage: ENSURE is a low-residue liquid food designed primarily as an oral nutritional supplement to be used with or between meals or, in appropriate amounts, as a meal replacement. ENSURE is lactose- and gluten-free, and is suitable for use in modified diets, including low-cholesterol diets. Although it is primarily an oral supplement, it can be fed by tube.

Patient Conditions:

- For patients on modified diets
- For elderly patients at nutrition risk
- For patients with involuntary weight loss
- For patients recovering from illness or surgery
- For patients who need a low-residue diet

Ingredients: -D Water, Sugar (Sucrose), Maltodextrin (Corn), Calcium and Sodium Caseinates, High-Oleic Safflower Oil, Soy Protein Isolate, Soy Oil, Canola Oil, Potassium Citrate, Calcium Phosphate Tribasic, Sodium Citrate, Magnesium Chloride, Magnesium Phosphate Dibasic, Artificial Flavor, Sodium Chloride, Soy Lecithin, Choline

Chloride, Ascorbic Acid, Carrageenan, Zinc Sulfate,
Ferrous Sulfate, Alpha-Tocopheryl Acetate, Gellan Gum,
Niacinamide,
Calcium Pantothenate, Manganese Sulfate, Cupric Sulfate,
5 Vitamin A Palmitate, Thiamine Chloride Hydrochloride,
Pyridoxine Hydrochloride, Riboflavin, Folic Acid, Sodium
Molybdate, Chromium Chloride, Biotin, Potassium Iodide,
Sodium Selenate.

10 B.ENSURE® BARS:

Usage: ENSURE BARS are complete, balanced nutrition for
supplemental use between or with meals. They provide a
delicious, nutrient-rich alternative to other snacks.

15 ENSURE BARS contain <1 g lactose/bar, and Chocolate Fudge
Brownie flavor is gluten-free. (Honey Graham Crunch flavor
contains gluten.)

Patient Conditions:

20 -For patients who need extra calories, protein, vitamins
and minerals.

-Especially useful for people who do not take in enough
calories and nutrients.

-For people who have the ability to chew and swallow

25 -Not to be used by anyone with a peanut allergy or any
type of allergy to nuts.

Ingredients: Honey Graham Crunch -- High-Fructose Corn
Syrup, Soy Protein Isolate, Brown Sugar, Honey,

Maltodextrin (Corn), Crisp Rice (Milled Rice,

30 Sugar [Sucrose], Salt [Sodium Chloride] and Malt), Oat
Bran, Partially Hydrogenated Cottonseed and Soy Oils, Soy
Polysaccharide, Glycerine, Whey Protein Concentrate,
Polydextrose, Fructose, Calcium Caseinate, Cocoa Powder,
Artificial Flavors, Canola Oil, High-Oleic Safflower Oil,

Nonfat Dry Milk, Whey Powder, Soy Lecithin and Corn Oil.
Manufactured in a facility that processes nuts.

Vitamins and Minerals: Calcium Phosphate Tribasic,
Potassium Phosphate Dibasic, Magnesium Oxide, Salt (Sodium
Chloride), Potassium Chloride, Ascorbic Acid, Ferric
Orthophosphate, Alpha-Tocopheryl Acetate, Niacinamide,
Zinc Oxide, Calcium Pantothenate, Copper Gluconate,
Manganese Sulfate, Riboflavin, Beta Carotene, Pyridoxine
Hydrochloride, Thiamine Mononitrate, Folic Acid, Biotin,
Chromium Chloride, Potassium Iodide, Sodium Selenate,
Sodium Molybdate, Phylloquinone, Vitamin D3 and
Cyanocobalamin.

Protein: Honey Graham Crunch - The protein source is a
blend of soy protein isolate and milk proteins.

| | |
|---------------------|-----|
| Soy protein isolate | 74% |
| Milk proteins | 26% |

Fat: Honey Graham Crunch - The fat source is a blend of
partially hydrogenated cottonseed and soybean, canola,
high oleic safflower, oils, and soy lecithin.

| | |
|---|-----|
| Partially hydrogenated cottonseed and soybean oil | 76% |
| Canola oil | 8% |
| High-oleic safflower oil | 8% |
| Corn oil | 4% |
| Soy lecithin | 4% |

Carbohydrate: Honey Graham Crunch - The carbohydrate
source is a combination of high-fructose corn syrup, brown

sugar, maltodextrin, honey, crisp rice, glycerine, soy polysaccharide, and oat bran.

| | | |
|----|--------------------------|-----|
| | High-fructose corn syrup | 24% |
| 5 | Brown sugar | 21% |
| | Maltodextrin | 12% |
| | Honey | 11% |
| | Crisp rice | 9% |
| | Glycerine | 9% |
| 10 | Soy Polysaccharide | 7% |
| | Oat bran | 7% |

C. ENSURE® HIGH PROTEIN:

15 Usage: ENSURE HIGH PROTEIN is a concentrated, high-protein liquid food designed for people who require additional calories, protein, vitamins, and minerals in their diets. It can be used as an oral nutritional supplement with or between meals or, in appropriate amounts, as a meal
20 replacement. ENSURE HIGH PROTEIN is lactose- and gluten-free, and is suitable for use by people recovering from general surgery or hip fractures and by patients at risk for pressure ulcers.

25 Patient Conditions:

-For patients who require additional calories, protein, vitamins, and minerals, such as patients recovering from general surgery or hip fractures, patients at risk for pressure ulcers, and patients on low-cholesterol diets.

30

Features:

-Low in saturated fat
-Contains 6 g of total fat and < 5 mg of cholesterol per serving

- Rich, creamy taste
- Excellent source of protein, calcium, and other essential vitamins and minerals
- For low-cholesterol diets
- 5 -Lactose-free, easily digested

Ingredients:

10 Vanilla Supreme: -D Water, Sugar (Sucrose), Maltodextrin
(Corn), Calcium and Sodium Caseinates, High-Oleic
Safflower Oil, Soy Protein Isolate, Soy Oil, Canola Oil,
Potassium Citrate, Calcium Phosphate Tribasic, Sodium
Citrate, Magnesium Chloride, Magnesium Phosphate Dibasic,
Artificial Flavor, Sodium Chloride, Soy Lecithin, Choline
15 Chloride, Ascorbic Acid, Carrageenan, Zinc Sulfate,
Ferrous Sulfate, Alpha-Tocopheryl Acetate, Gellan Gum,
Niacinamide,
Calcium Pantothenate, Manganese Sulfate, Cupric Sulfate,
Vitamin A Palmitate, Thiamine Chloride Hydrochloride,
20 Pyridoxine Hydrochloride, Riboflavin, Folic Acid, Sodium
Molybdate, Chromium Chloride, Biotin, Potassium Iodide,
Sodium Selenate, Phylloquinone, Vitamin D3 and
Cyanocobalamin.

25 Protein:

The protein source is a blend of two high-biologic-value proteins: casein and soy.

| | |
|---------------------------------------|-----|
| 30 Sodium and calcium caseinates | 85% |
| Soy protein isolate | 15% |

Fat:

The fat source is a blend of three oils: high-oleic safflower, canola, and soy.

| | |
|--------------------------|-----|
| High-oleic safflower oil | 40% |
| Canola oil | 30% |
| Soy oil | 30% |

5

The level of fat in ENSURE HIGH PROTEIN meets American Heart Association (AHA) guidelines. The 6 grams of fat in ENSURE HIGH PROTEIN represent 24% of the total calories, with 2.6% of the fat being from saturated fatty acids and 7.9% from polyunsaturated fatty acids. These values are within the AHA guidelines of < 30% of total calories from fat, < 10% of the calories from saturated fatty acids, and < 10% of total calories from polyunsaturated fatty acids.

10

15

Carbohydrate:

ENSURE HIGH PROTEIN contains a combination of maltodextrin and sucrose. The mild sweetness and flavor variety (vanilla supreme, chocolate royal, wild berry, and banana), plus VARI-FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, help to prevent flavor fatigue and aid in patient compliance.

20

Vanilla and other nonchocolate flavors:

25

| | |
|--------------|-----|
| Sucrose | 60% |
| Maltodextrin | 40% |

Chocolate:

30

| | |
|--------------|-----|
| Sucrose | 70% |
| Maltodextrin | 30% |

D. ENSURE® LIGHT

Usage: ENSURE LIGHT is a low-fat liquid food designed for use as an oral nutritional supplement with or between meals. ENSURE LIGHT is lactose- and gluten-free, and is suitable for use in modified diets, including low-cholesterol diets.

Patient Conditions:

-For normal-weight or overweight patients who need extra nutrition in a supplement that contains 50% less fat and 20% fewer calories than ENSURE.

-For healthy adults who do not eat right and need extra nutrition.

Features:

-Low in fat and saturated fat

-Contains 3 g of total fat per serving and < 5 mg cholesterol

-Rich, creamy taste

-Excellent source of calcium and other essential vitamins and minerals

-For low-cholesterol diets

-Lactose-free, easily digested

Ingredients:

French Vanilla: -D Water, Maltodextrin (Corn), Sugar (Sucrose), Calcium Caseinate, High-Oleic Safflower Oil, Canola Oil, Magnesium Chloride, Sodium Citrate, Potassium Citrate, Potassium Phosphate Dibasic, Magnesium Phosphate Dibasic, Natural and Artificial Flavor, Calcium Phosphate Tribasic, Cellulose Gel, Choline Chloride, Soy Lecithin, Carrageenan, Salt (Sodium Chloride), Ascorbic Acid, Cellulose Gum, Ferrous Sulfate, Alpha-Tocopheryl Acetate,

Zinc Sulfate, Niacinamide, Manganese Sulfate, Calcium
Pantothenate, Cupric Sulfate, Thiamine Chloride
Hydrochloride, Vitamin A Palmitate, Pyridoxine
Hydrochloride, Riboflavin, Chromium Chloride, Folic Acid,
5 Sodium Molybdate, Biotin, Potassium Iodide, Sodium
Selenate, Phylloquinone, Vitamin D3 and Cyanocobalamin.

Protein:

The protein source is calcium caseinate.

10 Calcium caseinate 100%

Fat:

15 The fat source is a blend of two oils: high-oleic
safflower and canola.

| | |
|--------------------------|-----|
| High-oleic safflower oil | 70% |
| Canola oil | 30% |

20 The level of fat in ENSURE LIGHT meets American Heart
Association (AHA) guidelines. The 3 grams of fat in ENSURE
LIGHT represent 13.5% of the total calories, with 1.4% of
the fat being from saturated fatty acids and 2.6%
25 from polyunsaturated fatty acids. These values are within
the AHA guidelines of < 30% of total calories from fat, <
10% of the, calories from saturated fatty acids, and < 10%
of total calories from polyunsaturated fatty acids.

30 Carbohydrate:

ENSURE LIGHT contains a combination of maltodextrin and
sucrose. The chocolate flavor contains corn syrup as
well. The mild sweetness and flavor variety (French
vanilla, chocolate supreme, strawberry swirl), plus VARI-

FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, help to prevent flavor fatigue and aid in patient compliance.

5

Vanilla and other nonchocolate flavors:

| | |
|--------------|-----|
| Sucrose | 51% |
| Maltodextrin | 49% |

10

Chocolate:

| | |
|--------------|-------|
| Sucrose | 47.0% |
| Corn Syrup | 26.5% |
| Maltodextrin | 26.5% |

15

Vitamins and Minerals:

An 8-fl-oz serving of ENSURE LIGHT provides at least 25% of the RDIs for 24 key vitamins and minerals.

20

Caffeine:

Chocolate flavor contains 2.1 mg caffeine/8 fl oz.

E.ENSURE PLUS®

25

Usage: ENSURE PLUS is a high-calorie, low-residue liquid food for use when extra calories and nutrients, but a normal concentration of protein, are needed. It is designed primarily as an oral nutritional supplement to be used

30

with or between meals or, in appropriate amounts, as a meal replacement. ENSURE PLUS is lactose- and gluten-free. Although it is primarily an oral nutritional supplement, it can be fed by tube.

Patient Conditions:

-For patients who require extra calories and nutrients,
but a normal concentration of protein, in a limited
volume.

5 -For patients who need to gain or maintain healthy weight.

Features:

-Rich, creamy taste

-Good source of essential vitamins and minerals

10

Ingredients:

Vanilla: -D Water, Corn Syrup, Maltodextrin (Corn), Corn
Oil, Sodium and Calcium Caseinates, Sugar (Sucrose), Soy
15 Protein Isolate, Magnesium Chloride, Potassium Citrate,
Calcium Phosphate Tribasic, Soy Lecithin, Natural and
Artificial Flavor, Sodium Citrate, Potassium Chloride,
Choline Chloride, Ascorbic Acid, Carrageenan, Zinc
Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate,
20 Niacinamide, Calcium Pantothenate, Manganese Sulfate,
Cupric
Sulfate, Thiamine Chloride Hydrochloride, Pyridoxine
Hydrochloride, Riboflavin, Vitamin A Palmitate, Folic
Acid, Biotin, Chromium Chloride, Sodium Molybdate,
25 Potassium Iodide, Sodium Selenite, Phylloquinone,
Cyanocobalamin and Vitamin D3.

Protein:

The protein source is a blend of two high-biologic-
30 value proteins: casein and soy.

| | |
|-------------------------------|-----|
| Sodium and calcium caseinates | 84% |
| Soy protein isolate | 16% |

Fat:

The fat source is corn oil.

Corn oil 100%

Carbohydrate:

ENSURE PLUS contains a combination of maltodextrin and sucrose. The mild sweetness and flavor variety (vanilla, chocolate, strawberry, coffee, butter pecan, and eggnog), plus VARI-FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, help to prevent flavor fatigue and aid in patient compliance.

Vanilla, strawberry, butter pecan, and coffee flavors:

| | |
|--------------|-----|
| Corn Syrup | 39% |
| Maltodextrin | 38% |
| Sucrose | 23% |

Chocolate and eggnog flavors:

| | |
|--------------|-----|
| Corn Syrup | 36% |
| Maltodextrin | 34% |
| Sucrose | 30% |

Vitamins and Minerals:

An 8-fl-oz serving of ENSURE PLUS provides at least 15% of the RDIs for 25 key Vitamins and minerals.

Caffeine:

Chocolate flavor contains 3.1 mg Caffeine/8 fl oz. Coffee flavor contains a trace amount of caffeine.

F. ENSURE PLUS® HN

Usage: ENSURE PLUS HN is a nutritionally complete high-calorie, high-nitrogen liquid food designed for people with higher calorie and protein needs or limited volume tolerance. It may be used for oral supplementation or for total nutritional support by tube. ENSURE PLUS HN is lactose- and gluten-free.

Patient Conditions:

- For patients with increased calorie and protein needs, such as following surgery or injury.
- For patients with limited volume tolerance and early satiety.

Features:

- For supplemental or total nutrition
- For oral or tube feeding
- 1.5 CaVmL,
- High nitrogen
- Calorically dense

Ingredients:

Vanilla: -D Water, Maltodextrin (Corn), Sodium and Calcium Caseinates, Corn Oil, Sugar (Sucrose), Soy Protein Isolate, Magnesium Chloride, Potassium Citrate, Calcium Phosphate Tribasic, Soy Lecithin, Natural and Artificial Flavor, Sodium Citrate, Choline Chloride, Ascorbic Acid, Taurine, L-Carnitine, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Niacinamide, Carrageenan, Calcium Pantothenate, Manganese Sulfate, Cupric Sulfate, Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, Vitamin A Palmitate, Folic Acid, Biotin, Chromium Chloride, Sodium Molybdate, Potassium Iodide,

Sodium Selenite, Phylloquinone, Cyanocobalamin and Vitamin D3.

G.ENSURE® POWDER:

5

Usage: ENSURE POWDER (reconstituted with water) is a low-residue

10

liquid food designed primarily as an oral nutritional supplement to be used with or between meals. ENSURE POWDER is lactose- and gluten-free, and is suitable for use in modified diets, including low-cholesterol diets.

Patient Conditions:

15

- For patients on modified diets
- For elderly patients at nutrition risk
- For patients recovering from illness/surgery
- For patients who need a low-residue diet

Features:

20

25

- Convenient, easy to mix
- Low in saturated fat
- Contains 9 g of total fat and < 5 mg of cholesterol per serving
- High in vitamins and minerals
- For low-cholesterol diets
- Lactose-free, easily digested

30

Ingredients: -D Corn Syrup, Maltodextrin (Corn), Sugar (Sucrose), Corn Oil, Sodium and Calcium Caseinates, Soy Protein Isolate, Artificial Flavor, Potassium Citrate, Magnesium Chloride, Sodium Citrate, Calcium Phosphate Tribasic, Potassium Chloride, Soy Lecithin, Ascorbic Acid, Choline Chloride, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Niacinamide, Calcium Pantothenate,

Manganese Sulfate, Thiamine Chloride Hydrochloride, Cupric Sulfate, Pyridoxine Hydrochloride, Riboflavin, Vitamin A Palmitate, Folic Acid, Biotin, Sodium Molybdate, Chromium Chloride, Potassium Iodide, Sodium Selenate,
5 Phylloquinone, Vitamin D3 and Cyanocobalamin.

Protein:

The protein source is a blend of two high-biologic-value proteins: casein and soy.

10

| | |
|-------------------------------|-----|
| Sodium and calcium caseinates | 84% |
| Soy protein isolate | 16% |

Fat:

15

The fat source is corn oil.

| | |
|----------|------|
| Corn oil | 100% |
|----------|------|

Carbohydrate:

20

ENSURE POWDER contains a combination of corn syrup, maltodextrin, and sucrose. The mild sweetness of ENSURE POWDER, plus VARI-FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, helps to prevent flavor fatigue and aid in patient compliance.

25

Vanilla:

| | |
|--------------|-----|
| Corn Syrup | 35% |
| Maltodextrin | 35% |
| 30 Sucrose | 30% |

H. ENSURE® PUDDING

Usage: ENSURE PUDDING is a nutrient-dense supplement providing balanced nutrition in a nonliquid form to be used with or between meals. It is appropriate for consistency-modified diets (e.g., soft, pureed, or full liquid) or for people with swallowing impairments. ENSURE PUDDING is gluten-free.

Patient Conditions:

- For patients on consistency-modified diets (e.g., soft, pureed, or full liquid)
- For patients with swallowing impairments

Features:

- Rich and creamy, good taste
- Good source of essential vitamins and minerals
- Convenient-needs no refrigeration
- Gluten-free

Nutrient Profile per 5 oz: Calories 250, Protein 10.9%, Total Fat 34.9%, Carbohydrate 54.2%

Ingredients:

Vanilla: -D Nonfat Milk, Water, Sugar (Sucrose), Partially Hydrogenated Soybean Oil, Modified Food Starch, Magnesium Sulfate, Sodium Stearoyl Lactylate, Sodium Phosphate Dibasic, Artificial Flavor, Ascorbic Acid, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Choline Chloride, Niacinamide, Manganese Sulfate, Calcium Pantothenate, FD&C Yellow #5, Potassium Citrate, Cupric Sulfate, Vitamin A Palmitate, Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, FD&C Yellow #6, Folic Acid, Biotin, Phylloquinone, Vitamin D3 and Cyanocobalamin.

Protein:

The protein source is nonfat milk.

| | | |
|---|-------------|------|
| 5 | Nonfat milk | 100% |
|---|-------------|------|

Fat:

The fat source is hydrogenated soybean oil.

| | | |
|----|--------------------------|------|
| 10 | Hydrogenated soybean oil | 100% |
|----|--------------------------|------|

Carbohydrate:

| | |
|----|--|
| 15 | ENSURE PUDDING contains a combination of sucrose and modified food starch. The mild sweetness and flavor variety (vanilla, chocolate, butterscotch, and tapioca) help prevent flavor fatigue. The product contains 9.2 grams of lactose per serving. |
|----|--|

| | |
|----|---|
| 20 | Vanilla and other nonchocolate flavors: |
|----|---|

| | | |
|--|----------------------|-----|
| | Sucrose | 56% |
| | Lactose | 27% |
| | Modified food starch | 17% |

| | |
|----|--|
| 25 | |
|----|--|

Chocolate:

| | | |
|----|----------------------|-----|
| | Sucrose | 58% |
| | Lactose | 26% |
| 30 | Modified food starch | 16% |

I. ENSURE® WITH FIBER:

Usage: ENSURE WITH FIBER is a fiber-containing, nutritionally complete liquid food designed for people who

can benefit from increased dietary fiber and nutrients. ENSURE WITH FIBER is suitable for people who do not require a low-residue diet. It can be fed orally or by tube, and can be used as a nutritional supplement to a regular diet or, in appropriate amounts, as a meal replacement. ENSURE WITH FIBER is lactose- and gluten-free, and is suitable for use in modified diets, including low-cholesterol diets.

10 Patient Conditions:

-For patients who can benefit from increased dietary fiber and nutrients

Features:

- 15 -New advanced formula-low in saturated fat, higher in vitamins and minerals
- Contains 6 g of total fat and < 5 mg of cholesterol per serving
- Rich, creamy taste
- 20 -Good source of fiber
- Excellent source of essential vitamins and minerals
- For low-cholesterol diets
- Lactose- and gluten-free

25 Ingredients:

Vanilla: -D Water; Maltodextrin (Corn), Sugar (Sucrose), Sodium and Calcium Caseinates, Oat Fiber, High-Oleic Safflower Oil, Canola Oil, Soy Protein Isolate, Corn Oil, Soy Fiber, Calcium Phosphate Tribasic, Magnesium Chloride, Potassium Citrate, Cellulose Gel, Soy Lecithin, Potassium Phosphate Dibasic, Sodium Citrate, Natural and Artificial Flavors, Choline Chloride, Magnesium Phosphate, Ascorbic Acid, Cellulose Gum, Potassium Chloride, Carrageenan, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Zinc Sulfate,

Niacinamide, Manganese Sulfate, Calcium Pantothenate,
Cupric Sulfate, Vitamin A Palmitate, Thiamine Chloride
Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, Folic
Acid, Chromium Chloride, Biotin, Sodium Molybdate,
5 Potassium Iodide, Sodium Selenate, Phylloquinone, Vitamin
D3 and Cyanocobalamin.

Protein:

The protein source is a blend of two high-biologic-
10 value proteins-casein and soy.

| | |
|-------------------------------|-----|
| Sodium and calcium caseinates | 80% |
| Soy protein isolate | 20% |

15 Fat:

The fat source is a blend of three oils: high-oleic
safflower, canola, and corn.

| | |
|-----------------------------|-----|
| 20 High-oleic safflower oil | 40% |
| Canola oil | 40% |
| Corn oil | 20% |

The level of fat in ENSURE WITH FIBER meets American Heart
25 Association (AHA) guidelines. The 6 grams of fat in ENSURE
WITH FIBER represent 22% of the total calories, with 2.01
% of the fat being from saturated fatty acids and 6.7%
from polyunsaturated fatty acids. These values are within
the AHA guidelines of $\leq 30\%$ of total calories from fat, <
30 10% of the calories from saturated fatty acids, and $\leq 10\%$
of total calories from polyunsaturated fatty acids.

Carbohydrate:

ENSURE WITH FIBER contains a combination of maltodextrin and sucrose. The mild sweetness and flavor variety (vanilla, chocolate, and butter pecan), plus VARI-FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, help to prevent flavor fatigue and aid in patient compliance.

Vanilla and other nonchocolate flavors:

| | | |
|----|--------------|-----|
| 10 | Maltodextrin | 66% |
| | Sucrose | 25% |
| | Oat Fiber | 7% |
| | Soy Fiber | 2% |

15 Chocolate:

| | | |
|----|--------------|-----|
| | Maltodextrin | 55% |
| | Sucrose | 36% |
| | Oat Fiber | 7% |
| 20 | Soy Fiber | 2% |

Fiber:

The fiber blend used in ENSURE WITH FIBER consists of oat fiber and soy polysaccharide. This blend results in approximately 4 grams of total dietary fiber per 8-fl. oz can. The ratio of insoluble to soluble fiber is 95:5.

The various nutritional supplements described above and known to others of skill in the art can be substituted and/or supplemented with the PUFAs produced in accordance with the present invention.

J.Oxepa™ Nutritional Product

Oxepa is a low-carbohydrate, calorically dense, enteral nutritional product designed for the dietary management of patients with or at risk for ARDS. It has a unique combination of ingredients, including a patented oil blend containing eicosapentaenoic acid (EPA from fish oil), γ -linolenic acid (GLA from borage oil), and elevated antioxidant levels.

Caloric Distribution:

Caloric density is high at 1.5 Cal/mL (355 Cal/8 fl oz), to minimize the volume required to meet energy needs. The distribution of Calories in Oxepa is shown in Table A.

Table A. Caloric Distribution of Oxepa

| | per 8 fl oz. | per liter | % of Cal |
|------------------|--------------|-----------|-----------|
| Calories | 355 | 1,500 | --- |
| Fat (g) | 22.2 | 93.7 | 55.2 |
| Carbohydrate (g) | | 25 | 105.528.1 |
| Protein (g) | 14.8 | 62.5 | 16.7 |
| Water (g) | 186 | 785 | --- |

Fat:

-Oxepa contains 22.2 g of fat per 8-fl oz serving (93.7 g/L).

-The fat source is an oil blend of 31.8% canola oil, 25% medium-chain triglycerides (MCTs), 20% borage oil, 20% fish oil, and 3.2 % soy lecithin. The typical fatty acid profile of Oxepa is shown in Table B.

-Oxepa provides a balanced amount of polyunsaturated, monounsaturated, and saturated fatty acids, as shown in Table VI.

-Medium-chain triglycerides (MCTs) -- 25% of the fat blend
-- aid gastric emptying because they are absorbed by the
intestinal tract without emulsification by bile acids.

5

The various fatty acid components of Oxepa™ nutritional
product can be substituted and/or supplemented with the
PUFAs produced in accordance with this invention.

Table B. Typical Fatty Acid Profile

| | | % Total | g/8 fl oz* | g/L* |
|----|---|---------|------------|-------|
| 5 | Fatty Acids | | | |
| | Caproic (6:0) | 0.2 | 0.04 | 0.18 |
| | Caprylic (8:0) | 14.69 | 3.1 | 13.07 |
| 10 | Capric (10:0) | 11.06 | 2.33 | 9.87 |
| | Palmitic (16:0) | 5.59 | 1.18 | 4.98 |
| | Palmitoleic | 1.82 | 0.38 | 1.62 |
| | Stearic | 1.94 | 0.39 | 1.64 |
| | Oleic | 24.44 | 5.16 | 21.75 |
| 15 | Linoleic | 16.28 | 3.44 | 14.49 |
| | α -Linolenic | 3.47 | 0.73 | 3.09 |
| | γ -Linolenic | 4.82 | 1.02 | 4.29 |
| | Eicosapentaenoic | 5.11 | 1.08 | 4.55 |
| | n-3-Docosapent- | 0.55 | 0.12 | 0.49 |
| 20 | aenoic | | | |
| | Docosahexaenoic | 2.27 | 0.48 | 2.02 |
| | Others | 7.55 | 1.52 | 6.72 |
| 25 | Fatty acids equal approximately 95% of total fat. | | | |

Table C. Fat Profile of Oxepa.

| | | |
|---|------------------------------|-----------------|
| | % of total calories from fat | 55.2 |
| | Polyunsaturated fatty acids | 31.44 g/L |
| | Monounsaturated fatty acids | 25.53 g/L |
| 5 | Saturated fatty acids | 32.38 g/L |
| | n-6 to n-3 ratio | 1.75:1 |
| | Cholesterol | 9.49 mg/8 fl oz |
| | | 40.1 mg/L |

Carbohydrate:

10 -The carbohydrate content is 25.0 g per 8-fl-oz serving (105.5 g/L).

-The carbohydrate sources are 45% maltodextrin (a complex carbohydrate) and 55% sucrose (a simple sugar), both of which are readily digested and absorbed.

15 -The high-fat and low-carbohydrate content of Oxepa is designed to minimize carbon dioxide (CO₂) production. High CO₂ levels can complicate weaning in ventilator-dependent patients. The low level of carbohydrate also may be useful for those patients who have developed stress-induced

20 hyperglycemia.

-Oxepa is lactose-free.

Dietary carbohydrate, the amino acids from protein, and the glycerol moiety of fats can be converted to glucose within the body. Throughout this process, the carbohydrate requirements of glucose-dependent tissues (such as the central nervous system and red blood cells) are met.

25 However, a diet free of carbohydrates can lead to ketosis, excessive catabolism of tissue protein, and loss of fluid and electrolytes. These effects can be prevented by daily ingestion of 50 to 100 g of digestible carbohydrate, if caloric intake is adequate. The carbohydrate level in Oxepa is also sufficient to minimize gluconeogenesis, if

30 energy needs are being met.

Protein:

-Oxepa contains 14.8 g of protein per 8-fl-oz serving
(62.5 g/L).

5 -The total calorie/nitrogen ratio (150:1) meets the need
of stressed patients.

-Oxepa provides enough protein to promote anabolism and
the maintenance of lean body mass without precipitating
respiratory problems. High protein intakes are a concern
10 in patients with respiratory insufficiency. Although
protein has little effect on CO₂ production, a high
protein diet will increase ventilatory drive.

-The protein sources of Oxepa are 86.8% sodium caseinate
and 13.2% calcium caseinate.

15 -The amino acid profile of the protein system in Oxepa
meets or surpasses the standard for high quality protein
set by the National Academy of Sciences.

* Oxepa is gluten-free.

Table 1*Saprolegnia diclina* (ATCC 56851) Desaturase Expression in Baker's Yeast

| CLONE | TYPE OF ENZYME ACTIVITY | % CONVERSION OF SUBSTRATE | |
|------------------------------------|----------------------------|------------------------------|----------------------|
| pRSP1 | $\Delta 9$ | 0 | (18:0 to 18:1n-9)* |
| (S. diclina $\Delta 6$ desaturase) | $\Delta 12$ | 0 | (18:1 to 18:2n-6) |
| | $\Delta 15$ | 0 | (18:2n-6 to 18:3n-3) |
| | $\Delta 6$ | 28 | (18:2n-6 to 18:3n-6) |
| | $\Delta 6$ | 37 | (18:3n-3 to 18:4n-3) |
| | $\Delta 5$ | 0 | (20:3n-6 to 20:4n-6) |
| pRSP3 | $\Delta 9$ | 0 | (18:0 to 18:1n-9) |
| (S. diclina $\Delta 5$ desaturase) | $\Delta 12$ | 0 | (18:1 to 18:2n-6) |
| | $\Delta 15$ | 0 | (18:2n-6 to 18:3n-3) |
| | $\Delta 6$ | 0 | (18:2n-6 to 18:3n-6) |
| | $\Delta 6$ | 0 | (18:3n-3 to 18:4n-3) |
| | $\Delta 5$ | 27 | (20:3n-6 to 20:4n-6) |

*above endogenous $\Delta 9$ activity

Table 2

Fatty Acid as a Percentage of Total Lipid Extracted from Yeast

| Clone | 18:1* Present | 18:2 (n-3) Produced | 18:2 (n-6) Incorporated | 18:3 (n-3) Produced | 18:3 (n-6) Produced | 18:3 (n-3) Incorporated | 18:4 (n-3) Produced | 20:3(n-6) Incorporated | 20:4 (n-6) Produced |
|---------------------|------------------|------------------------|----------------------------|------------------------|------------------------|----------------------------|------------------------|---------------------------|------------------------|
| pYX242 (control) | 15.07 | 0 | 11.14 | 0 | 0 | 11.35 | 0 | 11.55 | 0 |
| pRSP1 (Δ6) | 14.41 | 0 | 6.31 | 0 | 2.44 | 7.95 | 4.63 | 13.70 | 0 |
| pRSP3 (Δ5) | 15.34 | 0.08 | 10.72 | 0 | 0 | 10.43 | 0 | 20.69 | 7.74 |

50 μM substrate added

*18:1 is an endogenous fatty acid in yeast

Key:

| | |
|------------|---------------------------|
| 18:1 | = Oleic acid |
| 18:2 (n-6) | = Linoleic acid |
| 18:3 (n-3) | = α-Linolenic acid |
| 18:3 (n-6) | = γ-Linolenic acid |
| 18:4 (n-3) | = Stearidonic acid |
| 20:3 (n-6) | = Dihomo-γ-linolenic acid |
| 20:4 (n-6) | = Arachidonic acid |

Table 3

Fatty Acid as a Percentage of Total Lipid Extracted from Yeast

| Clone | Plasmid in yeast (enzyme) | 18:2 (n-6) Incorporated | 18:3 (n-6) Produced | 20:3 (n-6) Produced | % Conversion | 18:3 (n-3) Incorporated | 18:4 (n-3) Produced | 20:4 (n-3) Produced | % Conversion |
|---------|---|-------------------------|---------------------|---------------------|--------------|-------------------------|---------------------|---------------------|--------------|
| Control | pYX242 + pYES2 | 6.46 | 0 | 0 | 0 | 13.26 | 0 | 0 | 0 |
| pRSP5 | pRSP1 ($\Delta 6$) + pRAE73-A3 (human elongase) | 4.62 | 1.95 | 0.8 | 37.3 | 7.00 | 2.47 | 1.20 | 34.39 |
| pRSP8 | pRSP1 ($\Delta 6$) + pRPB2 (M. alpina elongase) | 4.08 | 2.31 | 0.63 | 41 | 5.93 | 2.01 | 0.85 | 32.53 |

50 μ M substrate added

Key:

18:2 (n-6) = Linoleic acid

18:3 (n-3) = α -Linolenic acid18:3 (n-6) = γ -Linolenic acid

18:4 (n-3) = Stearidonic acid

20:3 (n-6) = Dihomo- γ -linolenic acid

20:4 (n-3) = Eicosatetraenoic acid

$$\% \text{ Conversion} = \frac{[\% \text{ Product 1} + \% \text{ Product 2}]}{[\% \text{ substrate} + \% \text{ Product 1} + \% \text{ Product 2}]}$$

Table 4

Fatty Acid as a Percentage of Total Lipid Extracted from Yeast

| Clone | Plasmid in yeast (enzyme) | 18:3 (n-6) Incorporated | 20:3 (n-6) Produced | 20:4 (n-6) Produced | % Conversion | 18:4 (n-3) Incorporated | 20:4 (n-3) Produced | 20:5 (n-3) Produced | % Conversion |
|---------|---|-------------------------|---------------------|---------------------|--------------|-------------------------|---------------------|---------------------|--------------|
| Control | pYX242 + pYES2 | 8.17 | 0 | 0 | 0 | 5.61 | 0 | 0 | 0 |
| pRSP7 | pRSP3 ($\Delta 5$) + pRAE73-A3 (human elongase) | 6.25 | 2.30 | 1.63 | 38.6 | 4.12 | 1.98 | 1.56 | 46.2 |
| pRSP10 | pRSP3 ($\Delta 5$) + pRPB2 (M. alpina elongase) | 7.00 | 2.07 | 1.35 | 32.82 | 4.66 | 1.50 | 1.61 | 40.02 |

50 μ M substrate added

Key:

18:3 (n-6) = γ -Linolenic acid
 18:4 (n-3) = Stearidonic Acid
 20:3 (n-6) = Dihomo- γ -linolenic acid
 20:4 (n-6) = Arachidonic Acid
 20:4 (n-3) = Eicosatetraenoic acid
 20:5 (n-3) = Eicosapentanoic Acid

% Conversion = $\frac{[\% \text{ Product 1} + \% \text{ Product 2}]}{[\% \text{ substrate} + \% \text{ Product 1} + \% \text{ Product 2}]}$

Table 5*Thraustochytrium aureum* (ATCC 34304) Desaturase Expression in Baker's Yeast

| CLONE | TYPE OF ENZYME ACTIVITY | % CONVERSION OF SUBSTRATE | |
|--|----------------------------|------------------------------|----------------------|
| PRTA4 (<i>T. aureum</i> $\Delta 5$ desaturase) | $\Delta 9$ | 0 | (18:0 to 18:1n-9)* |
| | $\Delta 12$ | 0 | (18:1 to 18:2n-6) |
| | $\Delta 15$ | 0 | (18:2n-6 to 18:3n-3) |
| | $\Delta 6$ | 0 | (18:2n-6 to 18:3n-6) |
| | $\Delta 6$ | 0 | (18:3n-3 to 18:4n-3) |
| | $\Delta 5$ | 23.7 | (20:3n-6 to 20:4n-6) |
| | $\Delta 17$ | 0 | (20:4n-6 to 20:5n-3) |
| | $\Delta 19$ | 0 | (22:4n-6 to 22:5n-3) |
| | $\Delta 4$ | 0 | (22:4n-6 to 22:5n-6) |
| | $\Delta 4$ | 0 | (22:5n-3 to 22:6n-3) |

*above endogenous $\Delta 9$ activity

Table 6

Fatty Acid as a Percentage of Total Lipid Extracted from Yeast

| Clone | 18:1* | 18:2 Produced | 18:2(n-6) Incorporated | 18:3(n-6) Produced | 18:3(n-3) Incorporated | 18:4(n-3) Produced | 20:3(n-6) Incorporated | 20:4(n-6) Produced |
|---------------------|-------|------------------|---------------------------|-----------------------|---------------------------|-----------------------|---------------------------|-----------------------|
| PYX242 (control) | 32.13 | 0 | 8.68 | 0 | 54.42 | 0 | 4.3 | 0 |
| PRTA4 (Δ5) | 29.67 | 0 | 11.18 | 0 | 9.93 | 0 | 21.94 | 6.84 |

50 μM substrate added

*18:1 is an endogenous fatty acid in yeast

Key:

| | |
|-----------|--------------------------|
| 18:1 | =Oleic acid |
| 18:2(n-6) | =Linoleic acid |
| 18:3(n-3) | =α-Linolenic acid |
| 18:3(n-6) | =γ-Linolenic acid |
| 18:4(n-3) | =Stearidonic acid |
| 20:3(n-6) | =Dihomo-γ-linolenic acid |
| 20:4(n-6) | =Arachidonic acid |

Table 7

Fatty Acid as a Percentage of Total Lipid Extracted from Yeast

| Clone | 20:3 Incorporated | 20:4 Produced | 22:4 Produced | Conversion to products |
|--|----------------------|------------------|------------------|---------------------------|
| PYX242/ PYES2 (control) | 41.98 | 0 | 0 | 0 |
| PRTA4($\Delta 5$)/ PRAE73-A3 (human elongase) | 15.59 | 4.2 | 6.28 | 16.7 |

100 μ M substrate added

*18:1 is an endogenous fatty acid in yeast

Key:

 γ -18:3 = γ -Linolenic acid20:3 =Dihomo- γ -linolenic acid

20:4 =Arachidonic acid

22:4 =Adrenic acid

Table 8 Fatty acid profiles of yeast containing pRAT-2c, pYX242, pRAT-2c/pRAE-73-A3, or pYX242/pYES2, grown in the presence of various fatty acids.

| plasmid | pRAT-2c | pYX242 | pRAT-2c | pYX242 | pRAT-2c | pYX242 | pRAT-2c | pYX242 | pYX242 |
|-------------|---------|--------|--|--------|---------|--------|---------|--------|--------|
| 100 μ M | DGLA | DGLA | LA | LA | ALA | ALA | ALA | ALA | GLA |
| C18:2n-6 | | | 13.98 | 18.49 | | | | | |
| C18:3n-6 | | | | | | | 15.97 | | 15.1 |
| C18:3n-3 | | | | | 10.27 | | | 14.14 | |
| C18:4n-3 | | | | | | | | | |
| C20:2n-6 | | | 0.59 | 0.27 | | | | | |
| C20:3n-6 | 33.37 | 32.4 | | | | | 1.25 | | |
| C20:4n-6 | 22.98 | | | | | | 0.83 | | |
| C20:3n-3 | | | | | 1.58 | | | 0.25 | |
| C20:4n-3 | | | | | | | | | |
| | | | | | | | | | |
| | | | % conversion = [product/(substrate + product)] x 100 | | | | | | |
| elongase | | | 4.0% | 1.4% | 13.3% | | 1.7% | 11.5% | |
| $\Delta 5$ | 40.8% | | | | | | | 39.9% | |

Table 10
Fatty Acid as a Percentage of Total Lipid Extracted from Yeast

| Clone | 18:3n-3 | 18:4n-3 Produced | 20:3n-6 | 20:4n-6 Produced | percent conversion | 20:4n-3 | 20:5n-3 Produced | percent conversion |
|---------------------|---------|---------------------|---------|---------------------|-----------------------|---------|---------------------|-----------------------|
| PYX242 (control) | 2.65 | 0 | 7.2 | 0 | 0 | 11.36 | 0.38 | 3.2 |
| PRIG1 (Δ5) | 2.28 | 0 | 12.17 | 10.12 | 45.4 | 8.43 | 12.59 | 59.75 |

50 uM substrate added

Key:

- 18:3n-3 =αLinolenic acid
- 18:4n-3 =Stearidonic acid
- 20:3n-6 =Dihomo-γ-linolenic acid
- 20:4n-6 =Arachidonic acid
- 20:4n-3 =n-3 Eicosatetraenoic acid
- 20:5n-3 =Eicosapentaenoic acid

percent conversion= $\frac{\text{product}}{\text{substrate} + \text{product}} \times 100$

CLAIMS:

1. An isolated nucleic acid fragment comprising or
complementary to a nucleotide sequence encoding a
polypeptide having desaturase activity, wherein the amino
acid sequence of said polypeptide has at least 50%
sequence identity to an amino acid sequence selected from
the group consisting of SEQ ID NO:20, SEQ ID NO:29, SEQ ID
NO:31, SEQ ID NO:33 and SEQ ID NO:35.

2. An isolated nucleotide sequence comprising
or complementary to at least about 50% of the nucleotide
sequence selected from the group consisting of SEQ ID
NO:13, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30, SEQ ID
NO:32 and SEQ ID NO:34.

3. The isolated nucleotide sequence of claim 2 wherein
said sequence is selected from the group consisting of SEQ
ID NO:13, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30, SEQ ID
NO:32 and SEQ ID NO:34.

4. The isolated nucleotide sequence of claim 2 or 3
wherein said sequence encodes a functionally active
desaturase which utilizes a polyunsaturated fatty acid as
a substrate.

5. The nucleotide sequence of claim 4 wherein SEQ ID NO:13
and SEQ ID NO:19 are derived from *Saprolegnia diclina*.

6. The nucleotide sequence of claim 5 wherein
SEQ ID NO:28, SEQ ID NO:30 and SEQ ID NO:32 are derived
from *Thraustochytrium aureum*.

7. The nucleotide sequence of claim 6 wherein SEQ ID NO:34 is derived from *Isochrysis galbana*.

8. A purified polypeptide encoded by said nucleotide sequence of claim 1, 2 or 3.

9. A purified polypeptide which desaturates polyunsaturated fatty acids at carbon 5 and has at least about 50% amino acid identity to an amino acid sequence selected from the group consisting of SEQ ID NO:20, SEQ ID NO:29, SEQ ID NO:31 and SEQ ID NO:35.

10. A purified polypeptide which desaturates polyunsaturated fatty acids at carbon 6 and has at least about 50% amino acid identity to an amino acid sequence selected from the group consisting of SEQ ID NO:33 and SEQ ID NO:14.

11. A method of producing a desaturase comprising the steps of:

a) isolating a nucleotide sequence selected from the group consisting of SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32 and SEQ ID NO:34;

b) constructing a vector comprising: i) said isolated nucleotide sequence operably linked to ii) a regulatory sequence;

c) introducing said vector into a host cell for a time and under conditions sufficient for expression of said desaturase.

12. A vector comprising: a) a nucleotide sequence selected from the group consisting of SEQ ID NO:13, SEQ ID NO:19,

SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32 and SEQ ID NO:34, operably linked to b) a regulatory sequence.

13. A host cell comprising said vector of claim 12.

14. A mammalian cell comprising said vector of claim 12, wherein expression of said nucleotide sequence of said vector results in production of altered levels of AA, EPA, GLA or STA, when said cell is grown in a culture media comprising at least one fatty acid selected from the group consisting of LA, ALA, DGLA and ESP.

15. A plant cell, plant or plant tissue comprising said vector of claim 12, wherein expression of said nucleotide sequence of said vector results in production of a polyunsaturated fatty acid by said plant cell, plant or plant tissue.

16. The plant cell, plant or plant tissue of claim 15 wherein said polyunsaturated fatty acid is selected from the group consisting of AA, EPA, GLA and STA.

17. One or more plant oils or acids expressed by said plant cell, plant or plant tissue of claim 15.

18. A transgenic plant comprising said vector of claim 12, wherein expression of said nucleotide sequence of said vector results in production of a polyunsaturated fatty acid in seeds of said transgenic plant.

19. A method for producing a polyunsaturated fatty acid comprising the steps of:

a) isolating a nucleotide sequence selected from the group consisting of SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30 and SEQ ID NO:34;

5 b) constructing a vector comprising said isolated nucleotide sequence;

c) introducing said vector into a host cell for a time and under conditions sufficient for expression of $\Delta 5$ -desaturase enzyme; and

10 d) exposing said expressed $\Delta 5$ -desaturase enzyme to a substrate polyunsaturated fatty acid in order to convert said substrate to a product polyunsaturated fatty acid.

20. The method according to claim 19, wherein said
15 substrate polyunsaturated fatty acid is DGLA or 20:4n-3 and said product polyunsaturated fatty acid is AA or EPA, respectively.

21. The method according to claim 19 further comprising
20 the step of exposing said product polyunsaturated fatty acid to an elongase in order to convert said product polyunsaturated fatty acid to another polyunsaturated fatty acid.

22. The method according to claim 21 wherein said product
25 polyunsaturated fatty acid is AA or EPA and said another polyunsaturated fatty acid is adrenic acid or (n-3)-docosapentaenoic acid, respectively.

23. The method of claim 21 further comprising the
30 step of exposing said another polyunsaturated fatty acid to an additional desaturase in order to convert said

another polyunsaturated fatty acid to a final polyunsaturated fatty acid.

24. The method of claim 23 wherein said final
5 polyunsaturated fatty acid is (n-6)-docosapentaenoic acid or docosahexaenoic (DHA) acid.

25. A method for producing a polyunsaturated fatty acid comprising the steps of:

- 10 a) isolating a nucleotide sequence selected from the group consisting of SEQ ID NO:13 and SEQ ID NO:32;
b) constructing a vector comprising said isolated nucleotide sequence;
c) introducing said vector into a host cell for a time and
15 under conditions sufficient for expression of $\Delta 6$ -desaturase enzyme; and
d) exposing said expressed $\Delta 6$ -desaturase enzyme to a substrate polyunsaturated fatty acid in order to convert said substrate to a product polyunsaturated fatty acid.

20 26. The method according to claim 25, wherein said substrate polyunsaturated fatty acid is LA or ALA and said product polyunsaturated fatty acid is GLA or STA, respectively.

25 27. The method according to claim 25 further comprising the step of exposing said product polyunsaturated fatty acid to an elongase in order to convert said product polyunsaturated fatty acid to another polyunsaturated
30 fatty acid.

28. The method according to claim 27 wherein said product polyunsaturated fatty acid is GLA or STA and said another polyunsaturated fatty acid is DGLA or ETA, respectively.

5 29. The method of claim 27 further comprising the step of exposing said another polyunsaturated fatty acid to an additional desaturase in order to convert said another polyunsaturated fatty acid to a final polyunsaturated fatty acid.

10 30. The method of claim 29 wherein said final polyunsaturated fatty acid is AA or EPA.

15 31. A composition comprising at least one polyunsaturated fatty acid selected from the group consisting of said product polyunsaturated fatty acid produced according to the method of claim 19 or 25, said another polyunsaturated fatty acid produced according to the method of claim 21 or 27, and said final
20 polyunsaturated fatty acid produced according to the method of claim 23 or 29.

25 32. The composition of claim 31 wherein said product polyunsaturated fatty acid is at least one polyunsaturated fatty acid selected from the group consisting of AA, EPA, GLA and STA.

30 33. The composition of claim 31 wherein said another polyunsaturated fatty acid is at least one polyunsaturated fatty acid selected from the group consisting of adrenic acid, (n-3)-docosapentaenoic acid, DGLA and EPA.

34. The composition of claim 31 wherein said final
polyunsaturated fatty acid is at least one polyunsaturated
fatty acid selected from the group consisting of (n-6)-
docosapentaenoic acid, docosahexaenoic (DHA) acid, AA and
EPA.

35. A method of preventing or treating a condition in a
patient caused by insufficient intake of polyunsaturated
fatty acids comprising administering
to said patient said composition of claim 31 in an amount
sufficient to effect said prevention or treatment.

Figure 1
Fatty Acid Biosynthetic Pathway




Figure 2

Gene Sequence of Delta 6-Desaturase from *Nycturgus dilleni* (ATCC 56851)

```

1   ATGGTCCAGG GGCAAAAGGC CGAGAAGATC TCGTGGGCGA CCATCCGTGA
51  GCACAACCGC CAAGACAACG CGTGGATCGT GATCCACCAC AAGGTGTACG
101 ACATCTCGGC CTTTGAGGAC CAOCGCGGCG GCGTCGTGAT GTTCACGCGG
151 GCCGGCGAAG ACSCGACCGA TGGGTTGCGT GTCTTCCACG CGAGCTCGGC
201 GCTCAASCTC CTGAGCAGT ACTACGTCGG CGACGTCGAC CAGTCGACGG
251 CGGCGTCGCA CAGTTCGATC TCGGACGAGG TCAAGAAGAG CCAGTCGGAC
301 TTCATTGCGT CGTACGCAA GCTGCGCCTT GAGTCAAGC GCCTCGGCTT
351 GTACGACTCG AGCAAGCTCT ACTACCTCTA CAGTGCGCGC TCGACGCTGA
401 GCATTGCGCT TGTGTCGGCG GCCATTGCGC TCCACTTTGA CTGACGCGCC
451 ATGTACATGG TCGCGGCTGT CATCCTTGGC CTCTTTTACC AGCAGTGGCG
501 CTGGCTCGCC CATGACTTTC TGCACCACCA AGTGTTTGAG AACCACTTGT
551 TTGGCGACCT CGTCGGCGTC ATGGTCGCGA ACCTCTGGCA GGGCTTCTCG
601 GTGCACTGGT GGAAGAACAA GCACAACACG CACCATGCGA TCCCCAACCT
651 CCAOBCGACG CCGAGATCG CTTCCACGG CGACCCGGAC ATTGACAGCA
701 TGCGGATTCT CGCGTGGTCG CTCAGATGG CGCAGCACGC GGTGCACTCG
751 CCCGTCGGGC TCTTCTTCAT GCGCTACCAA GCGTACCTGT ACTTTCCCAT
801 CTTGCTCTTT GCGGTATCT CGTGGGTGAT CCAATCGGCG ATGTACGCTT
851 TCTACAAAGT TGGGCGCGGC GGCACCTTGG ACAAGGTCCA GTACCCGCTG
901 CTCGAGCGCG CCGGCTTCCT CCTCTACTAC GGTGGAACG TCGGCTTGT
951 GTAOGCAGCC AACATGTCGC TGCTCCAAGC GGTGCGTTC CTCTTTGTA
1001 GCCAGGCGTC GTGCGGCTC TTCTCGCGA TGGTCTTTAG CGTCGGCCAC
1051 AACGGCATGG AGGTCTTTGA CAAGGACAGC AAGCCCGATT TTGGAAGCT
1101 GCAGTGTCTC TCGACGCGCA ACGTGACGTC GTCGCTCGG ATCGACTGGT
1151 TCATGGGCGG CTTCAACTAC CAGATCGACC ACCACTTGT CCGATGGTG
1201 CCCGCGACA ACCTCCCGGC GCTCAACGTG CTCGTCAAGT CGCTCTGCAA
1251 GCAGTACGAC ATCCCATACC ACGAGACGGG CTTCATCGCG GGCATGGCGG
1301 AAGTCGTGCT GCACCTCGAG CGCATCTCGA TCGAGTTCTT CAAGGATTT
1351 CCCGCCATGT AA

```

Figure 3Amino Acid Sequence of Delta 6- Desaturase from *Syntherisma dactyli* (ATCC 56851)

```

1    MVQSCKAEKI SWATIREHNR QDNAMIVDHH KYVDISAFED HPGGVVMEFQ
51    AGEDATDAFA VEHPSALKL LEQYYVGDVD QSTAVDTSTI SDEVKKSQSD
101   FIASYRKLRRL EVKRLGLYDS SKLYYLYKCA STLSIALYSA AICLHEDSTA
151   MYMVAAYILG LEFYQCGWLA HDEIGHQVFE NHLEGDLVGV MYGNLWQGES
201   VQNMIONKHNT HHAIPNTHAT PEIAEHGDRD IDTMBILAMS LKMAQHAYDS
251   FVGLFEEMRYQ AYLYEPILIE ARISWYIQSA MYAFYNYGPG GTEDKQYFPL
301   IERAGLLLYY GWNIGIVYAA NMSLLQAAAF LFYSQASCGI FLAMVSVGH
351   NGNEVEIKDS KEDFNKIQVI STRNVTSSTH IDMEGSGIN Y QIDHHLEFMY
401   ERHNLPAENV LYKSLCKQYD IPYHE TGFIA GMAEVVHLE RISIEEFKEF
451   PAM*
```

Figure 4Gene Sequence of Delta 5- Desaturase from *Nycttherga dactylis* (ATCC 56851)

```

1  ATGGCCCCGC AGACGGAGCT CCGCCAGCGC CACGCCGCCG TCGCCGAGAC
51  GCCGCTGGCC GGCAGGAAGG CTTTACATG GCAGGAGGTC GCGCAGCACA
101 ACACGGCGGG CTGGCCCTGG ATCATATATC GCGGCAAGGT CTACGACGTG
151 ACCGAGTGGG CCAACAAGCA CCCCGGCGGG CCGGAGATGG TGCTGCTGCA
201 CGCCGCTCGC GAGGCCACCG ACACGTTCSA CTCGTACCAC CCCTTCAGCG
251 ACAAGGCCGA CTCGATCTTG AACAAATATG AGATTGGCAC GTTCACGGGC
301 CGCTCCGAGT TTCCGACCTT CAAGCCGGAC ACGGGCTTCT ACAAGGAGTG
351 CCGCAAGCGC GTTGGCGAGT ACTTCAAGAA GAACAACCTC CATCCGAGG
401 ACGGCTTCCC GGGCCTCTGG CGCATGATGG TCGTGTTTGC GGTGCGCGGC
451 CTCGCCTTGT ACGGCATGCA CTTTTCGACT ATCTTTGCGC TGCAGCTCGC
501 GGCCGCGGCG CTCCTTGGCG TCTGCCAGGC GCTGCCGCTG CTCCACGTCA
551 TGCACGACTC GTCGCACGCG TCGTACACCA ACATGCCGTT CTTCCATTAC
601 GTCGTGGGCC GCTTTGCCAT GGAATGGTTT GCCGGCGGCT CGATGGTGTG
651 ATGGCTCAAC CAGCACGTGG TGGGCCACCA CATCTACAGG AACGTGCGGG
701 GCTCGGACCC GGAATCTTCG GTCAACATGG ACGGCACAT CCGCCGCATC
751 GTGAACCGCC AGGTGTTCGA GCCCATGTAC GCATTCCAGC ACATCTACCT
801 TCCGCCGCTC TATGGCGTGC TTGGCCTCAA GTTCCGCATC CAGGACTTCA
851 CCGACACGTT CGGCTCGCAC ACGAACGGCC CGATCCGCGT CAACCCGCAC
901 GCGCTCTCSA CGTGGATGGC CATGATCAGC TCCAAATCGT TCTGGGCTTT
951 CTACCGCGTG TACCTTCCGC TTGCCGTGCT CCAGATGCCC ATCAAGAGCT
1001 ACCTTGCGAT CTTCTTCCTC GCCGAGTTTG TCACGGGCTG GTACCTCGCG
1051 TTCAACTTCC AAGTAAGCCA TGCTCGACC GAGTGCGGCT ACCCATGCGG
1101 CGACGAGGCC AAGATGGCGC TCCAGGACGA GTGGGCASTC TCGCAGGTCA
1151 AGACGTCGGT CGACTACGCC CATGGCTCGT GGATGACGAC GTTCCTTGCC
1201 GGCSCGCTCA ACTACCAGGT CGTGACCCAC TTGTTCCTCA GCGTGTGCGA
1251 GTACCACTAC CCGCGATCG CGCCCATCAT GGTGACGTC TGCAAGGAGT
1301 ACAACATCAA GTACGCCATC TTGCCGGACT TTACGGCGGC GTTCGTTGCC
1351 CACTTGAAGC ACCTCCGCAA CATGGGCCAG CAGGGCATCG CCGCCACGAT
1401 CCACATGGGC TAA

```


Figure 5

Amino Acid Sequence of Delta 5- Desaturase from *Styruyulus danieli* (ATCC 56851)

```

1   MAPQTEIRQR HAAYAEIFYA GKCAETWQEV AQHNTAASAM IIRGKVVDY
51  TEMANKHBBG REMVLHAGR EATDTEDSYH EFSDKAESIL NKYEIGTF TG
101 PSEFPTFKED TGFYKECRKR YGEYFKNNL HEDGDFPGLM RMMVYEAYAG
151 LALYGMHFSF IFAIQDAAA LFGVCQALPL LHVMDSSHA SYTMPEEHY
201 VVGREAMDWF AGGSMVSHLN QHVYGHHTYT NVAGSDPDLP VMDGDIRR I
251 VNRQVFQPMY AEQHTIYLPPL YGVLSIKERI QDFTDTEGSH TNGPIRVNPH
301 ALSTMMAMIS SKSEWAFYRY YLPPLAVLQMP IKTFLAIEF L AEFYTGWYLA
351 ENFQVSHVST ECGYPCGDEA KMAIQDEKAY SQVKTSVDYA HGSMTTFELA
401 GADNQQVVHH LEPVSQYHY PAIAPITVDV CKEYNKYAI LPDFTAIFYA
451 HLKHLRNMGQ QGIARTHMG *

```

Figure 6

Gene Sequence of Delta 5- Desaturase from *Thunnus thynnus* (ATCC 34304)

```

1   ATGGGACGCG GCGGCGAAGG TCAGGTGAAC AGCGCGCAGG TGGCACAAGG
51  CGGTGCGGGG ACGCCGAAAGG CGATCCTGAT CGAGGGCGAG GTCTACGATG
101 TCACCAACTT TAGGCACCCC GGCGGGTCGA TCATCAAGTT TCTCAGCACC
151 GACGGCACCG AGGCTGTGGA CGGACGGAAC GCGTTTCGCG AGTTTCACTG
201 CCGGTCGGGC AAGCGGAAA AGTACCTCAA GAGCCTGCCC AAGCTCGGCG
251 CGCGAGSCAA GATGAAGTTT GACGCCAAGG AGCAGGCCCG GCGCGACGCG
301 ATCAGCGGAG ACTACSTCAA GCTGCGCGAG GAGATGGTGG CCGAGGGCCT
351 CTTCAAGCCC GCGCCCCCTC ACATTGTCTA CAGGTTTGCG GAGATCGCAG
401 CCTGTTCGCG GGCTCGTTC TACCTGTTTT CGATGCGCGG AAACGTGTTT
451 GCGACGCTCG CGGCCATCGC AGTCGGGGGC ATCGCGCAGG GCGGCTGCGG
501 CTGGCTCATG CACGAGTGCG GACACTTCTC GATGACCGGG TACATCCCGC
551 TTGACGTGCG CCTGCAGGAG CTGGTGTACG GCGTGGGGTG CTGATGTGCG
601 GCGAGCTGGT GGCGCGTTCA GCACAACAAG CACCACGCGA CCGCGAGAA
651 ACTCAAGCAC GACGTCGACC TCGACACCCCT GCGGCTCGTT GCGTTCAACG
701 AGAAGATCGC CGCCAAGGTG CGCCCCECT CGTTCAGGC CAAGTGECTC
751 TCGGCGCAGG CGTACATTTT TCGCGCGGTG TCCTGCTTCC TGGTTGGTCT
801 CTTCTGGACC CTGTTTCTGC ACCCGCGCCA CATGCGCGCG ACGAGCCACT
851 TTGCTGAGAT GCGCGCCGTC GCGGTGCGCG TCGTGGGCTG GCGGCGCTC
901 ATGCACTCGT TCGGTACAG CGGGAGCGAC TCGTTCGGTC TCTACATGGC
951 CACCTTTGGC TTTGGCTGCA CCTACATCTT CACCAACTTT GCGGTCAGCC
1001 ACAAGCACCT CGACGTCACC GAGCCGAGCG AGTTCCTGCA CTGGGTGAG
1051 TACGCGCGCG TGACACGAC CAACGTGTCC AACGACTCGT GGTTCATCAC
1101 CTGGTGGATG TCGTACCTCA ACTTTCAGAT CGAGCACCAC CTCTTCCGT
1151 CGCTGCCCCA GCTCAACGCC CCGCGGCTCG CCGCGCGCT CCGCGCCCTC
1201 TTCGAGAAAG ACGGCATGGC TTACGACGAG CGCCCGTACC TTACCGCGCT
1251 TGGCGACAG TTTGCCAACC TGACGCGCT GGGCCAAAAC GCGGGCCAGG
1301 GGGCGCCAA GCGGCTTAG

```

Figure 7

Amino Acid Sequence of Delta 5- Desaturase from *Thermodictyon africanum* (ATCC 34304)

```

1  MERGGEGQVN  SAQVAQGGAG  TRKTLLIEGE  VYDVTNERHP  GGSIIKE LTT
51  DS TEAYDATN  AERE EHCRSG  KAERYLKSLP  KLGAPSQMGF  DAKEQARRDA
101 ITRD VYKERE  EMVAEG LEKP  APLHIVYREA  E IAALEAASE  YLE SMAGNYE
151 ATLAALAVGG  IAQGRCGHIM  HECGHE SMTG  YIFLDVRLQE  LVTGVGC SMS
201 ASHMYVQHKK  HHATEQKLKH  DYDEDTLELY  AFNEKIAAKV  REGSEQAKML
251 SAQRAYIFAPV  SCFLVGLFNT  LEIGHERRHMR  TSHEAEMAAV  AVR VVGMAAL
301 MHSE QVSGSD  SEGLYMATEG  EGCTYIEFTN  AVSHTHIDVT  E PDEE LHWVE
351 YAAALHTTNY  NDSHEITWMM  SYIMEQIEHM  LEPSLEQDNA  PRVAPRVRAI
401 EEKHGMAYDE  RPYLTALGDT  FANLHAYGQN  AGQAAAKAA

```

Figure 8

```

1  GAATTACCA  TGGGTCGGG  AGCACAGGA  GAGCCAAGGC  AGGCCACAGA
51  GCTGAAGAGC  AGCCCAAGTG  AGCAGCGTAA  GGTGTTGCTC  ATTGACGGGC
101  AGCTGTACGA  TGCAACCAAC  TTCAGGCATC  CTGGTGGCTC  CATCATCAAA
151  TATTGTGCA  CCGATGGCAA  GGAGGTAGTT  GATGCAACCG  AAGCGTACAA
201  GGAGTCCAC  TGCAGATCCT  CGAAGGCGGT  CAAGTACCTC  AACTCCCTGC
251  CAAAGATCGA  CGGCCCAATC  AAGTACAAAT  ACGACGAAA  GGAGCAGGCT
301  CGCCATGACA  AACTCACGAG  GGAGTATGTA  GCTCTCCGG  AACAGCTCGT
351  CAAGGAGGGA  TACTTTGACC  CCAGCCCGCT  CCACATTATC  TACAGATGCG
401  CCGAGTTGGC  AGCCATGTTT  GCTCTCTCGT  TCTACCTTTT  CTCCTTCAAG
451  GGTAAAGTCA  TGGCCACTAT  TGCTGCCATC  GTGATTGGGG  GGTGCCGTGA
501  GGGTCGTTGT  GGTGGCTCA  TGCATGAAGC  TGGCCACTAC  AGCATGACCG
551  GAAACATCCC  TGTTGACTTG  CGCCTTCAAG  AGTTTTGTA  CGGAATTGGG
601  TGTGGCATGA  GCGGGGCTTG  GTGGAGAAGC  CAGACAACA  AGCACCAAGC
651  CACCCCCCAA  AAGTCAAGC  ATGACGTTGA  TTTGGGACAT  CTTCTCTTTG
701  TCGCCTGGAA  CGAGAAAT  GCCCGTCGCG  TCAAGCCAGG  TAGCTTCCAG
751  GCAAAGTGGC  TTCAATCTCA  GGGATACATC  TTTGCCCCAG  TCTCCTGCCT
801  TCTCGTTGGT  CTCTTCTGGA  CTTTGTAATT  GCATCCTCGC  CACATGATCC
851  GCACCAAGCG  CAACITTCGAG  ATATTTTCTG  TCGCTCTGCG  CTACGTAATG
901  TGGTCTCGC  TTTCTTTTGG  CATGGGCTAC  ACTGTGGAG  AGTCTCTGGG
951  TCTCTATGTG  CTTACTTTTG  GACTTGGCTG  TACCTACATC  TTTACGCATT
1001  TTGCTGTAAG  CCACACCCAC  TTGCCAGTGT  CCGAGGAGGA  CGAGTACCTG
1051  CACTGGGTCTG  AGTACGCTGC  GCTGCACACC  ACGAACGTTG  CCATCGACTC
1101  GTACGTTGTC  ACCTGGCTGA  TGAGCTACCT  CAACTTTCAG  ATCGAGCACC
1151  ACTTGTTCCT  TTGCTGCCCG  CAGTTCGGCC  ACCCTGCAAT  CTCTTCTCGC
1201  GTCAAGAAAC  TTTTCGAGGA  CAATGGTCTG  GTATACGACG  CCCGCTCATA
1251  CGTCCAGGCG  CTCAGGATA  CCTTCGGCAA  CCTACACGAA  GTGGGCGTCA
1301  ACGCTGGCCA  AGCTGCCAAG  AGCGAGTAAG  ATCTCGAG

```

Start/stop underlined

Figure 9

1 MGRGAQGEPR QATELKSSPS EQRKVLLIDG QLYDAFNFRH PGGSIIKYIC
51 TDGKEVV DAT EAYKEFHCRS SKAVKYLNSL PKIDGPIKYK YDAKEQARHD
101 KLTREYVALR EQLVKEGYFD PSPLHIIYRC AELAAMFALS FYLFSEKGNV
151 MATIAAIVIG GCVQGRCGWL MHEAGHYSMT GNIPVDLRLQ EFLYGIGCGM
201 SGAWRSQHN KHHATPQKIK HDVDLDTLPL VAWNEKIARR VKPGSFQAKW
251 LHLOGYIFAP VSCLLVGLEW TLYLHPRHMI RTRNFEIFS VALRYVCWFS
301 LLLSMGYTVG ESLGLYVITF GIGCTYIFTH FAVSHTHLPV SEEDEYLHWV
351 EYAALHTTNV AIDSYYVVTWL MSYINFQIEH HLFPCCPQFR HPAISSRVKK
401 LEEDNGLVVD ARSYVQALKD TFGNIHEVGV NAGQAAKSE

Figure 10

1 CCATGGGCGG CGGCGGCGAG AAAAGCGAGG TGGACCAAGT GCAGCCACAA
51 AAGACCGAGC AGCTCCAGAA GGCCAAGTGG GAGGATGTTG TTCGCATCAA
101 TGGAGTCGAA TACGACGTCA CGGACTATCT CAGAAAACAC CCTGGTGGCA
151 GCGTGATCAA GTACGGGGCTT GCCAACACCG GCGTGATGC CACGTCCCTC
201 TTTGAAGCGT TCCACATGCG CTCAAAAGAAG CCTCAGATGG TGCTCAAGTC
251 TCTCCCAAAG CGTGCTCCGG TCCTCGAGAT CCAGCCAAAC CAGCTTCCAG
301 AGGAGCAGAC CAAGGAGGCG GAGATGCTGC GTGATTTTAA AAAATTTGAG
351 GATGAGATTG GCCGGGATGG ATTGATGGAA CCTTCCTTCT GGCAATCGCG
401 TTACAGATTA TCAGAGCTTG TAGGTATGTT CACGCTCGGC CTCTACCTCT
451 TCTCGTTAAA CACTCCTCTG TCTATTGCTG CTGGTGTCTT CGTCCACGGT
501 CTCTTTGGTG CATTCTGTGG ATGGTGCCAG CATGAGGCG GCCACGGCTC
551 CTTTTTTAC AGCCTTTGGT GGGCAAGCG GTTACAGGCC ATGTTGATCG
601 GGTTTGGTCT AGGAACATCC GCGACATGT GGAACATGAT GCACAACAAG
651 CATCATGCTG CCACCCAAA GGTTCATCAC GACCTTGACA TTGACACAAC
701 TCCTTTTGTA GCTTTCTTCA ACATGCAAT TGAGAAAAAC AGATGGAAGG
751 GCTTTTCCAA GGCTTGGGTC GCTTTTCAGG CTTTCACGTT CATTCCTGTC
801 ACCAGGGCA TGATCGTCAAT GCTGTTCTGG CTGTTTTTTC TCCACCCCTCG
851 CCGGCTCGTT CAAAAGAAGA ACTTTGAGGA GGGTTTTTGG ATGCTGTCTGA
901 GCCACATTGT GCGCACCTAT CTCTTCACCC TTGTGACCGG CTGGGAGAGC
951 CTCGCTGCAT GCTACCTTGT TGGGTATTGG GCGTGCAATG GGGTGTCCGG
1001 TATGTATTGG TTTGGCCACT TTTGCTCTC CCACACTCAT ATGGACATTG
1051 TGGAGGCGGA CGTGCAATAA AACTGGGTCA GGTACGCTGT TGACCACTT
1101 GTTGACATCA GCCCATCCAA CCCGCTCGTG TGCTGGGTCA TGGGTTACCT
1151 CAACATGCAG ACCATCCACC ACTTGTGGCC TGCCATGCCC CAGTACCACC
1201 AGGTGAGGT CTCACGCCGC TTGCCCCTCT TCGCAAAA ACACGGCCTC
1251 AACTACCGCG TCGTCTCTTA CTTTGAGGCT TGGCGCCTGA TGCTCCAAA
1301 TCTTGCTGAC GTCGGTTCCC ACTACCATGA GAACGGTGTG AAGCGGCGCC
1351 CAAAGAAAGC CAAGGCGCAG TAGAAAGCTA T

start/stop underlined

Figure 11

1 MGRGGEKSEV DOVQPKTEQ LQKAKWEDVV RINGVEYDVT DYLRKHPGGS
51 VIKYGLANTG ADATSLFEAF HMRSKKAQMV LKSLPKRAPV LEIQPNQLPE
101 EQTKEAEMLR DEKKFEDEIR RDGLMEPSFW HRAYRLSEIV GMFTIGLYLF
151 SLNTPLSIAA GVLVHGLFGA FCGWCQHEAG HGSEFFYSLMW GKRVOAMLIG
201 FGLGTSGDMW NMMHKKHAA TQKVHHDLDI DTPPFVAFEN TAFEKNRWKG
251 FSKAWVRFOA FTFIPVTSGM IVMLFWLFFL HP RRVVOKKN FEEGFWMLSS
301 HIVRTYLEHL VTGWESLAAC YLVGYWACMW VSGMYLFGHF SLSHTHMDIV
351 EADVHKNNVR YAVDHTVDIS PSNPLVCWM GYLNMQTIHH LWPAMPQYHQ
401 VEVSRRAIF AKKHGLNRYV VSYFEAWRLM LQNLADVGS YHENGVKRAP
451 KKAKAQ

Figure 12

| | | | | | |
|---------|-----|------------------------------------|--------------------------|---|-----|
| pRAT-2a | 1 | MGRGAQGEPRQATELKSSPSEQRKVL | LDGQQLYDATNFRHPPGGS | I | 45 |
| pRAT-2c | 1 | MGRGAQGEPRQATELKSSPSEQRKVL | LDGQQLYDATNFRHPPGGS | I | 45 |
| pRAT-2a | 46 | IKYLC TDGKEVVDA TEAYKEFHCRSSKADKY | LNSLPKIDGPIKYK | | 90 |
| pRAT-2c | 46 | IKYLC TDGKEVVDA TEAYKEFHCRSSKADKY | LNSLPKIDGPIKYK | | 90 |
| pRAT-2a | 91 | YDAKEQARHDKLTREYVALREQLVKEGYFDPSPL | HI IYRCAELAA | | 135 |
| pRAT-2c | 91 | YDAKEQARHDKLTREYVALREQLVKEGYFDPSPL | HI IYRCAELAA | | 135 |
| pRAT-2a | 136 | MFA LS FYLFSFKGNVVA TIAA I VIGGC | VQGRCGWLMHEAGHY SMT | | 180 |
| pRAT-2c | 136 | MFA LS FYLFSFKGNVVA TIAA I VIGGC | VQGRCGWLMHEAGHY SMT | | 180 |
| pRAT-2a | 181 | GNI PVDLRLQEEFLYGIGCGMSGAWWR | RQH NKHHATPQKLKHDVDL | | 225 |
| pRAT-2c | 181 | GNI PVDLRLQEEFLYGIGCGMSGAWWR | RQH NKHHATPQKLKHDVDL | | 225 |
| pRAT-2a | 226 | DTLPLVAWNEK IARRVKPGS FQAKWPHL | QGY I FAPVSC L LVGLFW | | 270 |
| pRAT-2c | 226 | DTLPLVAWNEK IARRVKPGS FQAKWPHL | QGY I FAPVSC L LVGLFW | | 270 |
| pRAT-2a | 271 | TLYLHPRHM IRTKRNFE IFSVALRYV | CVWFSL L L SMGYTVGESLGL | | 315 |
| pRAT-2c | 271 | TLYLHPRHM IRTKRNFE IFSVALRYV | CVWFSL L L SMGYTVGESLGL | | 315 |
| pRAT-2a | 316 | YVLT FGLGCTY I FTHFAVSH THLPV | SEEEDEY L HWVEY AALHTTNV | | 360 |
| pRAT-2c | 316 | YVLT FGLGCTY I FTHFAVSH THLPV | SEEEDEY L HWVEY AALHTTNV | | 360 |
| pRAT-2a | 361 | AIDSYVVTWLMSYLNFQIEHHLFPCCP | QFRHPA I SSRVKKLFEDN | | 405 |
| pRAT-2c | 361 | AIDSYVVTWLMSYLNFQIEHHLFPCCP | QFRHPA I SSRVKKLFEDN | | 405 |
| pRAT-2a | 406 | GLVYDARSYVQALKDTFGN LHEVGV | NAGQAAKSE | | 439 |
| pRAT-2c | 406 | GLVYDARSYVQALKDTFGN LHEVGV | NAGQAAKSE | | 439 |

12/15

Figure 13

| | | | |
|---------|-----|---|-----|
| pRAT-1a | 1 | MGRGGEKSEVDQVQPPQKTEQLQKAKWEDVVRINGVEYDVTDYLR | 44 |
| pRAT-1b | 1 | MGRGGEKSEVDQVQPPQKTEQLQKAKWEDVVRINGVEYDVTDYLR | 44 |
| pRAT-1a | 45 | KHPGGSVIKYGLANTGADATSLFEAFHMRSKKAQMVLKSLPKRA | 88 |
| pRAT-1b | 45 | KHPGGSVIKYGLANTGADATSLFEAFHMRSKKAQMVLKSLPKRA | 88 |
| pRAT-1a | 89 | PVLEIQPNQLPEEQTKAEEMLRDFFKKFEDEIRRDGLMEPSFWHR | 132 |
| pRAT-1b | 89 | PVLEIQPNQLPEEQTKAEEMLRDFFKKFEDEIRRDGLMEPSFWHR | 132 |
| pRAT-1a | 133 | AYRLSELVGMFTLGLYLFSLNTPLSIAAGVLVHGLFGAFCGWQC | 176 |
| pRAT-1b | 133 | AYRLSELVGMFTLGLYLFSLNTPLSIAAGVLVHGLFGAFCGWQC | 176 |
| pRAT-1a | 177 | HEAGHGSFFYSLWWGKRVQAMLIGFGLGTSGDMWNMMHNKHHAA | 220 |
| pRAT-1b | 177 | HEAGHGSFFYSLWWGKRVQAMLIGFGLGTSGDMWNMMHNKHHAA | 220 |
| pRAT-1a | 221 | TQKVHHDLDIDTTPFFVAFENTAFEKNRWKGFSAWVRFQAFTFI | 264 |
| pRAT-1b | 221 | TQKVHHDLDIDTTPFFVAFENTAFEKNRWKGFSAWVRFQAFTFI | 264 |
| pRAT-1a | 265 | PVTSGMIVMLFWLFFLHPRRVVQKKNFEEGFWMSSSHIVRTYLF | 308 |
| pRAT-1b | 265 | PVTSGMIVMLFWLFFLHPRRVVQKKNFEEGFWMSSSHIVRTYLF | 308 |
| pRAT-1a | 309 | HLVTGWESLAACYLVGYWACMWVSGMYLFGHFSLSHTHMDIVEA | 352 |
| pRAT-1b | 309 | HLVTGWESLAACYLVGYWACMWVSGMYLFGHFSLSHTHMDIVEA | 352 |
| pRAT-1a | 353 | DVHKNNVRYAVDHTVDISPSNPLVCWVMGYLNMQTIHHLWPA | 396 |
| pRAT-1b | 353 | DVHKNNVRYAVDHTVDISPSNPLVCWVMGYLNMQTIHHLWPA | 396 |
| pRAT-1a | 397 | QYHQVVEVSRRFAIFAKKHHGLNYRVVSYFEAWRLMLQNLA | 440 |
| pRAT-1b | 397 | QYHQVVEVSRRFAIFAKKHHGLNYRVVSYFEAWRLMLQNLA | 440 |
| pRAT-1a | 441 | YHENGVKRAPKKAKAQ | 456 |
| pRAT-1b | 441 | YHENGVKRAPKKAKAQ | 456 |

Figure 14

```

1   ATGGTGGCAG  GCAAATCAGG  CGCTGCGGCG  CACGTGACTC  ACAGCTCGAC
51  ATTGCCCCGT  GAGTACCATG  GCGCGACCAA  CGACTCGCGC  TCTGAGGCGG
101 CCGACGTCAC  CGTCTCTAGC  ATCGATGCTG  AAAAGGAGAT  GATCATCAAC
151 GGCCGCGTGT  ATGACGTGTC  GTCATTTGTG  AAGCGGCACC  CAGGTGGCTC
201 GGTGATCAAG  TTCCAGCTGG  GCGCCGACGC  GAGCGACGCG  TACAACAAC
251 TTCACGTCCG  CTCCAAGAAG  GCGGACAAGA  TGCTGTATT  GCTCCCGTCC
301 CGGCCGCGCG  AGGCCGGCTA  CGCCCAGGAC  GACATCTCCC  GCGACTTTGA
351 GAAGCTGCGC  CTCGAGCTGA  AGGAGGAGGG  CTACTTCGAG  CCCAACCTGG
401 TGCACGTGAG  CTACAGGTGT  GTGGAGGTTC  TTGCCATGTA  CTGGGCTGGC
451 GTCCAGCTCA  TCTGGTCCGG  GTACTGGTTC  CTCGGCGCGA  TCGTGGCCGG
501 CATTGCGCAG  GGCCGCTGCG  GCTGGCTCCA  GCATGAGGGT  GGGCACTACT
551 CGCTCACCGG  CAACATCAAG  ATCGACCGGC  ATCTGCAGAT  GGCCATCTAT
601 GGGCTTGGCT  GCGGCATGTC  GGGCTGCTAC  TGGCGCAACC  AGCACAACAA
651 GCACCACGCC  ACGCCGCAGA  AGCTCGGGAC  CGACCCCGAC  CTGCAGACGA
701 TGCCGCTGGT  GGCCTTCCAC  AAGATCGTCG  GCGCCAAGGC  GCGAGGCAAG
751 GGCAAGGCGT  GGCTGGCGTG  GCAGGCGCCG  CTCTTCTTTG  GCGGGATCAT
801 CTGCTCGCTC  GTCTCTTTTC  GCTGGCAGTT  CGTGCTCCAC  CCCAACCCAG
851 CGCTGCGCGT  GCACAATCAC  CTGGAGCTCG  CGTACATGGG  CCTGCGGTAC
901 GTGCTGTGGC  ACCTGGCCTT  TGGCCACCTC  GGGCTGCTGA  GCTCGCTCCG
951 CCTGTACGCC  TTTTACGTGG  CCGTGGGCGG  CACCTACATC  TTCACCAACT
1001 TCGCCGTCTC  GCACACCCAC  AAGGACGTCG  TCCCGCCAC  CAAGCACATC
1051 TCGTGGGCAC  TCTACTCGGC  CAACCACACG  ACCAACTGCT  CCGACTCGCC
1101 CTTTGTCAAC  TGGTGGATGG  CCTACCTCAA  CTTCAGATC  GAGCACCACC
1151 TCTTCCCGTC  GATGCCGCAG  TACAACCACC  CCAAGATCGC  CCCGCGGGTG
1201 CGCGCGCTCT  TCGAGAAGCA  CGGGGTCGAG  TATGACGTCC  GGCCATACCT
1251 GGAGTGTTTT  CGGGTCACGT  ACGTCAACCT  GCTCGCCGTA  GGCAACCCGG
1301 AGCACTCCTA  CCACGAGCAC  ACGCACTAG

```

15/15
Figure 15

1 MVAGKSGAAA HVTHSSTLPR EYHGATNDSR SEAADVTVSS IDAEKEMIIN
51 GRVYDVSSFV KRHPGGSVIK FQLGADASDA YNNFHVRSKK ADKMLYSLPS
101 RPAEAGYAQD DISRDFEKL R LELKEEGYFE PNLVHVSYRC VEVLAMYWAG
151 VQLIWSGYW F LGAI VAGIAQ GRCGWLQHEG GHYSLTGNIK IDRHLQMAIY
201 GLGCGMSGCY WRNQHNKHHA TPQKLGTDPD LQTMPLVAFH KIVGAKARGK
251 GKAWLAWQAP LFFGGIICSL VSFGWQFVLH PNHALRVHNNH LELAYMGLRY
301 VLWHLAFGHL GLLSSLRLYA FYVAVGGTYI FTNFAVSHTH KDVVPPTKHI
351 SWALYSANHT TNCSDSPFVN WWMAYLNFQI EHHLFPSMPQ YNHPKIAPRV
401 RALFEKHGVE YDVRPYLECF RVTYVNLLAV GNPEHSYHEH TH

1/24

SEQUENCE LISTING

<110> Abbott Laboratories
Mukerji, Pradip
Huang, Yung-Sheng
Das, Tapas
Thurmond, Jennifer M.
Pereira, Suzette L.

<120> DESATURASE GENES AND USES THEREOF

<130> 6763.PC.01

<140> Not Yet Assigned
<141> 2002-01-23

<150> US Not Yet Assigned
<151> 2002-01-22

<150> US 09/769,863
<151> 2001-01-25

<160> 55

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer R0834

<221> misc_feature
<222> (3)...(3)
<223> b = g or c or t/u at position 3

<221> misc_feature
<222> (6)...(6)
<223> y = t/u or c at position 6

<221> misc_feature
<222> (9)...(9)
<223> y = t/u or c at position 9

<221> misc_feature
<222> (12)...(12)
<223> b = g or c or t/u at position 12

<221> misc_difference
<222> (18)...(18)
<223> r = g or a at position 18

<221> misc_feature

2/24

<222> (24)...(24)
<223> b = g or c or t/u at position 24

<221> misc_feature
<222> (30)...(30)
<223> b = g or c or t/u at position 30

<221> misc_feature
<222> (33)...(33)
<223> y = t/u or c at position 33

<221> misc_feature
<222> (36)...(36)
<223> y = t/u or c at position 36

<221> misc_feature
<222> (39)...(39)
<223> h = a or c or t/u at position 39

<221> misc_feature
<222> (42)...(42)
<223> h = a or c or t/u at position 42

<400> 1
gtbtaygayg tbaccgartg ggtbaagcgy cayccbgghg gh

<210> 2
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward Primer R0835

<221> misc_feature
<222> (3)...(3)
<223> h = a or c or t/u at position 3

<221> misc_feature
<222> (6)...(6)
<223> y = t/u or c at position 6

<221> misc_feature
<222> (12)...(12)
<223> y = t/u or c at position 12

<221> misc_feature
<222> (27)...(27)
<223> y = t/u or c at position 27

<221> misc_feature
<222> (33)...(33)
<223> y = tu or c at position 33

<221> misc_feature
<222> (39)...(39)
<223> b = g or c or t/u at position 39

42

3/24

<221> misc_feature
<222> (41)...(41)
<223> y = t/u or c at position 41

<221> misc_feature
<222> (45)...(45)
<223> y = t/u or c at position 45

<400> 2
gghgcytccg cyaaactggtg gaagcaycag cayaacgtbc aycay

45

<210> 3
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse Primer RO836

<221> misc_feature
<222> (1)...(1)
<223> r = g or a at position 1

<221> misc_feature
<222> (4)...(4)
<223> r = g or a at position 4

<221> misc_feature
<222> (7)...(7)
<223> v = a or g or c at position 7

<221> misc_feature
<222> (13)...(13)
<223> r = g or a at position 13

<221> misc_feature
<222> (19)...(19)
<223> r = g or a at position 19

<221> misc_feature
<222> (34)...(34)
<223> r = g or a at position 34

<221> misc_feature
<222> (40)...(40)
<223> r = g or a at position 40

<221> misc_feature
<222> (43)...(43)
<223> d = a or g or t/u at position 43

<400> 3
rtgrtgvacg ttrtgctgrt gcttccacca gttgcggar gcdcc

45

<210> 4
<211> 36

4/24

<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse Primer R0838

<221> misc_feature
<222> (6)...(6)
<223> r = g or a at position 6

<221> misc_feature
<222> (12)...(12)
<223> r = g or a at position 12

<221> misc_feature
<222> (15)...(15)
<223> y = t/u or c at position 15

<221> misc_feature
<222> (18)...(18)
<223> r = g or a at position 18

<221> misc_feature
<222> (21)...(21)
<223> r = g or a at position 21

<221> misc_feature
<222> (24)...(24)
<223> s = g or c at position 24

<221> misc_feature
<222> (27)...(27)
<223> r = g or a at position 27

<221> misc_feature
<222> (30)...(30)
<223> v = a or g or c at position 30

<400> 4
ttgatrgtgtc arctygttgt rgasaarggv tggtag

<210> 5
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer R0753

<221> misc_feature
<222> (10)...(10)
<223> n = a or g or c or t/u, unknown, or other at
position 10

<221> misc_feature
<222> (13)...(13)
<223> r = g or a at position 13

36

5/24

<221> misc_feature
<222> (16)...(16)
<223> n = a or g or c or t/u, unknown, or other at
position 16

<221> misc_feature
<222> (18)...(19)
<223> r = g or a at positions 18-19

<221> misc_feature
<222> (22)...(22)
<223> r = g or a at position 22

<400> 5
catcatcatn ggraanarrt grtg

24

<210> 6
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer RO754

<221> misc_feature
<222> (15)...(15)
<223> y = t/u or c at position 15

<221> misc_feature
<222> (18)...(18)
<223> y = t/u or c at position 19

<221> misc_feature
<222> (21)...(21)
<223> n = a or g or c or t/u, unknown, or other at
position 21

<221> misc_feature
<222> (24)...(24)
<223> y = t/u or c at position 24

<221> misc_feature
<222> (27)...(27)
<223> n = a or g or c or t/u, unknown, or other at
position 27

<221> misc_feature
<222> (30)...(30)
<223> y = t/u or c at position 30

<400> 6
ctactactac tacaycayac ntayacnaay

30

<210> 7
<211> 29
<212> DNA

6/24

<213> Artificial Sequence

<220>

<223> Primer RO923

<400> 7

cgggtgcagtg gtggaagaac aagcacaac

29

<210> 8

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer RO899

<400> 8

agcggataac aatttcacac aggaaacagc

30

<210> 9

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer RO939

<400> 9

cgtagtactg ctcgaggagc ttgagcgccg

30

<210> 10

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer RO898

<400> 10

cccagtcacg acgttgtaaa acgacggcca g

31

<210> 11

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer RO951

<400> 11

tcaacagaat tcatggtcca ggggcaaaag gccgagaaga tctcg

45

<210> 12

<211> 47

<212> DNA

<213> Artificial Sequence

7/24

<220>

<223> Primer R0960

<400> 12

atacgtgaagc ttttacatgg cgggaaactc cttgaagaac tcgatcg

47

<210> 13

<211> 1362

<212> DNA

<213> Saprolegnia diclina

<400> 13

```

atggtccagg ggcaaaaggc cgagaagatc tcgtgggcca ccatccgtga gcacaaccgc 60
caagacaacg cgtggatcgt gatccaccac aagggtgtacg acatctcggc ctttgaggac 120
caccgggcg gcgtcgtcat gttcacgcag gccggcgaag acgcgacga tgcgttcgct 180
gtcttccacc cgagctcggc gctcaagctc ctcgagcagt actacgtcgg cgacgtcgac 240
cagtcgacgg cggccgtcga cagtcgatc tcggacgagg tcaagaagag ccagtcggac 300
ttcattgcgt cgtaccgcaa gctgcgcctt gaagtcaagc gcctcggctt gtacgactcg 360
agcaagctct actacctcta caagtgcgcc tcgacgtga gcattgcgt tgtgtcggcg 420
gccatttgcc tccactttga ctcgacggcc atgtacatgg tcgcggtgt catccttggc 480
ctcttttacc agcagtgcgg ctggctcgcc catgactttc tgcaccacca agtgtttgag 540
aaccacttgt ttggcgacct cgtcggcgtc atggtcggca acctctggca gggcttctcg 600
gtgcagtggg ggaagaacaa gcacaacacg caccatgcga tccccaacct ccacgcgacg 660
cccagatcg ccttccacgg cgaccgggac attgacacga tgccgattct cgcgtggctg 720
ctcaagatgg cgcagcacgc ggtcgactcg cccgtcgggc tcttcttcat gcgctaccaa 780
gcgtacctgt actttcccat cttgctcttt gcgcgtatct cgtgggtgat ccagtcggcc 840
atgtacgcct tctacaacgt tgggcccggc ggcacctttg acaaggcca gtacccgctg 900
ctcgagcgcg ccggcctcct cctctactac ggctggaacc tcggccttgt gtacgcagcc 960
aacatgtcgc tgctccaagc ggctgcgttc ctctttgtga gccaggcgtc gtgcggcctc 1020
ttcctcgcga tggctcttag cgtcggccac aacggcatgg aggtctttga caaggacagc 1080
aagcccgatt tttggaagct gcaagtgtc tcgacgcgca acgtgacgtc gtcgctctgg 1140
atcgactggg tcatgggagg cctcaactac cagatcgacc accacttggt cccgatgggtg 1200
ccccggcaca acctcccggc gctcaacgtg ctgctcaagt cgctctgcaa gcagtacgac 1260
atcccatacc acgagacggg cttcatcgcg ggcatggccg aggtcgtcgt gcacctcgag 1320
cgcatctcga tcgagttctt caaggagttt cccgccatgt aa 1362

```

<210> 14

<211> 453

<212> PRT

<213> Saprolegnia diclina

<400> 14

```

Met Val Gln Gly Gln Lys Ala Glu Lys Ile Ser Trp Ala Thr Ile Arg
 1             5             10             15
Glu His Asn Arg Gln Asp Asn Ala Trp Ile Val Ile His His Lys Val
      20             25             30
Tyr Asp Ile Ser Ala Phe Glu Asp His Pro Gly Gly Val Val Met Phe
      35             40             45
Thr Gln Ala Gly Glu Asp Ala Thr Asp Ala Phe Ala Val Phe His Pro
      50             55             60
Ser Ser Ala Leu Lys Leu Leu Glu Gln Tyr Tyr Val Gly Asp Val Asp
      65             70             75             80
Gln Ser Thr Ala Ala Val Asp Thr Ser Ile Ser Asp Glu Val Lys Lys
      85             90             95
Ser Gln Ser Asp Phe Ile Ala Ser Tyr Arg Lys Leu Arg Leu Glu Val
      100            105            110
Lys Arg Leu Gly Leu Tyr Asp Ser Ser Lys Leu Tyr Tyr Leu Tyr Lys

```

8/24

[illegible]

```
<210> 15
<211> 23
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Primer R0851

```
<400> 15
ccatcaagac gtaccttgcg atc
```

<210> 16

9/24

<211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer RO941

<400> 16
 gctgaacggg tggtacgagt cgaacgtg 28

<210> 17
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer RO953

<400> 17
 acgagagaat tcatggcccc gcagacggag ctccgccagc gc 42

<210> 18
 <211> 46
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer RO956

<400> 18
 aaaagactcg agttagccca tgtggatcgt ggcggcgatg ccctgc 46

<210> 19
 <211> 1413
 <212> DNA
 <213> Saprolegnia diclina

<400> 19
 atggccccgc agacggagct ccgccagcgc cagcccgccg tcgccgagac gccgggtggcc 60
 ggcaagaagg cctttacatg gcaggaggtc gcgcagcaca acacggcggc ctccggcctgg 120
 atcattatcc gcggcaaggc ctacgacgtg accgagtggtg ccaacaagca ccccgggcggc 180
 cgcgagatgg tgctgctgca cgccgggtcg gaggccaccg acacgttcga ctcgtagcac 240
 ccgttcagcg acaaggccga gtcgatcttg aacaagtatg agattggcac gttcacgggc 300
 ccgtccgagt ttccgacctt caagccggac acgggcttct acaaggagtg ccgcaagcgc 360
 gttggcgagt acttcaagaa gaacaacctc catccgcagg acggcttccc gggcctctgg 420
 cgcattgatg tcgtgtttgc ggtcgccggc ctcgccctgt acggcatgca cttttcgact 480
 atctttgcgc tgcagctcgc ggccgcggcg ctctttggcg tctgccaggc gctgcccgtg 540
 ctccacgtca tgcacgactc gtcgcacgog tcgtacacca acatgccgtt cttccattac 600
 gtcgctggcc gctttgccat ggactgggtt gccggcggtc cgatgggtgc atggctcaac 660
 cagcacgtcg tgggccacca catctacaag aacgtcgcgg gtcgggaccc ggatcttccg 720
 gtcaacatgg acggcgacat ccgccgcac gtgaaccgcc aggtgttcca gcccatgtac 780
 gcattccagc acatctacct tccgccgctc tatggcggtg ttggcctcaa gttccgcac 840
 caggacttca ccgacacgtt cggctcgcac acgaacggcc cgatccgcgt caaccgcac 900
 gcgctctcga cgtggatggc catgatcagc tccaagtcgt tctgggcctt ctaccgcgtg 960
 taccttcgc ttgccgtgct ccagatgccc atcaagacgt accttgcat cttcttctc 1020
 gccgagtttg tcacgggctg gtacctcgcg ttcaacttcc aagtaagcca tgtctcgacc 1080
 gagtgcggct acccatgcgg cgacgaggcc aagatggcgc tccaggacga gtgggcagtc 1140

10/24

```

tcgcagggtca agacgtcggg cgactacgcc catggctcgt ggatgacgac gttccttgcc 1200
ggcgcgctca actaccaggt cgtgcaccac ttgttcccca gcgtgtcgca gtaccactac 1260
ccggcgatcg cgcccatcat cgtcgacgtc tgcaaggagt acaacatcaa gtacgccatc 1320
ttgccgggact ttacggcggc gttcgttgcc cacttgaagc acctccgcaa catggggccag 1380
cagggcatcg ccgccacgat ccacatgggc taa 1413

```

<210> 20

<211> 470

<212> PRT

<213> *Saprolegnia diclina*

<400> 20

```

Met Ala Pro Gln Thr Glu Leu Arg Gln Arg His Ala Ala Val Ala Glu
 1          5          10          15
Thr Pro Val Ala Gly Lys Lys Ala Phe Thr Trp Gln Glu Val Ala Gln
 20          25          30
His Asn Thr Ala Ala Ser Ala Trp Ile Ile Ile Arg Gly Lys Val Tyr
 35          40          45
Asp Val Thr Glu Trp Ala Asn Lys His Pro Gly Gly Arg Glu Met Val
 50          55          60
Leu Leu His Ala Gly Arg Glu Ala Thr Asp Thr Phe Asp Ser Tyr His
 65          70          75          80
Pro Phe Ser Asp Lys Ala Glu Ser Ile Leu Asn Lys Tyr Glu Ile Gly
 85          90          95
Thr Phe Thr Gly Pro Ser Glu Phe Pro Thr Phe Lys Pro Asp Thr Gly
100          105          110
Phe Tyr Lys Glu Cys Arg Lys Arg Val Gly Glu Tyr Phe Lys Lys Asn
115          120          125
Asn Leu His Pro Gln Asp Gly Phe Pro Gly Leu Trp Arg Met Met Val
130          135          140
Val Phe Ala Val Ala Gly Leu Ala Leu Tyr Gly Met His Phe Ser Thr
145          150          155          160
Ile Phe Ala Leu Gln Leu Ala Ala Ala Leu Phe Gly Val Cys Gln
165          170          175
Ala Leu Pro Leu Leu His Val Met His Asp Ser Ser His Ala Ser Tyr
180          185          190
Thr Asn Met Pro Phe Phe His Tyr Val Val Gly Arg Phe Ala Met Asp
195          200          205
Trp Phe Ala Gly Gly Ser Met Val Ser Trp Leu Asn Gln His Val Val
210          215          220
Gly His His Ile Tyr Thr Asn Val Ala Gly Ser Asp Pro Asp Leu Pro
225          230          235          240
Val Asn Met Asp Gly Asp Ile Arg Arg Ile Val Asn Arg Gln Val Phe
245          250          255
Gln Pro Met Tyr Ala Phe Gln His Ile Tyr Leu Pro Pro Leu Tyr Gly
260          265          270
Val Leu Gly Leu Lys Phe Arg Ile Gln Asp Phe Thr Asp Thr Phe Gly
275          280          285
Ser His Thr Asn Gly Pro Ile Arg Val Asn Pro His Ala Leu Ser Thr
290          295          300
Trp Met Ala Met Ile Ser Ser Lys Ser Phe Trp Ala Phe Tyr Arg Val
305          310          315          320
Tyr Leu Pro Leu Ala Val Leu Gln Met Pro Ile Lys Thr Tyr Leu Ala
325          330          335
Ile Phe Phe Leu Ala Glu Phe Val Thr Gly Trp Tyr Leu Ala Phe Asn
340          345          350
Phe Gln Val Ser His Val Ser Thr Glu Cys Gly Tyr Pro Cys Gly Asp

```

11/24

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | 355 | | 360 | | 365 | | | | | | | | | | |
| Glu | Ala | Lys | Met | Ala | Leu | Gln | Asp | Glu | Trp | Ala | Val | Ser | Gln | Val | Lys |
| | 370 | | | | | 375 | | | | | 380 | | | | |
| Thr | Ser | Val | Asp | Tyr | Ala | His | Gly | Ser | Trp | Met | Thr | Thr | Phe | Leu | Ala |
| 385 | | | | | 390 | | | | | 395 | | | | | 400 |
| Gly | Ala | Leu | Asn | Tyr | Gln | Val | Val | His | His | Leu | Phe | Pro | Ser | Val | Ser |
| | | | 405 | | | | | | 410 | | | | | 415 | |
| Gln | Tyr | His | Tyr | Pro | Ala | Ile | Ala | Pro | Ile | Ile | Val | Asp | Val | Cys | Lys |
| | | | 420 | | | | | 425 | | | | | 430 | | |
| Glu | Tyr | Asn | Ile | Lys | Tyr | Ala | Ile | Leu | Pro | Asp | Phe | Thr | Ala | Ala | Phe |
| | | 435 | | | | | 440 | | | | | 445 | | | |
| Val | Ala | His | Leu | Lys | His | Leu | Arg | Asn | Met | Gly | Gln | Gln | Gly | Ile | Ala |
| | 450 | | | | | 455 | | | | | 460 | | | | |
| Ala | Thr | Ile | His | Met | Gly | | | | | | | | | | |
| 465 | | | | | 470 | | | | | | | | | | |

<210> 21
 <211> 914
 <212> DNA
 <213> Homo sapiens

<400> 21
 atggaacatt ttgatgcatc acttagtacc tatttcaagg cattgctagg ccctcgagat 60
 actagagtaa aaggatggtt tcttctggac aattatatac ccacatttat ctgctctgtc 120
 atatatattac taattgtatg gctgggacca aaatacatga ggaataaaca gccattctct 180
 tgccgggggga ttttagtggt gtataacctt ggactcacac tgctgtctct gtatatgttc 240
 tgtgagtttag taacaggagt atgggaaggc aaatacaact tcttctgtca gggcacacgc 300
 accgcaggag aatcagatat gaagattatc cgtgtcctct ggtggtacta cttctccaaa 360
 ctcatagaat ttatggacac tttcttcttc atcctgcgca agaacaacca ccagatcacg 420
 gtccctgcacg tctaccacca tgccctcgatg ctgaacatct ggtggtttgt gatgaactgg 480
 gtccccctgcg gccactctta ttttggtgac acacttaata gcttcatcca cgtectcatg 540
 tactcttact atggtttgtc gtcagtcctt tccatgcgtc catacctctg gtggaagaag 600
 tacatcactc aggggcagct gcttcagttt gtgctgacaa tcatccagac cagctgcggg 660
 gtcatctggc cgtgcacatt ccctcttggt tggttgtatt tccagattgg atacattatt 720
 tccctgattg ctctcttcac aaactttctac attcagacct acaacaagaa aggggcctcc 780
 cgaaggaaag accacctgaa ggaccaccag aatgggtccg tggctgctgt gaatggacac 840
 accaacagct tttcacccct ggaaaacaat gtgaagccaa ggaagctgcg gaaggattga 900
 agtcaaagaa ttga 914

<210> 22
 <211> 957
 <212> DNA
 <213> Mortierella alpina

<400> 22
 atggagtcga ttgcgccatt cctcccatca aagatgccgc aagatctgtt tatggacctt 60
 gccaccgcta tcggtgtccg ggccgcgccc tatgtcgatc ctctcgaggc cgcgctggtg 120
 gcccaggccg agaagtacat cccacagatt gtccatcaca cgcgtgggtt cctggctcgcg 180
 gtggagtcgc ctttggcccg tgagctgccg ttgatgaacc cgttccacgt gctgttgatc 240
 gtgctcgctt atttggtcac ggtctttgtg ggcatgcaga tcatgaagaa ctttgagcgg 300
 ttcgaggtca agacgttttc gctcctgcac aacttttgtc tggctctgat cagcgcctac 360
 atgtgcgggtg ggtacgtgta cgaggcttat caggccaact atggactgtt tgagaacgct 420
 gctgatcata ccttcaaggg tcttctctat gccaaagatga tctggctctt ctacttctcc 480
 aagatcatgg agtttgcga caccatgatc atggtcctca agaagaacaa ccgccagatc 540
 tcttctcttg acgtttacca ccacagctcc atcttcaacca tctggtggtt ggtcaccttt 600
 gttgcaccca acggtgaagc ctacttctct gctgcgttga actcgttcat ccatgtgatc 660

12/24

```

atgtacgget actacttctt gtcggccttg ggettcaagc aggtgtcgtt catcaagttc 720
tacatcacgc gctcgcagat gacacagttc tgcattgatgt cgggccagtc ttcctgggac 780
atgtacgcca tgaaggctct tggccgcccc ggatacccct tcttcattcac ggctctgott 840
tggtttctaca tgtggaccat gtcgggtctc ttctacaact ttacagaaa gaacgccaaag 900
ttggccaagc aggccaaagg cgacgctgcc aaggagaagg caaggaagtt gcagtaa 957

```

<210> 23

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer R0936

<400> 23

```

gtcgggcaag gcggaaaagt acctcaagag 30

```

<210> 24

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer R0937

<400> 24

```

aaacctgtag acaatgtgga ggggcgtggg 30

```

<210> 25

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer R0972

<400> 25

```

atacttgaat tcatgggacg cggcggcgaa ggtcagggtga ac 42

```

<210> 26

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer R0949

<400> 26

```

cttatactcg agctaagcgg ccttggecgc cgcctggcc 39

```

<210> 27

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer R0950

13/24

<400> 27

cttataactcgc agtaaatggc tcgcgagggcg aagcgagtgg c

41

<210> 28

<211> 1320

<212> DNA

<213> Thraustochytrium aureum

<400> 28

```

atggggacgcg gcggcgaagg tcaggtgaac agcgcgcagg tggcacaagg cgggtgcggga 60
acgcgaaaga cgatcctgat cgagggcgag gtctacgatg tcaccaactt taggcacccc 120
ggcgggtcga tcatcaagtt tctcacgacc gacggcaccg aggctgtgga cgcgacgaac 180
gcgtttcgcg agtttctactg ccggtcgggc aaggcggaaa agtacctcaa gagcctgccc 240
aagctcggcg cgccgagcaa gatgaagttt gacgccaagg agcaggcccc gcgcgacgcg 300
atcacgcgag actacgtcaa gctgcgcgag gagatggtgg ccgagggcct cttcaagccc 360
gcgccccctcc acattgtcta caggtttgcg gagatcgcag ccctgttcgc ggccctcggtc 420
tacctgtttt cgatgcgcgg aaacgtgttc gccacgctcg cggccatcgc agtcgggggc 480
atcgcgcagg gccgctgcgg ctggctcatg cagcagtgcg gacacttctc gatgaccggg 540
tacatcccgc ttgacgtgcg cctgcaggag ctggtgtacg gcgtgggggtg ctcgatgtcg 600
gcgagctggt ggcgcggtca gcacaacaag caccacgcga cccgcagaa actcaagcac 660
gacgtcgacc tcgacaccct gccgctcggt gcgttcaacg agaagatcgc cgccaaggtg 720
cgccccggct cgttccaggc caagtggctc tcggcgcagg cgtacatttt tgccgcgggtg 780
tcctgcttcc tggttggtct cttctggacc ctgtttctgc acccgcgcca catgccgcgc 840
acgagccact ttgctgagat ggccgcgcgc gcgggtgcgc tcgtgggctg ggccggcgctc 900
atgcactcgt tcgggtacag cgggagcgac tcgttcggtc tctacatggc cacccttggc 960
tttggtcgca cctacatctt caccaacttt gcggtcagcc acacgcacct cgacgtcacc 1020
gagccggacg agttcctgca ctgggtcgag tacgccgcgc tgcacacgac caacgtgtcc 1080
aacgactcgt ggttcacac ctggtggatg tcgtacctca actttcagat cgagcaccac 1140
ctctttccgt cgctgcccc gctcaacgcc ccgcgcgctg cccgcgcgct ccgcgcctc 1200
ttcgagaagc acggcatggc ttacgacgag cgcccgctacc ttaccgcgct tggcgacacg 1260
tttgccaacc tgcacgccgt gggccaaaac gcggggccagg cggcgggcaa ggccgcttag 1320

```

<210> 29

<211> 439

<212> PRT

<213> Thraustochytrium aureum

<400> 29

```

Met Gly Arg Gly Gly Glu Gly Gln Val Asn Ser Ala Gln Val Ala Gln
 1           5           10           15
Gly Gly Ala Gly Thr Arg Lys Thr Ile Leu Ile Glu Gly Glu Val Tyr
 20           25           30
Asp Val Thr Asn Phe Arg His Pro Gly Gly Ser Ile Ile Lys Phe Leu
 35           40           45
Thr Thr Asp Gly Thr Glu Ala Val Asp Ala Thr Asn Ala Phe Arg Glu
 50           55           60
Phe His Cys Arg Ser Gly Lys Ala Glu Lys Tyr Leu Lys Ser Leu Pro
 65           70           75           80
Lys Leu Gly Ala Pro Ser Lys Met Lys Phe Asp Ala Lys Glu Gln Ala
 85           90           95
Arg Arg Asp Ala Ile Thr Arg Asp Tyr Val Lys Leu Arg Glu Glu Met
100          105          110
Val Ala Glu Gly Leu Phe Lys Pro Ala Pro Leu His Ile Val Tyr Arg
115          120          125
Phe Ala Glu Ile Ala Ala Leu Phe Ala Ala Ser Phe Tyr Leu Phe Ser

```


14/24

| | | | | |
|---------------------------------|---------------------------------|---------------------|--|-----|
| 130 | | 135 | | 140 |
| Met Arg Gly Asn Val Phe | Ala Thr Leu Ala Ala | Ile Ala Val Gly Gly | | |
| 145 | | 150 | | 155 |
| Ile Ala Gln Gly Arg Cys Gly | Trp Leu Met His Glu Cys Gly | His Phe | | 160 |
| | 165 | 170 | | 175 |
| Ser Met Thr Gly Tyr Ile Pro Leu | Asp Val Arg Leu Gln Glu Leu | Val | | |
| | 180 | 185 | | 190 |
| Tyr Gly Val Gly Cys Ser Met Ser | Ala Ser Trp Trp Arg Val Gln His | | | |
| | 195 | 200 | | 205 |
| Asn Lys His His Ala Thr Pro Gln | Lys Leu Lys His Asp Val Asp Leu | | | |
| | 210 | 215 | | 220 |
| Asp Thr Leu Pro Leu Val Ala Phe | Asn Glu Lys Ile Ala Ala Lys Val | | | |
| | 225 | 230 | | 235 |
| Arg Pro Gly Ser Phe Gln Ala Lys | Trp Leu Ser Ala Gln Ala Tyr Ile | | | |
| | 245 | 250 | | 255 |
| Phe Ala Pro Val Ser Cys Phe Leu | Val Gly Leu Phe Trp Thr Leu Phe | | | |
| | 260 | 265 | | 270 |
| Leu His Pro Arg His Met Pro Arg | Thr Ser His Phe Ala Glu Met Ala | | | |
| | 275 | 280 | | 285 |
| Ala Val Ala Val Arg Val Val Gly | Trp Ala Ala Leu Met His Ser Phe | | | |
| | 290 | 295 | | 300 |
| Gly Tyr Ser Gly Ser Asp Ser Phe | Gly Leu Tyr Met Ala Thr Phe Gly | | | |
| | 305 | 310 | | 315 |
| Phe Gly Cys Thr Tyr Ile Phe Thr | Asn Phe Ala Val Ser His Thr His | | | |
| | 325 | 330 | | 335 |
| Leu Asp Val Thr Glu Pro Asp Glu | Phe Leu His Trp Val Glu Tyr Ala | | | |
| | 340 | 345 | | 350 |
| Ala Leu His Thr Thr Asn Val Ser | Asn Asp Ser Trp Phe Ile Thr Trp | | | |
| | 355 | 360 | | 365 |
| Trp Met Ser Tyr Leu Asn Phe Gln | Ile Glu His His Leu Phe Pro Ser | | | |
| | 370 | 375 | | 380 |
| Leu Pro Gln Leu Asn Ala Pro Arg | Val Ala Pro Arg Val Arg Ala Leu | | | |
| | 385 | 390 | | 395 |
| Phe Glu Lys His Gly Met Ala Tyr | Asp Glu Arg Pro Tyr Leu Thr Ala | | | |
| | 405 | 410 | | 415 |
| Leu Gly Asp Thr Phe Ala Asn Leu | His Ala Val Gly Gln Asn Ala Gly | | | |
| | 420 | 425 | | 430 |
| Gln Ala Ala Ala Lys Ala Ala | | | | |
| | 435 | | | |

<210> 30

<211> 1338

<212> DNA

<213> Thraustochytrium aureum

<400> 30

| | | | | | | |
|------------|------------|------------|-------------|-------------|-------------|-----|
| gaattcacca | tgggtcgcg | agcacaggga | gagccaaggc | aggccacaga | gctgaagagc | 60 |
| agcccaagt | g | agcagcgtaa | ggtgttgctc | attgacgggc | agctgtacga | 120 |
| ttcaggcatc | ctggtggctc | catcatcaaa | tattttgtgca | ccgatggcaa | ggaggtagtt | 180 |
| gatgcaaccg | aagcgtacaa | ggagttccac | tgcagatcct | cgaaggcgg | caagtacctc | 240 |
| aactccctgc | caaagatcga | cggcccaatc | aagtacaaat | acgacgcaaa | ggagcaggct | 300 |
| cgccatgaca | aactcacgag | ggagtatgta | gctctccgcg | aacagctcgt | caaggaggga | 360 |
| tactttgacc | ccagcccgct | ccacattatc | tacagatgcg | ccgagttggc | agccatgttc | 420 |
| gctctctcgt | tctacctttt | ctccttcaag | ggtaacgtca | tggccactat | tgctgccatc | 480 |
| gtgattgggg | ggtgcgtgca | gggtcgttgt | gggtgggtca | tgcatgaagc | tggccactac | 540 |
| agcatgaccg | gaaacatccc | tgttgacttg | cgccttcaag | agttttttgta | cgggaattggg | 600 |

15/24

```

tgtggcatga gcggggcttg gtggagaagc cagcacaaca agcaccacgc cccccccaa 660
aagctcaagc atgacgttga tttggacact cttcctcttg tcgcctggaa cgagaaaatt 720
gcccgtcgcg tcaagccagg tagcttccag gcaaagtggc ttcactctcca gggatacatc 780
tttgccccag tctcctgcct tctcgttggg ctcttctgga ctttgtactt gcacctctgc 840
cacatgatcc gcaccaagcg caacttcgag atattttctg tcgctctgcg ctacgtatgc 900
tggttctcgc ttcttttgag catgggctac actgtcggag agtctctggg tctctatgtg 960
cttacttttg gacttggctg tacctacatc tttacgcatt ttgctgtaag ccacaccac 1020
ttgccagtgt ccgaggagga cgagtacctg cactgggtcg agtacgctgc gctgcacacc 1080
acgaacgttg ccatcgactc gtacgttgtc acctggctga tgagctacct caactttcag 1140
atcgagcacc acttgttccc ttgctgcccg cagttccgcc accctgcaat ctcttctcgc 1200
gtcaagaaac ttttcgagga caatggtctg gtatacgacg cccgctcata cgtccaggcg 1260
ctcaaggata ccttcggcaa cctacacgaa gtgggcgtca acgctggcca agctgccaag 1320
agcgagtaag atctcgag 1338

```

<210> 31

<211> 439

<212> PRT

<213> *Thraustochytrium aureum*

<400> 31

```

Met Gly Arg Gly Ala Gln Gly Glu Pro Arg Gln Ala Thr Glu Leu Lys
 1      5      10      15
Ser Ser Pro Ser Glu Gln Arg Lys Val Leu Leu Ile Asp Gly Gln Leu
 20      25      30
Tyr Asp Ala Thr Asn Phe Arg His Pro Gly Gly Ser Ile Ile Lys Tyr
 35      40      45
Leu Cys Thr Asp Gly Lys Glu Val Val Asp Ala Thr Glu Ala Tyr Lys
 50      55      60
Glu Phe His Cys Arg Ser Ser Lys Ala Val Lys Tyr Leu Asn Ser Leu
 65      70      75      80
Pro Lys Ile Asp Gly Pro Ile Lys Tyr Lys Tyr Asp Ala Lys Glu Gln
 85      90      95
Ala Arg His Asp Lys Leu Thr Arg Glu Tyr Val Ala Leu Arg Glu Gln
100      105      110
Leu Val Lys Glu Gly Tyr Phe Asp Pro Ser Pro Leu His Ile Ile Tyr
115      120      125
Arg Cys Ala Glu Leu Ala Ala Met Phe Ala Leu Ser Phe Tyr Leu Phe
130      135      140
Ser Phe Lys Gly Asn Val Met Ala Thr Ile Ala Ala Ile Val Ile Gly
145      150      155      160
Gly Cys Val Gln Gly Arg Cys Gly Trp Leu Met His Glu Ala Gly His
165      170      175
Tyr Ser Met Thr Gly Asn Ile Pro Val Asp Leu Arg Leu Gln Glu Phe
180      185      190
Leu Tyr Gly Ile Gly Cys Gly Met Ser Gly Ala Trp Trp Arg Ser Gln
195      200      205
His Asn Lys His His Ala Thr Pro Gln Lys Leu Lys His Asp Val Asp
210      215      220
Leu Asp Thr Leu Pro Leu Val Ala Trp Asn Glu Lys Ile Ala Arg Arg
225      230      235      240
Val Lys Pro Gly Ser Phe Gln Ala Lys Trp Leu His Leu Gln Gly Tyr
245      250      255
Ile Phe Ala Pro Val Ser Cys Leu Leu Val Gly Leu Phe Trp Thr Leu
260      265      270
Tyr Leu His Pro Arg His Met Ile Arg Thr Lys Arg Asn Phe Glu Ile
275      280      285
Phe Ser Val Ala Leu Arg Tyr Val Cys Trp Phe Ser Leu Leu Leu Ser

```

16/24

| | | | | |
|---|---|-----|--|-----|
| 290 | | 295 | | 300 |
| Met Gly Tyr Thr Val | Gly Glu Ser Leu Gly Leu Tyr Val Leu Thr Phe | | | |
| 305 | | 310 | | 315 |
| Gly Leu Gly Cys Thr Tyr Ile Phe Thr His Phe Ala Val Ser His Thr | | | | |
| | | 325 | | 330 |
| His Leu Pro Val Ser Glu Glu Asp Glu Tyr Leu His Trp Val Glu Tyr | | | | |
| | | 340 | | 345 |
| Ala Ala Leu His Thr Thr Asn Val Ala Ile Asp Ser Tyr Val Val Thr | | | | |
| | | 355 | | 360 |
| Trp Leu Met Ser Tyr Leu Asn Phe Gln Ile Glu His His Leu Phe Pro | | | | |
| | | 370 | | 375 |
| Cys Cys Pro Gln Phe Arg His Pro Ala Ile Ser Ser Arg Val Lys Lys | | | | |
| 385 | | 390 | | 395 |
| Leu Phe Glu Asp Asn Gly Leu Val Tyr Asp Ala Arg Ser Tyr Val Gln | | | | |
| | | 405 | | 410 |
| Ala Leu Lys Asp Thr Phe Gly Asn Leu His Glu Val Gly Val Asn Ala | | | | |
| | | 420 | | 425 |
| Gly Gln Ala Ala Lys Ser Glu | | | | 430 |
| | | 435 | | |

<210> 32

<211> 1381

<212> DNA

<213> Thraustochytrium aureum

<400> 32

| | | | | | | |
|------------|-------------|-------------|-------------|------------|--------------|------|
| ccatgggccc | cggcggcgag | aaaagcgcgag | tggaccaggt | gcagccacaa | aagaccgcgagc | 60 |
| agctccagaa | ggccaagtgg | gaggatgttg | ttcgcatcaa | tggagtcgaa | tacgacgtca | 120 |
| cggactatct | cagaaaacac | cctggtggca | gcgtgatcaa | gtacgggctt | gccaacaccg | 180 |
| gcgctgatgc | cacgtccctc | tttgaagcgt | tccacatgcg | ctcaaagaag | gctcagatgg | 240 |
| tgctcaagtc | tctcccaaag | cgtgctccgg | tctcgcagat | ccagccaaac | cagcttccag | 300 |
| aggagcagac | caaggaggcg | gagatgctgc | gtgattttaa | aaaatttgag | gatgagattc | 360 |
| gccgggatgg | attgatggaa | ccttccttct | ggcatcgcg | ttacagatta | tcagagcttg | 420 |
| taggtatgtt | cacgctcggc | ctctacctct | tctcgttaaa | cactcctctg | tctattgctg | 480 |
| ctggtgtcct | cgtccacggc | ctcttttggt | cattctgttg | atggtgccag | catgaggcag | 540 |
| gccacggctc | ctttttttac | agcctttggt | ggggcaagcg | tgtacaggcc | atgttgatcg | 600 |
| ggtttggtct | aggaacatcc | ggcgacatgt | ggaacatgat | gcacaacaag | catcatgctg | 660 |
| ccacccaaaa | ggttcatcac | gaccttgaca | ttgacacaac | tccttttgta | gctttcttca | 720 |
| acactgcatt | tgagaaaaac | agatggaagg | gcttttccaa | ggcttgggtc | cgctttcagg | 780 |
| ctttcacgtt | cattcctgtc | accagcggca | tgatcgatcat | gctgttctgg | ctgttttttc | 840 |
| tccaccctcg | ccgcgtcgtt | caaaagaaga | actttgagga | gggttttttg | atgctgtcga | 900 |
| gccacattgt | gcgcacctat | ctcttcacc | ttgtgaccgg | ctgggagagc | ctcgctgcat | 960 |
| gctaccttgt | tgggtatttg | gcgtgcatgt | gggtgtccgg | tatgtatttg | tttggccact | 1020 |
| tttgcgtctc | ccacactcat | atggacattg | tggaggcgga | cgtgcataag | aactgggtca | 1080 |
| ggtacgctgt | tgaccacact | gttgacatca | gcccatacaa | cccgtcgtg | tgctgggtca | 1140 |
| tgggttacct | caacatgcag | accatccacc | acttgtggcc | tgccatgcc | cagtaccacc | 1200 |
| aggtcgaggt | ctcacgccgc | tttgccatct | tcgccaaaaa | acacggcctc | aactaccgog | 1260 |
| tcgtctctta | ctttgaggct | tggcgccctga | tgctccaaaa | tcttgctgac | gtcgggttccc | 1320 |
| actaccatga | gaacgggtgtc | aagcgcgccc | caaagaaagc | caaggcgcag | tagaaagcta | 1380 |
| t | | | | | | 1381 |

<210> 33

<211> 456

<212> PRT

<213> Thraustochytrium aureum

<400> 33

17/24

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Gly | Arg | Gly | Gly | Glu | Lys | Ser | Glu | Val | Asp | Gln | Val | Gln | Pro | Gln |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Lys | Thr | Glu | Gln | Leu | Gln | Lys | Ala | Lys | Trp | Glu | Asp | Val | Val | Arg | Ile |
| | | 20 | | | | | | 25 | | | | | 30 | | |
| Asn | Gly | Val | Glu | Tyr | Asp | Val | Thr | Asp | Tyr | Leu | Arg | Lys | His | Pro | Gly |
| | | 35 | | | | | 40 | | | | | 45 | | | |
| Gly | Ser | Val | Ile | Lys | Tyr | Gly | Leu | Ala | Asn | Thr | Gly | Ala | Asp | Ala | Thr |
| | 50 | | | | | 55 | | | | | 60 | | | | |
| Ser | Leu | Phe | Glu | Ala | Phe | His | Met | Arg | Ser | Lys | Lys | Ala | Gln | Met | Val |
| 65 | | | | | 70 | | | | | 75 | | | | 80 | |
| Leu | Lys | Ser | Leu | Pro | Lys | Arg | Ala | Pro | Val | Leu | Glu | Ile | Gln | Pro | Asn |
| | | | 85 | | | | | | 90 | | | | | 95 | |
| Gln | Leu | Pro | Glu | Glu | Gln | Thr | Lys | Glu | Ala | Glu | Met | Leu | Arg | Asp | Phe |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Lys | Lys | Phe | Glu | Asp | Glu | Ile | Arg | Arg | Asp | Gly | Leu | Met | Glu | Pro | Ser |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Phe | Trp | His | Arg | Ala | Tyr | Arg | Leu | Ser | Glu | Leu | Val | Gly | Met | Phe | Thr |
| | 130 | | | | | 135 | | | | | 140 | | | | |
| Leu | Gly | Leu | Tyr | Leu | Phe | Ser | Leu | Asn | Thr | Pro | Leu | Ser | Ile | Ala | Ala |
| 145 | | | | | 150 | | | | | 155 | | | | 160 | |
| Gly | Val | Leu | Val | His | Gly | Leu | Phe | Gly | Ala | Phe | Cys | Gly | Trp | Cys | Gln |
| | | | | 165 | | | | 170 | | | | | | 175 | |
| His | Glu | Ala | Gly | His | Gly | Ser | Phe | Phe | Tyr | Ser | Leu | Trp | Trp | Gly | Lys |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Arg | Val | Gln | Ala | Met | Leu | Ile | Gly | Phe | Gly | Leu | Gly | Thr | Ser | Gly | Asp |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Met | Trp | Asn | Met | Met | His | Asn | Lys | His | His | Ala | Ala | Thr | Gln | Lys | Val |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| His | His | Asp | Leu | Asp | Ile | Asp | Thr | Thr | Pro | Phe | Val | Ala | Phe | Phe | Asn |
| 225 | | | | | 230 | | | | | 235 | | | | 240 | |
| Thr | Ala | Phe | Glu | Lys | Asn | Arg | Trp | Lys | Gly | Phe | Ser | Lys | Ala | Trp | Val |
| | | | | 245 | | | | | 250 | | | | | 255 | |
| Arg | Phe | Gln | Ala | Phe | Thr | Phe | Ile | Pro | Val | Thr | Ser | Gly | Met | Ile | Val |
| | | | 260 | | | | | 265 | | | | | 270 | | |
| Met | Leu | Phe | Trp | Leu | Phe | Phe | Leu | His | Pro | Arg | Arg | Val | Val | Gln | Lys |
| | 275 | | | | | | 280 | | | | | 285 | | | |
| Lys | Asn | Phe | Glu | Glu | Gly | Phe | Trp | Met | Leu | Ser | Ser | His | Ile | Val | Arg |
| | 290 | | | | | 295 | | | | | 300 | | | | |
| Thr | Tyr | Leu | Phe | His | Leu | Val | Thr | Gly | Trp | Glu | Ser | Leu | Ala | Ala | Cys |
| 305 | | | | | 310 | | | | | 315 | | | | 320 | |
| Tyr | Leu | Val | Gly | Tyr | Trp | Ala | Cys | Met | Trp | Val | Ser | Gly | Met | Tyr | Leu |
| | | | | 325 | | | | | 330 | | | | 335 | | |
| Phe | Gly | His | Phe | Ser | Leu | Ser | His | Thr | His | Met | Asp | Ile | Val | Glu | Ala |
| | | | 340 | | | | | 345 | | | | | 350 | | |
| Asp | Val | His | Lys | Asn | Trp | Val | Arg | Tyr | Ala | Val | Asp | His | Thr | Val | Asp |
| | | 355 | | | | | 360 | | | | | 365 | | | |
| Ile | Ser | Pro | Ser | Asn | Pro | Leu | Val | Cys | Trp | Val | Met | Gly | Tyr | Leu | Asn |
| | 370 | | | | | 375 | | | | | 380 | | | | |
| Met | Gln | Thr | Ile | His | His | Leu | Trp | Pro | Ala | Met | Pro | Gln | Tyr | His | Gln |
| 385 | | | | | 390 | | | | | 395 | | | | 400 | |
| Val | Glu | Val | Ser | Arg | Phe | Ala | Ile | Phe | Ala | Lys | Lys | His | Gly | Leu | |
| | | | | 405 | | | | 410 | | | | | 415 | | |
| Asn | Tyr | Arg | Val | Val | Ser | Tyr | Phe | Glu | Ala | Trp | Arg | Leu | Met | Leu | Gln |
| | | | 420 | | | | | 425 | | | | | 430 | | |
| Asn | Leu | Ala | Asp | Val | Gly | Ser | His | Tyr | His | Glu | Asn | Gly | Val | Lys | Arg |
| | | 435 | | | | | 440 | | | | | 445 | | | |
| Ala | Pro | Lys | Lys | Ala | Lys | Ala | Gln | | | | | | | | |

18/24

450

455

<210> 34
 <211> 1329
 <212> DNA
 <213> *Isochrysis galbana*

<400> 34
 atgggtggcag gcaaatacagg cgctgcggcg cacgtgactc acagctcgac attgccccgt 60
 gagtaccatg gcgcgaccaa cgactcgcgc tctgaggcgg ccgacgtcac cgtctctagc 120
 atcgaatgctg aaaaggagat gatcatcaac ggccgcgtgt atgacgtgtc gtcatttgtg 180
 aagcggcacc cagggtggctc ggtgatcaag ttccagctgg gcgcgcgacgc gagcgacgcg 240
 tacaacaact ttacagtcgg ctccaagaag gcggacaaga tgctgtattc gctcccgtcc 300
 cggccggcgg aggcgggcta cgcccaggac gacatctccc gcgactttga gaagctgcgc 360
 ctcgagctga aggaggaggg ctacttcgag cccaacctgg tgcacgtgag ctacaggtgt 420
 gtggagggttc ttgccatgta ctgggctggc gtccagctca tctgggtccg gtactgggtc 480
 ctcggcgcga tcgtggccgg cattgcgcag ggccgctgcg gctggctcca gcatgagggt 540
 gggcactact cgctcaccgg caacatcaag atcgaccggc atctgcagat ggcatctat 600
 gggcttgggt gcggcatgtc gggctgctac tggcgcaacc agcacaacaa gcaccacgcc 660
 acgcccagga agctcgggac cgaccccgac ctgcagacga tgccgctggg ggccttccac 720
 aagatcgtcg gcgccaaggc gcgaggcaag ggcaaggcgt ggctggcgtg gcaggcgccg 780
 ctcttctttg gcgggatcat ctgctcgtc gtctctttcg gctggcagtt cgtgctccac 840
 cccaaccaag cgctgcgcgt gcacaatcac ctggagctcg cgtacatggg cctgcggtac 900
 gtgctgtggc acctggcctt tggccacctc gggctgctga gctcgtccg cctgtacgcc 960
 ttttacgtgg ccgtgggcgg cacctacatc ttaccaact tcgccgtctc gcacaccac 1020
 aaggacgtcg tcccgcacc caagcacatc tcgtgggcac tctactcggc caaccacag 1080
 accaactgct ccgactcggc ctttgtcaac tgggtgatgg cctacctcaa cttccagatc 1140
 gagcaccacc tcttcccgtc gatgccgcag tacaaccacc ccaagatcgc ccgcgggtg 1200
 cgcgcgctct tcgagaagca cggggtcgag tatgacgtcc ggccatacct ggagtgtttt 1260
 cgggtcacgt acgtcaacct gctcgccgta ggcaaccggg agcactccta ccacgagcac 1320
 acgcactag 1329

<210> 35
 <211> 442
 <212> PRT
 <213> *Isochrysis galbana*

<400> 35
 Met Val Ala Gly Lys Ser Gly Ala Ala Ala His Val Thr His Ser Ser
 1 5 10 15
 Thr Leu Pro Arg Glu Tyr His Gly Ala Thr Asn Asp Ser Arg Ser Glu
 20 25 30
 Ala Ala Asp Val Thr Val Ser Ser Ile Asp Ala Glu Lys Glu Met Ile
 35 40 45
 Ile Asn Gly Arg Val Tyr Asp Val Ser Ser Phe Val Lys Arg His Pro
 50 55 60
 Gly Gly Ser Val Ile Lys Phe Gln Leu Gly Ala Asp Ala Ser Asp Ala
 65 70 75 80
 Tyr Asn Asn Phe His Val Arg Ser Lys Lys Ala Asp Lys Met Leu Tyr
 85 90 95
 Ser Leu Pro Ser Arg Pro Ala Glu Ala Gly Tyr Ala Gln Asp Asp Ile
 100 105 110
 Ser Arg Asp Phe Glu Lys Leu Arg Leu Glu Leu Lys Glu Glu Gly Tyr
 115 120 125
 Phe Glu Pro Asn Leu Val His Val Ser Tyr Arg Cys Val Glu Val Leu
 130 135 140
 Ala Met Tyr Trp Ala Gly Val Gln Leu Ile Trp Ser Gly Tyr Trp Phe

19/24

```

145              150              155              160
Leu Gly Ala Ile Val Ala Gly Ile Ala Gln Gly Arg Cys Gly Trp Leu
              165              170              175
Gln His Glu Gly Gly His Tyr Ser Leu Thr Gly Asn Ile Lys Ile Asp
              180              185              190
Arg His Leu Gln Met Ala Ile Tyr Gly Leu Gly Cys Gly Met Ser Gly
              195              200              205
Cys Tyr Trp Arg Asn Gln His Asn Lys His His Ala Thr Pro Gln Lys
              210              215              220
Leu Gly Thr Asp Pro Asp Leu Gln Thr Met Pro Leu Val Ala Phe His
225              230              235              240
Lys Ile Val Gly Ala Lys Ala Arg Gly Lys Gly Lys Ala Trp Leu Ala
              245              250              255
Trp Gln Ala Pro Leu Phe Phe Gly Gly Ile Ile Cys Ser Leu Val Ser
              260              265              270
Phe Gly Trp Gln Phe Val Leu His Pro Asn His Ala Leu Arg Val His
              275              280              285
Asn His Leu Glu Leu Ala Tyr Met Gly Leu Arg Tyr Val Leu Trp His
              290              295              300
Leu Ala Phe Gly His Leu Gly Leu Leu Ser Ser Leu Arg Leu Tyr Ala
305              310              315              320
Phe Tyr Val Ala Val Gly Gly Thr Tyr Ile Phe Thr Asn Phe Ala Val
              325              330              335
Ser His Thr His Lys Asp Val Val Pro Pro Thr Lys His Ile Ser Trp
              340              345              350
Ala Leu Tyr Ser Ala Asn His Thr Thr Asn Cys Ser Asp Ser Pro Phe
              355              360              365
Val Asn Trp Trp Met Ala Tyr Leu Asn Phe Gln Ile Glu His His Leu
              370              375              380
Phe Pro Ser Met Pro Gln Tyr Asn His Pro Lys Ile Ala Pro Arg Val
385              390              395              400
Arg Ala Leu Phe Glu Lys His Gly Val Glu Tyr Asp Val Arg Pro Tyr
              405              410              415
Leu Glu Cys Phe Arg Val Thr Tyr Val Asn Leu Leu Ala Val Gly Asn
              420              425              430
Pro Glu His Ser Tyr His Glu His Thr His
              435              440

```

<210> 36

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer RO838

<221> misc_feature

<222> (7)...(7)

<223> v = a or g or c at position 7

<221> misc_feature

<222> (10)...(10)

<223> r = g or a at position 10

<221> misc_feature

<222> (13)...(13)

<223> s = g or c at position 13

20/24

<221> misc_feature
<222> (16)...(16)
<223> r = g or a at position 16

<221> misc_feature
<222> (19)...(19)
<223> r = g or a at position 19

<221> misc_feature
<222> (22)...(22)
<223> y = t/u or c at position 22

<221> misc_feature
<222> (25)...(25)
<223> r = g or a at position 25

<221> misc_feature
<222> (31)...(31)
<223> r = g or a at position 31

<400> 36
catggtvggr aasagrtgrt gytcratctg rtagtt 36

<210> 37
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer RO1065

<400> 37
cgacaagagg aagagtgtcc aaatc 25

<210> 38
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer RO1064

<400> 38
cgccttcaag agtttttgta cggaattggg 30

<210> 39
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer RO1097

<400> 39
cttgtaccat gggtcgcgga gcacagggag 30

21/24

<210> 40
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer RO1098

<400> 40
tgaagcttac tcgctcttgg cagcttggcc 30

<210> 41
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer RO1107

<400> 41
tttaaccatg ggccgcggcg gcgagaaaag 30

<210> 42
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer RO1108

<400> 42
gggaagaagc tttctactgc gccttggcctt tctttg 36

<210> 43
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer RO1235

<400> 43
cgaagtgggt gaagatgtag gtgccg 26

<210> 44
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer RO1232

<400> 44
gagcgacgcg tacaacaact ttcacgt 27

<210> 45
<211> 23

22/24

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 45

cgactggagc acgaggacac tga

23

<210> 46

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> GeneRacer 3 Prime Primer

<400> 46

gctgtcaacg atacgctacg taacg

25

<210> 47

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Nested Primer RO1234

<400> 47

agctccaggt gattgtgcac gcgcag

26

<210> 48

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer RO1233

<400> 48

gactttgaga agctg'gcct cgagctg

27

<210> 49

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Nested 5 Prime Primer

<400> 49

ggacactgac atggactgaa ggagta

26

<210> 50

<211> 23

<212> DNA

<213> Artificial Sequence

23/24

<220>

<223> Nested 3 Prime Primer

<400> 50

cgctacgtaa cggcatgaca gtg

23

<210> 51

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer RO1309

<400> 51

atgatggaat tcatgggtggc aggcaaatca ggcgc

35

<210> 52

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer RO1310

<400> 52

aataatgtcg acctagtgcg tgtgctcgtg gtagg

35

<210> 53

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Consensus Peptide Sequence

<400> 53

Val Tyr Asp Val Thr Glu Trp Val Lys Arg His Pro Gly Gly
1 5 10

<210> 54

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Consensus Peptide Sequence

<400> 54

Gly Ala Ser Ala Asn Trp Trp Lys His Gln His Asn Val His His
1 5 10 15

<210> 55

<211> 12

<212> PRT

<213> Artificial Sequence

24/24

<220>

<223> Consensus Peptide Sequence

<400> 55

| | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Tyr | Gln | Ile | Glu | His | His | Leu | Phe | Pro | Thr | Met |
| 1 | | | | 5 | | | | 10 | | | |